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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Post-translational modifications in biological systems 
 
Post-translational modifications (PTMs) on proteins are known to play a 
substantial role in the complexity and diversity of biological systems. This chapter 
discusses two key PTMs- protein phosphorylation and glycosylation – including 
their biological roles, associated diseases, significance in relation to each other, 
and how they are currently characterized. A number of challenges exist in 
characterizing each type of PTM, such as lability of the modification during MS 
fragmentation, substoichiometry, and difficulty in separation of the modified 
protein or peptide from complex mixtures. New methodologies that circumvent 
many of these challenges using lanthanide-based labeling and two mass 
spectrometry (MS) platforms - MALDI-TOFMS and ion mobility-mass 
spectrometry (IM-MS) - are proposed.  An outline of objectives and research 
goals is highlighted.  
 
1.1.1 The relevance of protein phosphorylation and glycosylation 
 
The majority of cellular processes, particularly cell to cell interaction, cell 
differentiation, proliferation, mobility, division, and apoptosis, are governed by 
protein expression and post-translational modifications (PTMs) on proteins, 
which commonly take the form of phosphorylation, glycosylation, acetylation, 
methylation, etc. O-linked protein phosphorylation and glycosylation are 
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considered two of the most common PTMs and often compete for the same 
positions during a number of cellular functions. It has been shown that regulation 
of phosphorylation vs. glycosylation stoichiometries govern many cellular 
processes, outlined below. For this reason, phosphoproteomics and glycomics 
have moved to evaluate the direct role of these PTMs in regulating proteins 
responsible for the progression of Alzheimer’s disease,1-4 cancer proliferation,5, 6 
inflammatory diseases,7, 8 and the onset of developmental neurological 
diseases.9 
 
1.1.1.2 Protein phosphorylation 
Phosphorylation of serine (Ser), threonine (Thr), and tyrosine (Tyr) 
residues (O-phosphorylation) occur with the assistance of kinases, which 
account for approximately 2% of the human genome.10 It has been estimated that 
50% of all proteins in a typical eukaryotic cell are phosphorylated.11, 12  Protein 
phosphorylation is reported to play a critical role in the regulation of cell 
proliferation,11 differentiation,13 migration,14-18 signalling,11 survival,11, 19 and 
apoptosis20  Moreover, varying the stoichiometry of protein phosphorylation has 
been shown to regulate signaling cascades and rates of turnover of cell migration 
proteins, which are known to play a significant role in neurological disorders, pro-
inflammatory disorders (e.g., psoriasis and rheumatoid arthritis) and cellular 
behaviors associated with cancer cell proliferation.10, 21, 22 
Protein phosphorylation is challenging to characterize due to the dynamic 
nature of the modification. There exist significant differences in the occurrence of 
pSer, pThr, and pTyr residues, in that these residues are typically observed in a 
ratio of 1800:200:1, respectively.23 Adding to the complexity, the degree of 
phosphorylation changes according to the temporal cellular response. Moreover, 
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phosphorylated serine and threonine residues are labile in basic conditions 
encountered in common buffers and also during tandem MS fragmentation. 
Phosphates have been reported to rearrange in collision cells of MS instruments, 
resulting in increased noise, false positives, and reduction of signal 
corresponding to the original site of modification.24, 25 These factors often result in 
substoichiometric levels of phosphorylated proteins available for analysis, which 
compound the challenges in phosphoproteomic characterization.  
 
1.1.1.3 Protein glycosylation 
 Protein glycosylation is a common and complex form of post-translational 
modification which regulates the structure, stability, and function of proteins 
within the cell. Glycosylation is ubiquitous among all eukaryotes, and it is 
estimated that glycosylation occurs on 50% of all eukaryotic proteins.26 It is 
reported to play a key role in functions on the cell membrane such as hormone 
uptake,27 recognition of toxins or pathogens,28, 29 and signaling to other cells.30 It 
also plays a further role in cellular processes such as organization31 and 
division.6 Furthermore, glycosylation is required for the biological function of 
certain proteins, such as the Fc-effector function of immunoglobulin G (IgG).7, 32-35 
Moreover, glycosylation has been linked to reproduction,36 embryonic stem cell 
development,37 and the development of Alzheimer’s disease,3 arthritis,8 and 
diabetes.38 O-linked glycosylation exists on serine, threonine, and tyrosine 
residues, and occurs most frequently on serine. Proteins bearing O-linked N-
Acetyl Glucoseamine (O-GlcNAc) have been implicated in AIDS-related 
lymphomas and viral and parasitic proteins.31 
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Characterization of protein glycosylation is challenging for a number of 
reasons, including substoichiometry and difficulty in determining the glycan 
structure. For example, O-GlcNAc (O-linked N-acetylglucosamine) is highly 
dynamic and deglycosylation is a rapid step for regulatory functions, resulting in 
substoichiometric amounts. Glycan branching is often complex and positional 
isomers are difficult to separate using traditional online separation methods for 
MS. Building blocks for the glycan comprise a large number of carbohydrates, 
and the functionality of the glycan is dependent upon its branching structure and 
terminal saccharides. Furthermore, glycosylation may be interchangeable with 
phosphorylation in some regulatory systems. Moreover, glycans are difficult to 
separate from complex biological mixtures, and often require a number of 
laborious chromatography steps to generate a pure mixture for analysis. 
 
1.2 Current characterization strategies for PTMs 
 
1.2.1 Characterization of phosphorylated proteins 
Characterization of a phosphoprotein involves determination of the site of 
phosphorylation and determination of stoichiometry between different states. 
Traditionally, these two analyses are performed in separate experiments, as a 
priori knowledge of the sites of phosphorylation greatly facilitate targeted 
quantitative approaches. Moreover, site identification typically requires 
enrichment, as sequence coverage detected may be suppressed by more 
abundant concomitant species.  
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Classical phosphoproteomic enrichment includes separation and 
purification by 2-D gels, immunoprecipitation, immobilized metal affinity columns 
(IMAC), reversed-phase liquid chromatography (RPLC), or the use of selective 
enrichment via phospho-specific antibodies and 2-D gel separation. Each method 
offers advantages and disadvantages. A brief overview of separation 
methodologies and quantitative methodologies discussed below is provided in 
Table 1.  
Classical phosphoproteomic quantitative and site elucidation 
methodologies include the use of 32P radiolabels.39 In this method, protein 
mixtures are typically separated by 2-D gel electrophoresis and subsequently 
imaged. Varying samples may quantitated by the relative amounts of radiation 
emitted, and site elucidation is performed by Edman degradation. This method is 
still in common use because of demonstrated dynamic range, but is restricted by 
three important limitations. First, this method requires the use of 2-D gels, which 
limit applicability to soluble and relatively abundant proteins. In many cases, 
protein phosphorylation occurs rapidly and is frequently observed in low 
abundance. Second, phosphoaminoacid analysis suffers from poor site 
specificity, and a significant amount of a priori knowledge is required about the 
sequence and potential sites of phosphorylation. Third, this method is labor-
intensive, time consuming, and requires the use of radioactive labeling. Typical 
labeling experiments take between 3-7 days and  
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Table 1. Purification and Quantitation Methods for Phosphoproteomics 
 
Method Principle Pros Cons 
Purification method 
2-D gel 
electrophoresis 
(2DIGE)
11, 40
 
 
 
 
Separation of 
proteins by 
isoelectric point 
and size.  
 
 
Can be done in vivo 
or in vitro, large 
dynamic range. 
 
 
Limited to soluble 
proteins, spot 
overlap requires 
additional 
purification 
 
Antibody enrichment Generalized 
enrichment of 
phosphoproteins by 
binding to 
phosphorylation-
specific antibodies. 
Selective for 
phosphorylated 
tyrosine antibodies. 
 
Not selective for 
phosphoserine and 
phosphotyrosine. 
Immobilized metal-
affinity 
chromatography 
(IMAC)
41, 42
 
Enrichment of 
phosphoproteins 
and phospho-
peptides via affinity 
toward positively 
charged metal ions 
(Fe
3+
, Al
3+
, Ga
3+
, or 
Co
2+
) chelated to a 
solid support. 
Generalized 
phosphorylation 
enrichment without 
need for antibodies 
or radioactive 
materials. 
Non-specific 
interactions require 
additional cleanup 
for phospho-
proteomic 
characterization 
Reversed-phase 
liquid 
chromatography 
(RPLC)
43
 
Separation of 
phosphoproteins 
and phospho-
peptides non-
selectively by 
elution based on 
polarity and 
interaction with C-4 
or C-18 column.  
Standardized 
protocol, readily 
reproducible and 
commonly reported. 
High abundance 
phosphorylation 
sites are readily 
identified. 
Does not enrich for 
phosphorylated 
peptides and 
proteins, all peaks 
from chromatogram 
must be 
fragmented for 
identification.  
Immunoprecipitation 
11, 44, 45
 
Enrich specific 
phosphorylated 
proteins of interest 
via selective 
antibodies for the 
target protein (does 
not necessarily 
target 
phosphorylation 
domain). 
Selective for 
targeted 
phosphorylated 
peptide or protein.  
Significant a priori 
knowledge of the 
phosphorylation 
site required, not 
for phosphopeptide 
discovery. Custom 
antibody generation 
is costly. 
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Table 1 (cont’d). Purification and Quantitation Methods for Phosphoproteomics. 
 
Quantitation 
method 
32
P radiolabels
39
  
 
 
 
 
 
Labeling of 
phosphoproteins or 
phosphopeptides in 
vivo or in vitro with 
32
P or 
33
P. 
Detection using 
Edman degradation 
and 
autoradiography. 
 
 
 
May be done in vivo, 
established method in 
the biological sciences. 
 
 
 
 
Radioactive 
phosphorus 
requires special 
handling and 
special disposal. 
Enzymatic stable 
isotope labeling
9, 46-48
 
Stable isotope 
introduction to 
phosphoproteins or 
phosphopeptides in 
vitro via enzymatic 
digestion in H2
18
O. 
Each peptide may be 
labeled via 
18
O/
16
O 
incorporation by trypsin. 
Trypsin reaction is 
highly versatile and may 
be performed in a 
number of conditions 
and varying pH. Method 
is relatively cheap. 
Variable 
incorporation of 
1 or 2 
18
O due 
to pH 
dependence. 
Missed 
cleavages must 
be accounted 
for and may 
confound 
quantitation. 
Metabolic stable 
isotope labeling
9, 49
 
Stable isotope 
introduction to 
phosphoproteins or 
phospho-peptides 
via incorporation of 
isotopically “heavy” 
or “light” amino 
acids containing 
14
N or 
15
N,
 12
C or 
13
C, etc. 
Reduces error due to 
sample handling, nearly 
all peptides may be 
labeled. 
Requires in-vivo 
labeling and 
subsequent 
purification prior 
to analysis. May 
not be done on 
in-vitro samples 
that are isolated 
from separate, 
non-quantitative 
experiments, 
labeling time 
dependent on 
cell culture time, 
limitation of 
available amino 
acids 
Chemical 
modification stable 
isotope labeling
50-58
 
Stable isotope 
introduction to 
phosphoproteins or 
phospho-peptides 
via chemical 
modification of 
isotopically “light” 
and “heavy” labels. 
Selective for intended 
functionalities, available 
with additional built-in 
advantages such as 
reporter ion tags, biotin 
affinity, or ICP 
ionization. 
Limited mass 
shifts (2-8 Da)  
limit analysis to 
small (<2500 
Da) peptides or 
use of high 
resolution (FT-
ICR-MS) 
instrumentation. 
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require extensive prior purification using affinity purification and treatment before 
analysis. 
Many of these challenges can be addressed using mass spectrometry 
(MS) techniques. To circumvent the time intensive requirements of affinity 
chromatography methods, data-dependent scanning (tandem MS/MS 
experiments, typically on triple quadrupole instruments) followed by bioinformatic 
analysis is often used for PTM site localization. Although these methods are 
sufficiently sensitive to the substoichiometric amounts of phosphorylated 
sequences, they make inefficient use of chromatography time and require 
tandem spectra acquisition for each peak in the chromatogram regardless of 
whether the peak corresponds to the modifications of interest. Moreover, a 
substantial amount of manual validation is required, as phosphorylation site 
rearrangement has been noted.24  
Quantitation is routinely performed using mass spectrometry. Current 
methods for MS-based quantitation include stable isotope and metal labeling 
techniques that take advantage of nearly identical labeled structures, differing 
only by the incorporation of a limited number of heavy isotopes. Contemporary 
stable isotope labeling was first introduced by three independent labs in the late 
1990’s and is now implemented enzymatically (e.g. O18 labeling), 46-48 
metabolically (e.g. SILAC),49, 56 or by chemical modification.53, 59-61 Typically, 
these labeling strategies provide relative quantitation through incorporation of 
different stable isotopes for comparing relative protein expression profiles. 
Relative quantitation information can be expected, because the labeled peptides 
are isotopologues and hence their ionization efficiencies are assumed to be 
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identical. Protein expression is then elucidated by comparing the relative peak 
areas of each differentially labeled peptide (Figure 1).  
The most prevalent method for enzymatic introduction of stable isotope 
labels is proteolytic 18O-labeling first reported by Desiderio et al.46 in 1983 and 
later improved by Mirgorodskaya et al. in 2000.47 In this experiment, proteolytic 
enzymes are reacted with the protein of interest in H2
18O, resulting in 
incorporation of an 18O atom at the carboxyl terminus of each enzymatically 
cleaved peptide. This method suffers from variable incorporation of the isotope 
(one or two atoms can be incorporated, depending on pH and time scale of 
digestion), resulting in reduced signal intensity and moderate convolution of peak 
intensity comparisons.9 
The most prevalent method for metabolic introduction of stable isotope 
labels is the stable isotope labeling by amino acids in cell culture (SILAC) method 
reported by Ong et al.49 In this method, differentially expressed cells are grown in 
separate medium containing either native arginine and lysine or isotope labeled 
13C6-arginine and 
13C6-lysine that is taken into the cell and incorporated into the 
proteome. This ensures that all tryptic peptides carry at least one labeled residue 
corresponding to its unlabeled counterpart. An advantage of this method is that 
differentially labeled peptides may be combined at the culture level, eliminating 
errors typical of late-stage combination quantification techniques. It suffers, 
however, from high cost, insufficient selectivity, and relatively high time 
requirements for total isotope incorporation and preparation. Additionally, in  
 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. In a typical relative quantitation experiment, differentially expressed 
samples are encoded with isotopically “light” or “heavy” labels enzymatically, 
metabolically, or by chemical modification that generates mass shifts of 2-8 Da. 
Relative peak areas provide relative quantitation information. Adapted from 
reference.9 
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order for the method to be useful in phosphoproteomic determination, additional 
purification steps are also required to improve detection. 
Chemical modification of phosphorylation sites has been achieved using 
several different methods. Aebersold and colleagues reported a tagging method 
in which a cysteamine linker is covalently bound to the phosphate group via an 
N,N’-dimethylaminopropyl ethyl carbodiimide (EDC) coupling reaction.62 Smith 
and colleagues reported a method for relative quantitation of phosphorylated 
peptides and proteins (i.e. Phosphoprotein Isotope-Coded Affinity Tags, or 
PhIAT)52 analogous to a protein quantitation method previously described by 
Gygi and colleagues termed isotope-coded affinity tags, or ICAT, which labels at 
cysteine residues. In the PhIAT method, phosphorylation at serine and threonine 
is converted to a cysteine-like moiety containing a free thiol via beta-elimination 
to yield dehydrobetaalanine or dehydroaminobutyric acid, respectively. 
Subsequent thiol Michael addition of an isotopically labeled dithiol linker provides 
the isotopologues and chemical reactivity for a covalent attachment to biotin. The 
labeled phosphorylated peptides are then digested, purified by affinity 
chromatography, and analyzed by LC-MS/MS. Relative quantitation information 
is gained by comparing relative peak areas for the isotopically “light” and “heavy” 
labeled peptides.52, 57 
PhIAT provides versatile, selective relative quantitation information for 
phosphorylated peptides. However, all of these strategies limit the peptide mass 
that can be quantitated by a limited range of isotopic mass differences. For 
example, peptide mass is limited by the 2-8 Dalton mass shift afforded by the 
isotopically enriched linker portion of the label.  At higher masses, (greater than 
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ca. 2500 Da), the natural isotopic envelopes of the isotopologues begin to 
overlap resulting in poorer relative quantitation accuracy.9 
 
1.2.2 Characterization of glycosylated proteins 
Characterization of a glycoprotein is occasionally required to fully explore 
the biological significance of protein phosphorylation. In this context, the 
sequence position and stoichiometry of the modification are desirable to probe 
any dynamic phosphorylation/glycosylation switching. Further glycomic 
characterization includes determination of the glycan structure. Glycan site 
determination is frequently accomplished using a combination of proteases, 
glycosidases, affinity chromatography, and LC-tandem mass spectrometry 
(Figure 2).63, 64 Identifying the site of modification is challenging due to the 
temporal nature of glycosylation and the lability of the modification in basic pH 
and tandem MS. This characterization of the glycan is also complicated by noise 
from branch fragmentation, labile terminal saccharides, and fragments that are 
isobaric with concomitant species.63, 64 These challenges in characterization 
compound when a protein has multiple glycosylation sites. Thus, classic glycomic 
methodologies require extensive separation and purification strategies to simplify 
analysis. Identification of the site of modification is accomplished with the use of 
endoproteases to cleave the protein into peptides and isolate each modification 
site onto individual peptides. High-performance liquid chromatography is then 
required to separate each peptide and tandem MS analysis is performed to 
determine the site of modification.  
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Figure 2. Traditional protocol for full glycoprotein characterization by MS. 
Stoichiometric information is typically not obtained. 
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Structural characterization of the attached glycan is then accomplished 
through the use of glycosidases, which cleave the attached glycan from the 
protein. Lectin chromatography is used to separate glycans from peptides, and 
high-performance liquid chromatography is used prior to tandem MS analysis. 
Although these separation methods can resolve glycans and facilitate 
characterization, similar polarities and size of the carbohydrate limits complete 
separation. Furthermore, offline chromatographic and affinity separations are 
known to be laborious and time consuming, requiring hours to days to complete. 
 
1.3 Mobility shift labeling using ion mobility-mass spectrometry 
 
Typical time intensive separation strategies for PTM analysis are 
circumvented using mobility shift labels and ion mobility-mass spectrometry. Ion 
mobility spectrometry is a well-developed gas-phase separation technique 
whereby ions are rapidly (µs to ms) separated based on their apparent surface 
area or collision cross section (CCS). Ions undergo elastic collisions with an inert 
buffer gas at pressures of 0.5-10 Torr as they move through the drift cell under 
the influence of either a traveling wave or a weak electrostatic field (Figure 3a). In 
traveling wave ion mobility, ions traverse the mobility cell under the influences of 
a transient DC voltage and an alternating RF voltage that acts as a potential 
barrier. Ions with larger apparent surface area will have slower drift times due to 
more ion-neutral collisions than ions with smaller surface areas. An illustration of 
this concept is provided in Figure 3b.  
When coupled with mass spectrometry (Figure 3c), IM-MS can 
differentiate ions of interest from analyte ions having the same mass but different  
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Figure 3. a) Ion mobility separates on the basis of collisions with a neutral buffer 
gas under the influence of a weak electrostatic field, resulting in differing arrival 
time distributions for conformers of a peptide. b) An example of two 
conformations of example peptide [Ac-Y(AEAAKA)5F-NH2+Na]
+. The folded 
version (blue, also indicated above in blue), exhibits a faster arrival time than the 
extended version (red, also indicated above in red) due to a reduction in 
apparent surface area for collisions in the mobility cell. Structures shown are two 
representative conformers obtained through molecular dynamics calculations and 
represent local maxima. c) Ion mobility may be coupled to mass spectrometry 
using a number of platforms, but the general arrangement is presented in this 
schematic. 
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structures (i.e., isobaric species). An instrument schematic of this combination is 
provided in Figure 4. IM separations are slow relative to mass analysis (ms vs 
ns), and many mass spectra are acquired over the elution profile of the ions from 
the drift cell. The resultant IM-MS data is 3-dimensional, typically shown with 
arrival time distribution (IM drift time) on the y-axis, m/z on the x-axis, and relative 
abundance on the z-axis. Such 3D data is typically projected in two dimensions 
with false coloring for relative abundance as illustrated in Figure 5.   
For a particular molecular class of given density, ion mobility scales as 
length squared, while mass scales as length cubed. Because mobility 
separations are not completely orthogonal to mass detection, molecular classes 
exhibit correlation lines in IM-MS 2-D conformation space. For example, a 
sample of approximately 600 singly-charged peptide signals occupied a narrow 
band of arrival time distribution vs. m/z with greater than 99% of the peptides 
having less than a 7% deviation from the mean.65 Lipids, carbohydrates, and 
nucleotides were also reported to reside in their own correlation lines in the 2D 
conformation space.66 Differences in the relative gas-phase packing efficiencies 
of each type of biomolecule (nucleotides> carbohydrates> peptides> lipids) can 
be exploited to separate each biomolecular class, illustrated in Figure 6.  
Structural separation of all four types of biomolecules was demonstrated in our 
group using IM-MS.66  
This is an advantage to a number of “omics” strategies,66 including 
lipidomics,67 proteomics,68 phosphoproteomics,69 and glycomics.70 IM-MS has 
also been demonstrated on complex samples such as whole-cell lysates,71 non- 
covalent complexes,72 and thin tissue sections73 as a more rapid separation and 
detection method than traditional LC-MS analysis. 
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Figure 4. Schematic diagram of the MALDI-TWIM-TOFMS Instrument (Synapt 
HDMS G2, Waters Corp., Manchester, UK). 
 
 
 
 
 18 
 
 
 
Figure 5. Data projection from three-dimensional (arrival time distribution vs. m/z 
vs. relative abundance) to two dimensional (arrival time distribution vs. m/z), with 
false coloring representing relative abundance. 
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Figure 6. Differences in the relative gas-phase packing efficiencies of each type 
of biomolecule (nucleotides> carbohydrates> peptides> lipids) are shown. a) Ion 
surface areas vs. m/z from a pool of 53 lipids, 610 peptides, 191 carbohydrates, 
and 110 oligonucleotides. b) Mean correlation lines ion surface area vs. m/z for 
each biomolecular class. c) Separation of biomolecular class in real time (as 
acquired from the Synapt HDMS IM-MS instrument). Adapted from reference 66.  
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It should be noted, however, that minor modifications (e.g., 
phosphorylation sites) within each biomolecular class were not significantly 
resolved (0-6% deviation) from unmodified molecules.69 
 
1.3.1 Mobility shift strategies 
One of the central aims of this project is to resolve post-translationally 
modified peptides and proteins from their unmodified counterparts in IM-MS 
using mobility shift strategies for further characterization. Mobility shift strategies 
have been previously described.72, 74 In these strategies, labeled functionalities 
are shifted to an area outside of the IM-MS correlation band where signals are 
not predicted to occur in the absence of labeling. Due to the curvature of the 
correlation band, two mobility shift strategies are possible – shift reagents of 
either low or high density (Figure 7) whereby labeled signals are shifted to an 
area above or below the peptide correlation band, respectively. Lanthanide-
based chelating label are selected as covalent high density IM-MS shift reagents 
since the lanthanide metal imparts a larger increase in mass to the labeled 
peptide than apparent surface area.  
 
1.3.1.1 Lanthanide-based labeling strategies 
Most commonly, lanthanide-based (Ln-based) labeling strategies utilize a 
trivalent lanthanide metal (Ln(III)) specific tag (Figure 8) that contains a linker 
portion and a functionally reactive portion. Because the ionic radii of all Ln(III) are 
nearly invariant, the chelating moiety is insensitive to which lanthanide is 
incorporated. Thus, any lanthanide metal may be  
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Figure 7. Conceptually, an ion mobility shift reagent either increases surface 
area with a small increase in mass, or increases mass with a small increase in 
surface area, respectively. These two possibilities are indicated by filled-circles 
(●) coupled to parachutes and anchors. Note that owing to the curvature of the 
peptide correlation, increasing surface area provides greater deviations from the 
fit at higher mass, while increasing mass (or density) provides greater deviations 
from the fit at lower mass.  
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Figure 8. An illustration of the structure of lanthanide-based relative quantitation 
reagents. The tag consists of a (i) metal chelation region, (ii) a linker region, and 
a (iii) region chemically selective for cysteine. 
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selected to encode a particular quantitative sample for up to 15 multiplexed 
analyses. The subsequent mass shift between differentially labeled samples can 
then be tuned by selection of the Ln(III), (e.g. La/Lu result in a mass difference of 
36 Da), which are sufficiently large to circumvent limitations for quantitation of 
larger peptides using isotopologue quantitation strategies. Ionization efficiency of 
different lanthanide metals can be expected to be nearly identical. Another 
advantage to using DOTA-Ln complexes is that it may be bound to a natural 
antibody (i.e., antibody 2d12.5) with no known analogues for selective purification 
of Ln-labeled peptides.75 
 Two common strategies using lanthanide-based labeling are termed 
element-coded affinity tagging (ECAT)58 and metal-coded affinity tagging 
(MeCAT).50 Note that in principle both strategies are specific to labeling at the 
sulfhydryl group of cysteine. Labeling for primary amines has been reported,55 
however Ln-labeling strategies have been reported for PTMs have not been 
reported to date. 
 Here, the potential for lanthanide-based labeling strategies as mobility 
shift reagents for ion mobility-mass spectrometry is explored. It is hypothesized 
that addition of Ln-chelated labels will shift labeled peptides out of IM-MS regions 
where signals are predicted to occur and that this approach will provide a rapid 
means for identifying a separated modified peptide for subsequent analysis. This 
approach will reduce extensive online separations prior to analysis and will 
circumvent processing of hundreds of thousands of spectra as is typical in LC-
MS analysis. Furthermore, incorporation of different metals provides both a shift 
in IM and the potential for relative quantitation information. This is significant, 
because in contrast with MS-only measurements, shifting signals away from 
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endogenous chemical noise improves the accuracy in peak area analysis for 
relative quantitation of protein expression profiles. 
In this work, I explore the potential for lanthanide-based labeling as an an 
alternative to isotopologue-based quantitation labels and as IM-MS mobility shift 
reagents for protein phosphorylation and glycosylation. Phosphorylated and 
glycosylated peptides and proteins may be modified by beta-elimination/Michael 
addition (BEMA) chemistry that converts the labile phosphorylation site to a 
functionality that is readily labeled.76-81 In the proposed strategy, phosphorylated 
and glycosylated peptides are converted into free thiols using BEMA chemistry 
and subsequently lanthanide-encoded via maleimide chemistry (Figure 9). 
Samples are then identified and quantitated. The potential use of this method to 
quantitate between glycosylation and phosphorylation is discussed in Chapter 6. 
 
1.4 Summary and Objectives 
 
For my dissertation research, I aimed to simplify phosphoproteomic 
characterization by achieving simultaneous site identification and quantitation 
using lanthanide-based tagging.  Characterization of this modification is often 
accomplished in separate experiments and involves determination of the site of 
modification, the stoichiometry, and in some cases, the elucidation of glycan 
stoichiometry when it temporally replaces phosphorylation. I explored the 
potential for lanthanide-based labeling to overcome challenges associated with 
quantitative labeling, and the potential for these labels to serve as mobility shift 
labels to facilitate the characterization for post-translationally modified peptides in 
ion mobility-mass spectrometry biomolecular conformation space. It was  
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Figure 9. Beta-elimination/Michael addition strategy for labeling phosphorylated 
and glycosylated peptides and proteins. i) The site of modification is beta-
eliminated in basic conditions, resulting in dehydroalanine or dehydroamino-
butyric acid for modified serine and threonine residues, respectively. ii) A dithiol 
linker is added by Michael addition chemistry. iii) A bifunctional ligand containing 
a lanthanide-chelating moiety and a thiol-selective moiety is added via maleimide 
chemistry. iv) Finally, the samples are encoded with lanthanide metals via 
chelation to the Ln-chelation region. 
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hypothesized that, when used as mobility shift reagents, lanthanide-based labels 
would provide enhanced separation of selected PTMs from the peptide 
correlation line in IM-MS, facilitating additional analysis such as quantitation and 
site identification. Furthermore, I also evaluated the utility of these labels in 
profiling glycan stoichiometry. The objectives, which are addressed in the 
following chapters, are outlined below: 
 
1. What are the advantages and challenges in performing traditional data-
dependent analysis for phosphorylation characterization when analyzing a 
previously uncharacterized, non-model phosphorylated protein? What areas of 
these routine analyses can be improved? Evaluation of this question is 
addressed in the work detailing phosphorylation site analysis on the cell 
migration signaling protein APPL1 in Chapter 2: Identification of phosphorylation 
sites within the signaling adaptor APPL1 by mass spectrometry.  
 
2. Can lanthanide-based labeling strategies be used to circumvent 
challenges associated with the quantitation and site identification of 
phosphorylated peptides and proteins?  These questions are explored in Chapter 
3: Simultaneous relative quantitation and site identification of phosphorylated 
peptides and proteins using lanthanide-based labeling for MALDI-TOFMS 
analysis.  
 
3. Can lanthanide-based labels effectively be used as mobility shift labels 
to separate phosphorylated peptides and proteins from their unphosphorylated 
counterparts in IM-MS conformation space? What advantages does this 
separation method provide over traditional phosphoproteomic characterization by 
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data-dependent MS analysis?  This is discussed in Chapter 4: Rapid separation, 
identification, and quantitation of phosphorylated peptides and proteins using 
lanthanide-based labels as ion mobility-mass spectrometry mobility shift labels. 
 
4. Can lanthanide-based mobility shift labeling be applied to probe the 
stoichiometry of phosphorylation vs. glycosylation? This is addressed in Chapter 
5: Enhanced separation and characterization of glycosylated peptides using 
lanthanide-based labeling and ion mobility-mass spectrometry. 
 
Completion of these experiments revealed that lanthanide-based labels 
have great utility in circumventing challenges associated with phoshoproteomic 
and glycomic characterization by reducing separation steps and reducing 
analysis time while provided the added advantages of more versatile 
quantitation. Overall, the strategies described in the following chapters present 
simplify phosphoproteomic and glycoproteomic analysis by providing 
simultaneous modification site identification and stoichiometric information while 
facilitating rapid separation when used as a mobility shift label in IM-MS 
conformation space. 
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CHAPTER 2 
 
 
 
IDENTIFICATION OF PHOSPHORYLATION SITES WITHIN THE SIGNALLING 
ADAPTOR APPL1 BY MASS SPECTROMETRY 
 
2.1 Introduction 
 
In this chapter, phosphopeptide site identification, one segment of full 
phosphoproteomic characterization, is performed using established data-
dependent tandem MS methods to evaluate the robustness and to identify the 
challenges associated with phosphoproteomics using data-dependent 
methodologies and the subsequent bioinformatics processing. Site identification 
is accomplished for the uncharacterized protein Adaptor protein containing a PH 
domain, PTB domain and Leucine zipper motif (APPL1), speculated to play a role 
in the signaling cascade that governs cell migration. APPL1 is a 709 amino acid 
membrane associated protein that has been reported to play a key role in the 
regulation of apoptosis, cell proliferation, cell survival, and vesicular trafficking.82, 
83 APPL1 is widely expressed and found in high levels in the heart, brain, ovary, 
pancreas, and skeletal muscle.82 Although a significant amount of interest has 
been generated in the interactions and function of APPL1, the complete 
phosphorylation profile of this protein has not been described. To date, 
phosphorylation of three residues, threonine 399, and serines 401 and 691, 
which were identified from global profiling studies,19, 84-87 are reported in protein 
databases, including Phosphosite, Proteinpedia/Human Protein Reference 
Database, and Expasy-SwissProt. 
APPL1 mediates its function through a series of domains, including an N-
terminal Bin-Amphiphysin-Rvs (BAR), a central Pleckstrin homology (PH), and a 
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C-terminal phospho-tyrosine binding domain (PTB).82, 88 Both the BAR and PH 
domains are involved in binding to cell membranes. The BAR domain is a 
dimerization motif associated with the sensing and/or induction of membrane 
curvature, while the PH domain binds to phosphoinositol lipids.89, 90 The BAR 
domain has also been shown to be critical in the ability of APPL1 to localize to 
endosomal structures.91 In APPL1, the BAR and PH domains are thought to act 
together as a functional unit forming an integrated, crescent-shaped, symmetrical 
dimer that mediates membrane interactions.92, 93 Moreover, the BAR and PH 
domains function together to create the binding sites for Rab5, which is a small 
GTPase involved in endosomal trafficking.93, 94 The C-terminal PTB domain of 
APPL1 has been shown to be critical in the ability of APPL1 to bind to several 
signaling molecules, including the serine/threonine kinase Akt, the neurotrophin 
receptor TrkA, the adiponectin receptors AdipoR1 and AdipoR2, Human Follicle-
Stimulating Hormone (FSHR), and the tumor suppressor DCC (deleted in 
colorectal cancer).82, 95-98  
In this study, phosphorylation sites were identified on APPL1 using both 
contemporary mass spectrometry (MS)-based methods, namely, by liquid 
chromatography (LC)-coupled to data-dependent tandem MS on both an LTQMS 
and LTQ-Orbitrap-MS. The bioinformatic algorithm SEQUEST was used to 
process the MS/MS data obtained in these phosphorylation mapping 
experiments. However, spectral assignments required manual validation of all 
identified phosphorylation site spectra. To obtain near-complete coverage of 
APPL1, multiple proteases were used in parallel phosphorylation site mapping 
experiments in the contemporary approaches. Proteolytic digestion with Glu C, 
trypsin, and chymotrypsin yielded sequence coverages of 44.6%, 88.3%, and 
81.1%, respectively, with a combined sequence coverage of APPL1 of greater 
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than 99%. A total of 13 phosphorylation sites were detected and four of these 
sites were found within APPL1 interacting domains, suggesting a potential 
regulatory role in APPL1 function. 
 
 
2.2 Experimental 
 
 
2.2.1 Reagents and plasmids  
FLAG M2-agarose affinity gel, FLAG peptide (DYKDDDDK), and mouse 
IgG agarose were purchased from Sigma (St. Louis, MO). Calyculin A was 
purchased from Calbiochem (San Diego, CA). Sodium vanadate was obtained 
from Fischer Scientific (Fairlawn, NJ). Peroxovanadate was prepared as 
previously described.99 FLAG-GFP plasmid was prepared by inserting the FLAG 
epitope sequence into pcDNA3 (Invitrogen, Carlsbad, CA) and cloning EGFP C1 
(Clonetech) into the vector at KpnI and BamHI sites. Human APPL1 (accession 
number GI: 124494248) was then cloned into the FLAG-GFP plasmid at EcoRI 
and the insertion, as well as orientation, of APPL1 was confirmed by sequencing. 
Proteases were purchased from Promega Corp. (Madison, WI), and all additional 
buffers were purchased in solid form from Sigma and prepared as stated. 
 
2.2.2 Protein expression  
Protein expression was performed in collaboration with Donna J. Webb 
and colleagues. Human embryonic kidney 293 (HEK-293) cells were maintained 
in Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen) supplemented with 
10% fetal bovine serum (FBS) (Hyclone) and penicillin/streptomycin (Invitrogen). 
HEK-293 cells were transfected with FLAG-GFP-APPL1 (12 μg per 150 mm dish) 
using Lipofectamine 2000 (Invitrogen). After 36 h, cells were incubated with 1 
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mM peroxovanadate and 50 nM calyculin A in DMEM with 10% FBS for 30 min 
and extracted with 25 mM Tris, 100 mM NaCl, and 0.1% NP-40 (pH 7.4). The 
lysates were precleared twice with mouse IgG-agarose for 1 h at 4 °C, and 
immunoprecipitated with FLAG-agarose (Sigma, St. Louis, MO) for 2 h at 4 °C. 
Samples were washed three times with 25 mM Tris and 100 mM NaCl, pH 7.4, 
and FLAG tagged APPL1 was eluted by incubation of the beads with 0.2 mg/mL 
FLAG peptide in 25 mM Tris, pH 7.4, for 1 h at 4 °C. Purified APPL1 protein was 
subjected to sodium dodecyl sulfate−polyacrylamide gel electrophoresis (SDS-
PAGE) followed by Coomassie blue staining. The concentration of APPL1 was 
quantified with a LI-COR Biosciences ODYSSEY Infrared Imaging System using 
bovine serum albumin (BSA) as a standard. 
 
2.2.3 Proteolytic digestion 
For MS analyses, APPL1 was separated into three equal aliquots and 
proteolytically digested by trypsin, chymotrypsin, and Glu C proteases, 
respectively. Briefly, proteolysis was performed by taking 2.6 μg of APPL1 (20 
μL) and diluting to 25 μL with 25 mM ammonium bicarbonate. Cysteine sulfhydryl 
groups were reduced by the addition of 1.5 μL of 45 mM dithiothreitol (DTT) for 
30 min at 55 °C followed by alkylation with 2.5 μL of 100 mM iodoacetamide for 
30 min at room temperature in the dark. Digestion was performed using 100 ng 
(1:40 enzyme/substrate, w/w) of trypsin gold (Promega, Madison, WI), 
chymotrypsin (Princeton Separations, Freehold, NJ), or endoproteinase Glu C 
(Calbiochem EMD Biosciences, Gibbstown, NJ) at 37 °C for 16, 4, or 6 h, 
respectively. Proteolysis was quenched by adding 1 μL of 88% formic acid. 
Subsequently, the digest was lyophilized and then reconstituted in 25 μL of 0.1% 
formic acid. 
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2.2.4 Western blot analysis  
Western blot analysis was performed in collaboration with Donna J. Webb 
and colleagues. Briefly, purified APPL1 protein was subjected to SDS-PAGE, 
and then transferred to a nitrocellulose membrane. The membrane was 
incubated with primary antibody against GFP (Invitrogen) or 4G10 (a kind gift 
from Steve Hanks, Vanderbilt University) at a dilution of 1 μg/mL. The membrane 
was then incubated with IR Dye 800 Conjugated Affinity Purified anti-Rabbit IgG 
or anti-Mouse IgG (Rockland) at a dilution of 0.1 μg/mL, and visualized using a 
LI-COR Biosciences ODYSSEY Infrared Imaging System. 
 
2.2.5 Linear ion trap and LTQ-Orbitrap MS  
LC-MS/MS analyses of APPL1 digests were performed using a linear ion 
trap mass spectrometer (LTQ, Thermo Electron, San Jose, CA) equipped with an 
autosampler (MicroAS, Thermo) and an HPLC pump (Surveyor, Thermo), and 
Xcalibur 2.0 SR2 instrument control. Ionization was performed by using 
nanospray in the positive ion mode. Spectra were obtained using data-dependent 
scanning tandem mass spectrometry in which one full MS scan, using a mass 
range of 400−2000 amu, was followed by up to 5 MS/MS scans of the most 
intense peaks at each time point in the HPLC separation. Incorporated into the 
method was data-dependent scanning for the neutral loss of phosphoric acid or 
phosphate (−98 m/z, −80 m/z), for which MS3 was performed. Dynamic exclusion 
was enabled to minimize redundant spectral acquisitions. High resolution data 
was collected using a similar strategy on a LTQ-Orbitrap mass spectrometer with 
the exception that the full MS scan was performed in the Orbitrap at 30,000 m/z 
 33 
resolution, rather than at unit mass resolution on the LTQMS. Further 
instrumental details are available in the supplementary information. 
 
2.2.6 Bioinformatic analysis  
Tandem MS/MS spectra acquired in LTQMS and LTQ-Orbitrap-MS 
experiments were identified using SEQUEST (University of Washington). MS/MS 
spectra were extracted from the raw data files into .dta format with spectra 
containing fewer than 25 peaks being excluded. Files labeled as singly charged 
were created if 90% of the total ion current occurred below the precursor ion, and 
all other spectra were processed as both doubly- and triply charged ions. 
Proteins were identified using the TurboSEQUEST version 27 (rev. 12) algorithm 
(Thermo Electron) and the IPI Human database version 3.33 (67837) sequences. 
Search parameters are outlined in the supplementary information. Manual 
verification was performed on all phosphorylation assignments having an Xcorr 
value above 1, 2, and 2.5 for charges +1, +2, and +3, respectively. Validation 
was performed as previously described.100 All spectra are hosted online at the 
address listed in the Appendices according to MIAPE standards.101 
 
 
2.3 Results and Discussion 
 
2.3.1 Comprehensive phosphorylation map of human APPL1 by LTQ- and 
Orbitrap-MS  
 
In this study, a comprehensive phosphorylation profile of APPL1 is 
described for the first time. To accomplish this, FLAG-GFP-APPL1 was 
expressed in HEK-293 cells by the Webb group and subsequently 
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immunoprecipitated for MS analysis according to the purification scheme outlined 
in Figure 10 a. A major band corresponding to the molecular mass of APPL1 was 
observed when the immunoprecipitate was subjected to SDS-PAGE and stained 
with Coomassie blue (Figure 10 b). The band was confirmed to be APPL1 by 
Western blot analysis (Figure 10 c). A total of 15 μg was expressed for this 
characterization and divided between multiple protease digests and instrumental 
platforms. Before subjecting APPL1 to MS analysis, we examined the 
phosphorylation state of this protein using 4G10 phosphotyrosine antibody. 
APPL1 was phosphorylated on tyrosine residues as determined by Western blot 
analysis with 4G10 (Figure 10 c). Several other minor bands were detected in the 
immunoprecipated samples, which could correspond to endogenous APPL1 or 
APPL1 binding proteins. However, insufficient peptide signal from MS analyses 
precluded positive protein identification of these additional minor bands. 
At least 13 (as discussed below) phosphorylation sites with 99.6% total 
amino acid sequence coverage were identified using multiple proteases, 
including trypsin, chymotrypsin, and Glu C, followed by LC-MS analyses using 
both an LTQMS instrument and an LTQ-Orbitrap instrument. Of these reported 
phosphorylation sites, three could not be located to a single amino acid (i.e., 
phosphorylation was determined to exist within a range of potential sites within a 
peptide). Table 2 shows each confirmed phosphorylation site assignment by 
sequence position using the LTQMS instrument. In total, 10 phosphorylation sites 
were identified by combining the data obtained for trypsin, chymotrypsin, and Glu 
C digests to obtain a sequence coverage of 95.3%. Of these 10 sites, only two 
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Figure 10. a) Schematic showing the generalized protocol used for purifying 
FLAG-tagged proteins. b) SDS-PAGE gel of immunoprecipiated FLAG-GFP-
APPL1 stained with Coomassie blue. Arrow points to purified FLAG-GFP-APPL1. 
c) Western blot with GFP-specific antibody (left panel) or phospho-tyrosine 
antibody (right panel). Left panel shows the purified protein is FLAG-GFP-APPL1 
(IB: GFP) and right panel shows that APPL1 is phosphorylated on tyrosine 
residues (IB: 4G10). 
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Table 2. Phosphorylation Sites within APPL1 Identified by LTQMS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. The “p” denotes pa. “pX” and/or boldface denotes phosphorylation; asterisk, “*” 
denotes carboxyamidomethylation. 
b. The symbol “‡” denotes sequence regions where single residue is known to be 
phosphorylated between the residues underlined. Phosphorylation on a specific 
residue on those regions cannot be confirmed. 
c. Represents digestion by multiple proteases. Trp, Chymo and Glu C 
correspond to the proteases, trypsin, chymotrypsin, and Glu C, respectively. 
 
peptides position Protease [M + H]
+
 (m/z) 
 
92
VIDELSSCHAVLSTQLADAMMFPITQFK
119 
 
 
‡ 
 
Trp 
 
3175.53 
 
376
QIpYLSENPEETAAR
389 
 
 
378Y 
 
Trp 
 
1700.75 
 
390
VNQSALEAVTPSPSFQQR
407 
 
 
‡ 
 
Trp 
 
2038.99 
 
456
DIIpSPVC*EDQPGQAKAF
472 
 
 
459S 
 
Chymo 
 
1954.93 
 
479
TNPFGESGGSTKpSETEDSILHQLFIVR
505 
 
 
491S 
 
Trp 
 
3029.46 
 
595
SESNLSSVCpYIFESNNEGEK
614 
 
 
604Y 
 
Trp 
 
2315.94 
 
669
LIAASSRPNQASSEGQFVVLpSSSQSEE 
SDLGEGGK
703 
 
 
689S 
 
Trp 
 
3631.71 
 
683
GQFVVLSSpSQSEESDLGEGGKKRE
706 
 
 
691S 
 
Glu C 
 
2633.24 
 
683
GQFVVLSSSQpSEEpSDLGEGGKKRE
706 
 
 
693S, 
696S 
 
Glu C 
 
2713.24 
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could not be located to a specific residue, that is, phosphorylation was confirmed 
to exist between amino acids 97−98 (SS) and 401−403 (SPS). Table 3 shows the 
confirmed phosphorylation sites using the LTQ-Orbitrap instrument. By 
combining the data obtained for Glu C, trypsin, and chymotrypsin digests, nine 
phosphorylation sites were identified with sequence coverage of 99.6%. Several 
of these phosphorylation sites were detected in multiple peptides derived from 
proteolytic miscleavages corresponding to the same site of phosphorylation. Of 
these nine sites, two could not be located to a specific residue, but were 
confirmed to exist between amino acids 401−403 (SPS) and 689−691 (SSS). 
Moreover, a number of potential phosphorylation sites were eliminated from 
consideration, as phosphorylation site rearrangement prevented a confident 
assignment. A comparison of the phosphorylation sites identified using the 
LTQMS and LTQ-Orbitrap yielded four unique sites by the former and three 
unique sites by the latter. We detected five phosphorylation sites, including 
serines 401/403, 459, 691, 693, and 696 by both methods. Interestingly, most of 
the phosphorylation sites we detected in human APPL1 are conserved in rat and 
mouse APPL1 (Table 4), raising the possibility that these sites serve a functional 
role.  
Two of the previously identified phosphorylation sites in APPL1, 401S and 
691S, were detected in our analysis while one additional site, 399T, was not 
definitively assigned. Phosphorylation of 401S was initially identified in epithelial 
carcinoma (HeLa) cells as part of a large-scale characterization of nuclear 
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Table 3. Phosphorylation Sites Identified within APPL1 by LTQ-Orbitrap-MS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. The “p” denotes phosphorylation; asterisk, “*” denotes 
carboxyamidomethylation. 
b. The symbol “‡” denotes sequence regions where single residue is known to be 
phosphorylated between the residues underlined. Phosphorylation on specific 
residue cannot be confirmed. 
c. Represents digestion by multiple proteases. Trp, Chymo and Glu C 
correspond to the proteases, trypsin, chymotrypsin, and Glu C, respectively. 
 
Peptide 
 
position 
 
protease 
 
[M+ H]
+ 
(m/z) 
 
Mass error 
 (ppm) 
 
367
IC*TINNIpSKQIYLSENPEETAARVNQSAL
395
 
 
374S 
 
Chymo 
 
3356.66 
 
3.30 
 
390
VNQSALEAVTPSPSFQQR
407 
 
‡ 
 
Trp 
 
2038.96 
 
−2.45 
 
415
AGQSRPPTARTSpSSGSLGSESTNL
438
 
 
427S 
 
Chymo 
 
2428.11 
 
−0.62 
 
418
SRPPTARTSpSSGpSLGSESTNL
438
 
 
427S, 430S 
 
Chymo 
 
2251.96 
 
0.93 
 
418
SRPPTARTSpSSGSLGSESTNL
438 
 
427S 
 
Chymo 
 
2171.99 
 
1.10 
 
451
TPIQFDIIpSPVC*EDQPGQAKAF
472 
 
459S 
 
Chymo 
 
2541.17 
 
0.08 
 
456
DIIpSPVC*EDQPGQAKAF
472 
 
459S 
 
Chymo 
 
1954.91 
 
−1.64 
 
457
IIpSPVC*EDQPGQAKAF
472 
 
459S 
 
Chymo 
 
1839.86 
 
0.33 
 
669
LIAASSRPNQASSEGQFVVLSSSQSEES 
DLGEGGK
703 
 
‡ 
 
Trp 
 
3631.68 
 
−3.71 
 
683
GQFVVLSSpSQSEESDLGEGGKKRE
706 
 
691S 
 
Glu C 
 
2633.21 
 
−0.46 
 
683
GQFVVLSSSQpSEESDLGEGGKKRESE
708 
 
693S 
 
Glu C 
 
2849.28 
 
5.58 
 
683
GQFVVLSSSQpSEESDLGEGGKKRE
706 
 
693S 
 
Glu C 
 
2633.21 
 
−0.57 
 
686
VVLSSpSQSEESDLGEGGKKRE
706 
 
691S 
 
Glu C 
 
2301.06 
 
0.13 
 
686
VVLSSSQpSEEpSDLGEGGKKRE
706 
 
693S, 696S 
 
Glu C 
 
2381.03 
 
−1.89 
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Table 4. Comparison of Peptide Sequence Surrounding Identified 
Phosphorylation Sites in APPL1 
 
 
 
 
a. The symbol “‡” denotes sequence regions where single residue is known to be 
phosphorylated between the residues underlined. Phosphorylation on specific 
residue on those regions cannot be confirmed. 
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phosphoproteins and in an analysis of protein phosphorylation in developing 
mice brains.86, 87 This site was subsequently shown to be phosphorylated in HeLa 
cells in two additional studies.84, 85 Phosphorylation of 691S was detected in 
HEK-293 cells in response to DNA damage using ionizing radiation.19 We also 
identified phosphorylation of this site in HEK 293 cells under physiological 
conditions. Phosphorylation at 399T was identified in a global profiling study,84 
but a positive identification could not be definitively made in our experiments. Our 
spectra potentially suggested phosphorylation at 399T, but in these spectra, this 
site was not the highest confidence assignment. Furthermore, the previous study 
examined protein phosphorylation during mitosis using HeLa cells arrested in the 
mitotic phase of the cell cycle while our analysis was performed in HEK-293 cells 
under conditions in which they were progressing through the cell cycle. Thus, it is 
possible that phosphorylation of this site is transient if it is regulated by cell cycle 
progression and difficult to detect. 
 
2.3.2 Phosphorylation sites within APPL1 functional domains  
The confirmed phosphorylation sites obtained on both instruments are 
shown in Figure 11a. Of the confirmed sites, four were found in APPL1 
interacting domains. Namely, serines 97/98 were located in the BAR domain, 
raising the possibility that phosphorylation at these sites could disrupt APPL1 
dimerization as well as endosomal localization. Interestingly, as shown in the 
crystal structure of the BAR and PH domains, serines 97/98 are located on the 
concave surface of the BAR domain, which is thought to interact with 
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Figure 11. a) Phosphorylation sites identified in APPL1, using LTQMS and LTQ-
Orbitrap MS. Underlined sites indicate that one phosphorylation is known to exist 
within the region. b) A schematic of APPL1 is shown with identified 
phosphorylation sites relative to the position of APPL1 domains. Interacting 
regions within APPL1 for several proteins and receptors are also indicated. 
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 membranes (Figure 11b).92, 102 
Therefore, phosphorylation at this site could potentially regulate 
membrane interactions. Serine 374 and tyrosine 378 are clustered near the edge 
of the PH domain (Figure 11b), suggesting a potential link to APPL1 localization. 
Collectively, these sites in the BAR and PH domains may contribute to altered 
APPL1 binding to Rab5, since together these domains are important for this 
interaction. Finally, tyrosine 604 was found in the PTB domain, which is typically 
involved in protein−protein interactions, and phosphorylation in this domain may 
regulate the ability of APPL1 to bind to its interacting protein partners. 
Interestingly, a significant number of identified phosphorylation sites are found 
outside of known domains. Even though these sites are outside described 
domains, it does not imply a lack of functional significance. These sites may have 
importance in regulating the structure and molecular interactions of APPL1. 
 
2.3.3 Advantages and challenges to contemporary phosphoproteomic 
methodologies  
 
Figures 12 and 13 demonstrate the necessity of manual verification and 
challenges associated with site identification using bioinformatics analyses. For 
example, the peptide in Figure 12, GQFVVLSSSQpSEESDLGEGGKKRE, was 
identified correctly, but because the incorrect peak was used as the monoisotopic 
peak, the mass error of the precursor ion (−381 ppm) was outside of the 
acceptable range (−5 to 5 ppm). Conversely, an example of an erroneous 
SEQUEST assignment is shown in Figure 13. Although b and y ion coverage 
bracketing the phosphorylation site is sufficient for a high X-corr value and high 
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Figure 12. Tandem MS/MS spectrum acquired using an LTQ-Orbitrap illustrates 
peak validation for accurate SEQUEST assignments. Inset illustrates a situation 
whereby the instrument selected the peak at 878.7426 as the monoisotopic peak 
resulting in erroneous mass accuracy (−381 ppm). Manual validation of the data 
correctly assigns the accurate monoisotopic peak at 878.4084 resulting in a 
mass accuracy for the parent species of 0.56 ppm. 
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Figure 13. Tandem MS/MS spectrum of a phosphorylation site incorrectly 
assigned by SEQUEST having the highest Xcorr value of 2.19. SEQUEST 
assignments report 15% b-ion sequence coverage and 55% y-ion coverage from 
the y5 ion to the y16 ion. Of the eight most abundant peaks in the spectrum, six 
ions, indicated by an asterisk, correspond to neither b nor y ions, or to 
characteristic neutral losses. Manual verification was performed to detect such 
errors in the bioinformatic assignments. Additionally, the b and y ion coverage 
fails to bracket the suggested sites of phosphorylation, namely, tyrosine 378 and 
serine 380.  
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sequence coverage confidence, high abundance peaks do not correspond to b 
and y ions or their respective neutral losses. Collectively, these examples and 
ambiguity arising from gas-phase rearrangement illustrate the continuing need to 
validate sequencing data in phosphorylation site mapping experiments.24, 25  
Phosphorylation site validation is challenging for a number of reasons, 
including low stoichiometries and co-elution of these low abundant peptides with 
more abundant and easily ionized peptides. Furthermore, though the objective of 
phosphorylation site discovery was met for characterization of APPL1, significant 
laborious manual interpretation, validation, and confirmation were needed. 
Moreover, due to the challenges associated with site discovery, quantitative 
information is typically not gained in the same experiment, requiring additional 
time and resources to complete a full characterization. Thus the need for a more 
selective and rapid strategy for online separation of phosphorylated peptides to 
facilitate protein phosphorylation characterization is evident.  
 
 
 
2.4 Conclusion 
 
 
Emerging data indicate an important role for APPL1 in regulating various 
cellular processes, such as cell proliferation, apoptosis, and survival, which 
points to a need to gain insight in to the regulation of this protein.  Since 
phosphorylation is an important regulatory mechanism, we generated a 
comprehensive map of phosphorylation sites within APPL1. We 
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detected 13 phosphorylation sites within APPL1, with four of these being 
identified in functional domains. These sites have potential implications in 
regulating APPL1 function and interactions, which represents an important 
avenue for future study. A number of challenges exist in determining the sites of 
modification for an uncharacterized protein, such as coelution, reversible 
phosphorylation, phosphorylation site rearrangement, and the impracticality of 
performing quantitation in the same experiment. Lanthanide-based 
phosphorylation-specific labeling is introduced in the following chapters, which 
circumvents many of the challenges encountered in traditional data-dependent 
protein phosphorylation characterization. 
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CHAPTER 3 
 
SIMULTANEOUS RELATIVE QUANTITATION AND SITE IDENTIFICATION OF 
PHOSPHORYLATED PEPTIDES AND PROTEINS USING LANTHANIDE-
BASED LABELING FOR MALDI-TOFMS ANALYSIS 
 
3.1 Introduction 
 
As outlined in Chapter 2, there is a demonstrated need for a 
comprehensive protein phosphorylation characterization strategy whereby 
phosphorylated peptides are selectively separated from their unphosphorylated 
counterparts and sites of phosphorylation are identified and quantitated in the 
same experiment. In this chapter, challenges associated with phosphopeptide 
quantitation and site identification are addressed. 
Current mass spectrometry based strategies for quantifying sites of 
protein phosphorylation include stable isotope techniques that take advantage of 
mass shifts provided by isotopologues. Challenges associated with isotopologue 
quantitative labeling include isotopic overlap of modified peptides of higher mass. 
Lanthanide-based labeling strategies allow for greater mass separation than 
current isotope-based strategies due to incorporation of lanthanide metals of 
greater mass differences (2-36 Da), but have not been previously demonstrated 
for selective phosphopeptide quantitation. In this chapter, we demonstrate a 
strategy for site identification and relative quantitation of phosphorylated peptides 
and proteins using a phosphorylation-specific lanthanide-based labeling strategy. 
Because the chemistry is specific for phosphorylation, we term this labeling 
strategy Phosphopeptide-Element Coded Affinity Tagging, or PhECAT. In this 
benchmarking report, phosphorylated peptides are selectively modified at the 
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phosphorylation site via beta-elimination/anionic thiol Michael addition chemistry. 
In this manner, phosphorylated peptides are converted to cysteine-like residues, 
which then readily react with cysteine-specific labels. This lanthanide-chelating 
label is added via maleimide chemistry and selected lanthanide metals are 
subsequently chelated to a macrocycle moiety. Because these labels replace a 
labile phosphate with a covalent moiety, phosphorylation site rearrangement can 
be avoided and phosphorylation site identification is less challenging. To 
demonstrate this technique, model phosphorylated peptides and those derived 
through proteolytic digestion of a model phosphorylated protein are quantitated in 
1:5, 1:1, and 5:1 molar ratios with comparable sensitivity and relative error 
(~10%) to current isotopologue-based relative quantitation strategies. Moreover, 
the site of phosphorylation for bovine beta-casein fragment 48-63 was identified 
without any site rearrangement of the label evident. 
 
3.2 Experimental 
 
3.2.1 Materials and preparation 
Model phosphorylated peptides and proteins were investigated for proof-
of-concept experiments. Phosphorylated peptide samples having the sequence 
WAGGDApSGE (m/z 928.8) were purchased from American Peptide Company 
(Sunnyvale, CA) and used without further purification. Phosphorylated peptide 
samples having the sequence KKKKKRFpSFKKpSFKLSGFpSFKKNKK was 
purchased from Anaspec (Freemont, CA). Phosphorylated protein bovine β-
casein was purchased from Sigma-Aldrich (St. Louis, MO). Trypsin was 
purchased from Promega Corp. (Madison, WI). C-18 spin columns were 
purchased from Pierce (Rockford, IL). 1,4,7,10-Tetraazacyclododecane- 1,4,7- 
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tris- acetic acid-1-maleimidoethylacetamide, or Maleimido-mono-amide-DOTA 
was purchased from Macrocyclics (Dallas, TX) and dissolved in DMSO. 1,2-
ethanedithiol (EDT) was purchased from Fluka (St. Gallen, Switzerland). 2,5-
dihydroxybenzoic acid (DHB) was purchased from Sigma and dissolved in 50% 
methanol to a final concentration of 30 mg/mL. Lanthanide metals were 
purchased from Strem Chemicals (Newburyport, MA) and dissolved in distilled 
deionized water (18 MΩ cm-1) to a final concentration of 25 mg/mL. 
Dimethylsulfoxide, acetonitrile, and ethanol were purchased from Sigma. 
 
3.2.2 Digestion of phosphorylated proteins 
Proteins were dissolved in ammonium bicarbonate buffer (pH 8.0) and 
thermally denatured at 90˚C for 20 minutes and quenched at -20˚C.34 Cysteine-
cysteine bonds and free cysteines were reduced with dithiothreitol (final molarity 
of 4 mM) and alkylated with iodoacetamide (final molarity of 20 mM). Proteins 
were subsequently digested with trypsin in a 1:40 weight to weight ratio for 16-20 
hours at room temperature and purified by C-18 spin columns (Pierce, Rockford, 
IL) prior to derivatization. 
 
3.2.3 Selective derivatization of phosphorylated peptides and proteins 
Model and tryptic peptides were subjected to a beta-elimination (Figure 14(i)) 
and anionic thiol Michael addition reaction (Figure 14(ii)) resulting in the selective 
elimination of phosphoric acid followed by addition of ethanedithiol. In this 
reaction, each sample was derivatized in a reaction mixture containing 2.5 mM 
EDTA, 0.2 M ethanedithiol, 0.5 M NaOH, 1.5 M acetonitrile, 1.5 M ethanol, 5 M 
DMSO, and water for 1-2 hrs under nitrogen at 55ºC in a manner similar to  
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Figure 14. Reaction scheme for PhECAT (i) Phosphoric acid is removed via 
Beta-elimination in basic conditions (ii) Ethanedithiol is subsequently added to 
the conjugated diene via anionic thiol Michael addition (iii) The remaining free 
thiol is attached to the macrocylic via maleimide chemistry (iv)Finally, lanthanides 
are chelated to the macrocyclic portion of the tag. 
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reaction conditions described previously.79, 103, 104 This resulted in conversion of 
phosphorylated serine and threonine into dehydroalanine or dehydroaminobutyric 
acid, respectively. The samples were then neutralized and purified by gel 
filtration (Sephadex G-10, Sigma) and reaction completion was confirmed by 
MALDI-TOFMS. Subsequently, the thiolated peptides were labeled with a 10-fold 
excess of maleimido-DOTA (Figure 14(iii)) in a mixture containing acetate buffer 
(pH 5.5) and DMSO in 1:1 ratio (v/v), resulting in a covalent bond between the 
free sulfhydryl group and the maleimide portion of the lanthanide-based tag. 
Finally, selected lanthanide metals were chelated to the maleimide portion of the 
tag by adding a 100-fold molar excess of metal to peptide and heating to 80ºC for 
45 minutes (Figure 14(iv)). Differentially labeled samples were then combined 
and purified by C-18 spin columns and analyzed using MALDI-TOFMS.  
 
3.2.4 Instrumentation and data analysis 
Spectra were obtained using a Voyager-DE STR (Applied Biosystems, 
Inc.) MALDI-TOFMS instrument in the delayed extraction (DE), positive, reflector 
mode. MALDI matrix preparation consisted of 2,5-dihydroxybenzoic acid (DHB) 
in 50% methanol. The samples were spotted using the dried-droplet method. 
Data analysis was performed using Data Explorer software version 4.3 (Applied 
Biosystems, Foster City, CA). At least 3 trials were analyzed for each relative 
quantitation experiment. Spectra were acquired by rastering the MALDI laser at 
random over the entire matrix spot. Relative molar amounts were calculated by 
dividing the relative peak area of the derivatized state 1 by the relative peak area 
of derivatized state 2. 
Fragmentation of the labeled phosphorylated peptides and proteins were 
performed on a Waters Synapt© HDMS (Waters, Inc. Milford, MA) instrument 
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with MALDI as the ionization source. Data analysis was performed using 
MassLynx© software (Waters). Six Dalton doublets (the anticipated mass shift 
afforded by the Tb and Ho metals selected for labeling) were manually selected 
for fragmentation and analyzed for potential phosphorylation sites in order to 
assess the stability of the lanthanide label. 
 
3.3 Results and Discussion 
 
While methods for MS-based relative quantitation of peptides and 
proteins using chemical modification methodologies have been described in 
detail, there are few reports of label-based relative quantitation strategies that are 
selective for phosphorylation that provide sufficient mass shift for large peptides. 
The available methods have enormous utility in quantitation of phosphorylated 
peptides and proteins, but suffer from three important limitations – (i) they are 
limited to low mass peptides due to spectral congestion caused by an overlap of 
increasingly larger isotopic envelopes, (ii) they are limited in affinity purification to 
avidin/streptavidin, which can pull down non-specific peptides as well as labeled 
peptides, and (iii) the number of simultaneously analyzed peptides is limited 
(simultaneous quantitation of 2-8 samples are commonly reported).  
Here, we report a multiplexed relative quantitation strategy that addresses 
these limitations with the added utility of site assignment using PhECAT. 
Subsequent to the reduction and alkylation of free thiol groups of cysteine, 
phosphoryl groups on serine and threonine are selectively removed in the form of 
phosphoric acid via beta-elimination chemistry perfomed under basic conditions, 
followed by an addition of ethanedithiol via anionic thiol Michael addition 
chemistry, resulting in a conversion of a phosphate moiety to a free thiol. Thiol-
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selective chemistry is performed on the remaining free thiol to attach the 
PhECAT label to the modified phosphorylated peptide. When the relative 
phosphorylation concentrations of different cell states are compared, these labels 
can be chelated to any lanthanide metal, which provides the necessary mass 
shift for quantitative comparisons. Furthermore, the number of samples that may 
be quantitated is only limited by the number of available isotopically enriched 
lanthanide metals (simultaneous quantitation of 2-15 samples is possible). A 
schematic diagram of this strategy is illustrated in Figure 15.  Moreover, 
antibodies selective for lanthanide-DOTA complexes with no natural analogs 
have been reported as an alternative to biotin/streptavidin purification.75 
 
3.3.1 Relative quantitation of phosphorylated peptides and Proteins using 
PhECAT 
 
Varying molar amounts of phosphorylated peptides and proteins were 
derivatized in this manner and quantitated in proof-of-concept experiments. An 
example of a typical relative quantitation experiment is illustrated in Figure 16. In 
this example, the peptide WAGGDApSGE was differentially tagged with Tb and 
Ho labels in a 1 to 5 molar mixture, respectively. The calculated peak area ratio 
was 0.199, exhibiting a 0.5% experimental error from the known relative molar 
amounts. Molar ratios of 1:5, 1:1, and 5:1 were demonstrated with Tb and Ho-
chelated tags, purified, and spotted with matrix before being analyzed by MALDI-
MS. Table 5 depicts the results from varying the molar ratios of the 
phosphorylated peptides. 
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Figure 15. Labeling of multiple sample states with DOTA tags coordinated to 
different lanthanide metals. In this illustrative figure, a 5:1:2.5 may be 
differentially coded with different lanthanide metals. Thus, the number of 
simultaneous samples that can be combined for relative quantitation is limited 
only be the number of different metals (or metal isotopes) that are used. 
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Figure 16. The phosphorylated peptide having the sequence WAGGDApSGE 
was derivatized in the manner previously described. The full scan m/z is shown. 
Although there are several minor peaks associated with excess labeling reagent, 
the labeled peptide is the dominant peak in this spectrum. (Inset) Relative 
quantitation between Tb and Ho labeled peptides having a molar ratio of 1:5, 
respectively. The measured peak areas were 1898.93 and 9529.45 for Tb and 
Ho, respectively, resulting in a calculated molar ratio of 0.199.  
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Table 5. Relative Quantitation of phosphorylated peptides and proteins using 
lanthanide-chelating tags in MALDI-TOFMS. 
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
___________________________________________________________________ 
a. "p" denotes phosphorylation, sequence positions bracket the sequence for tryptic peptides 
b. Phosphorylated peptides purchased and used without additional purification. 
c. Monoisotopic masses for unlabeled phosphorylated peptides. 
d. Calculated monoisotopic peaks for labeled phosphorylated peptides. “*”denotes PhECAT 
labeling, “‡“ denotes relative quantitation calculations where the peak having the highest relative 
abundance was selected for peak area quantitation rather than the monoisotopic peaks. This is 
primarily due to the fact that, here, the monoisotopic peak has the lowest intensity. In this case, the 
peaks of highest intensity (2741.1, 2747.1) were selected. 
e. Percent errors are reported according to the following formula: 
(Average Peak Area Ratio – Anticipated Peak Area Ratio) / Anticipated Peak Area Ratio 
Peptide Sequence
a,b 
 
 
 
[M+H]
+ c 
 
 
 
 
[M*+H]
+
 
Tb, Ho
d
 
 
 
 
 
Molar ratio of 
derivatized 
peptides 
 
 
 
Measured 
molar ratio of 
peptides 
derivatized with 
Ho-tag and Tb-
tag (average # 
of trials) 
 
 
Relative 
Percent 
Error
e
 
 
 
WAGGDApSGE from delta 
sleep-inducing peptide 
 
 
928.8 
 
 
1607.2, 
1613.2 
 
 
 
5.0: 1.0 
(Tb:Ho) 
 
 
 
 
5.408 (3) 
 
 
 
 
+8.2 
WAGGDApSGE from delta 
sleep-inducing peptide 
 
 
928.8 
 
 
1607.2, 
1613.2 
 
1.0: 1.0 
(Tb:Ho) 
 
 
1.029 (4) 
 
+2.9 
WAGGDApSGE from delta 
sleep-inducing peptide 
 
 
928.8 
 
 
1607.2, 
1613.2 
 
 
1.0: 5.0 
(Tb:Ho) 
 
 
0.207 (5) 
 
+3.5 
48 FQpSEEQQQTEDELQDK 63 
from bovine B-casein 
 
2060.7 
 
 
 
2739.1
‡
, 
2745.1
‡
 
 
1.0: 5.0 
(Ho:Tb) 
 
 
 
0.217 (3) 
 
 
+8.4 
48 FQpSEEQQQTEDELQDK 63 
from bovine B-casein 
 
2060.7 
 
 
 
2739.1
‡
,
 
 
2745.1
‡
 
 
1.0: 1.0 
(Tb:Ho) 
 
 
 
1.089 (3) 
 
 
+8.9 
48 FQpSEEQQQTEDELQDK 63 
from bovine B-casein 
 
2060.7 
 
 
 
2739.1
‡
, 
2745.1
‡
 
 
1.0: 5.0 
(Tb:Ho) 
 
 
 
0.226 (3) 
 
 
+12.8 
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For the peptide WAGGDApSGE, the average error associated with three 
separate quantitation experiments (i.e., the average of errors associated with 
three experiments profiling three separate molar ratios) was calculated to be 
8.5%. For the protein bovine beta-casein the tryptic peptide 
FQpSEEQQQTEDELQDK was quantitated using the same range of molar ratios. 
A typical quantitation experiment is shown in Figure 17. In this example, beta-
casein was derivatized in a 1 to 5 molar ratio with Tb- and Ho-chelated labels, 
respectively. The measured molar ratio of Tb-labeled sample to Ho-labeled 
sample was 0.203, which has a relative error of 1.67%. The average error 
associated with three separate quantitation experiments was calculated as 6.4%. 
These errors are comparable to current isotope coded affinity labels, with the 
added advantages larger shifts in mass doublets afford, i.e. 2-36 Da for single 
phosphorylation sites, allowing for quantitation of high- mass peptides without 
peak convolution from adjacent isotopes. For multiple phosphorylation sites, the 
mass difference scales with the number of the labels, providing even greater 
separation. These results also indicate that this method has error competitive to 
current quantitative phosphoproteomic methods and should have utility in relative 
quantitative studies of complex biological samples. The utility of lanthanide ions 
as luminescent chromophores in LC separations have been well described, and 
may increase confidence in phosphorylation site labeling at an additional stage of 
analysis.41 Moreover, the addition of a macrocycle may shift LC elution times for 
phosphorylated peptides, which may assist in separation of closely spaced 
phosphorylated and non-phosphorylated species.  
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Figure 17. Bovine beta-casein was derivatized in the manner previously 
described. The full m/z is shown. In addition to standard digest peaks (tryptic 
beta-casein peptides), the labeled phosphorylated peptide having the sequence 
FQpSEEQQQTEDELQDK is observed, and is one of the dominant peaks in this 
spectrum. (Inset) Relative quantitation between a 1:5 molar mixture of Tb and Ho 
labeled beta-casein. The measured peak areas are 455.77 and 2241.51 for Tb 
and Ho, respectively, resulting in a calculated molar ratio of 0.2039.  
 
 59 
3.3.2 Fragmentation and phosphorylation site identification 
 
PhECAT labeled peptides were examined by tandem MS to evaluate the 
utility of these tags for phosphorylation site-identification. An example of a typical 
tandem spectrum is shown in Figure 18. The expected b/y series ions were 
observed, including full b ion coverage from the b3 to the b15 ion, all labeled and 
several unlabeled y ions including y9, y11, and y13-15, and several labeled water 
loss ions with little evidence for fragmentation of the label. It should be noted that 
all fragment ions covalently bound to the PhECAT label exhibit higher intensities 
than unlabeled fragment ions. The stability of this label enables predictable mass 
shifts of anticipated b and y ions which gives an indication of the site of 
modification previously phosphorylated. Furthermore, because this tag is not 
labile and does not show phosphorylation site rearrangement (as is the case with 
phosphoric acid and phosphate plus water loss), it has an added advantage of 
more confident phosphorylation site assignment. 
 
3.3.3 Challenges in quantitation of phosphorylated threonine. 
 Beta-elimination/Michael addition of phosphorylated threonine has been 
reported to be more challenging due to steric hinderance caused by the 
methylated alpha carbon.51 The PhECAT labeling strategy was applied toward 
two peptides containing phosphorylated threonine. The peptide containing the 
sequence KKALRRQEpTVDAL was incubated for 4 and 6 hours using the 
reaction conditions described above. Although beta-elimination reacted to 
completion, Michael addition was not achieved to completion. Figure 19 
illustrates the minimal impact of increased incubation  
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Figure 18. i) Structure of a terbium-labeled tryptic beta-casein phosphorylated 
peptide having the sequence FQpSEEQQQTEDELQDK. An asterisk indicates 
that the ion is covalently modified with the PhECAT. Observed fragmentation 
peaks are indicated on the peptide structure. Fragmentation coverage of 86.7% 
and 33.3% of the labeled peptide was observed for b and y ions, respectively. 
Five additional y ions were located, but were not reported due to inadequate S/N. 
Fragmentation coverage of b and y water loss ions is provided in the appendices. 
Importantly, all of the anticipated ions corresponding to labeled positions are 
observed, demonstrating the utility of this label for phosphopeptide site 
identification as well as relative quantitation. ii) Fragmentation spectrum of 
labeled FQpSEEQQQTEDELQDK. Fragment ions are labeled. It should also be 
noted that labeled fragment ion species exhibit greater intensity than non-labeled 
fragment ion species. Spectral peaks from 500 m/z to 2600 m/z were intensified 
10x to increase visibility of b and y spectral assignments. 
 61 
 
 
Figure 19. a) Completion of the beta-elimination/Michael addition reaction for 
KKALRRQEpTVDAL with a 4-hour incubation time at 50°C. b) Completion of the 
beta-elimination/Michael addition reaction for KKALRRQEpTVDAL after a 6-hour 
incubation time at 50°C. Incubation time does not increase the Michael addition 
product.  
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time on the Michael addition product. The peptide containing the sequence 
LKRApTLG was incubated for 24 hours, resulting in a marginal increase of 
Michael addition product (Figure 20). These results are consistent with a report 
from Gross and colleagues,51 which describes minimal Michael addition product 
increase with respect to increased incubation time (in the Supplementary 
Material of Gross, et al).  To circumvent this, Gross and colleagues included an 
additional separation step between beta-elimination and Michael addition, 
transforming the chemistry from a one-pot to a two-pot process.  It can be 
reasoned that even though phosphorylated threonine generates a low yield of 
labeled product, the relative quantitation of phosphorylated threonine is still 
possible to within acceptable error (<10%), and percent yields are expected to 
remain consistent between samples with consistent labeling technique.  
 
3.3.4 The role of arginine in phosphorylation site stabilization 
 
Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) peptide 
fragment 151-175 (KKKKKRFpSFKKpSFKLSGFpSFKKNKK) was derivatized in 
the manner above and beta-elimination/Michael addition was checked for 
completeness. Although this peptide contains three phosphorylated serine 
residues, beta-elimination/Michael addition was only observed for one 
phosphorylated residue (Figure 21). This is consistent with observations made by 
Woods and colleagues,105-107 where observations of non-covalent complexes of 
phosphorylated residues and quarternary amines (i.e., arginines) were reported. 
It is speculated that the two unlabeled phosphorylation sites form a strong 
complex with the excess of quarternary amines in the peptide. Woods, et al. 
suggests the addition of aromatic compounds (e.g., hexachlorobenzene) to  
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Figure 20.  Completion of the beta-elimination/Michael addition reaction for 
LKRApTLG with a 24-hour incubation time at 50°C. Significant increases in 
incubation time do not affect the yield of the Michael addition product. 
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Figure 21. Spectra profiling the completion of the beta-elimination/Michael 
addition reaction for the triply phosphorylated MARCKS peptide. One 
phosphorylated residue is labeled, indicating a near-covalent cation pi-interaction 
of the phosphorylated residues and the guanidinium group of the arginine 
residues in the peptide sequence.105, 106 Moreover, the Michael addition reaction 
is not quantitative, as indicated by the relative low abundance with respect to the 
beta-eliminated peptide. Additional fragmentation peaks corresponding to b and y 
ions from in-source fragmentation are indicated. 
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solution to compete with electrostatic interactions between arginines and 
phosphorylation sites. To circumvent unanticipated arginine-phosphorylation 
interactions of peptides, peptides that contain arginine should be treated with 
aromatic compounds prior to derivatization to ensure that the phosphorylation 
site is available for modification. 
The solvent-accessible phosphorylated residue on MARCKS was 
quantitated using Tb- and Ho-chelated lanthanide labels. A typical quantitation 
experiment is shown in Figure 22. In this experiment, a 1 to 3 (Tb to Ho, 
respectively) molar mixture was quantitated. For peptides above 3000 Da, a 6-Da 
shift was not adequate to resolve the differentially labeled peaks, illustrating the 
need for labels to provide larger mass shifts and the utility of lanthanide- based 
labels to design quantitative strategies using mass shifts that support the mass of 
the peptides of interest. 
 
3.4 Conclusions 
 
Current methods of MS-based protein quantitation primarily focus on 
quantifying relative expression profiles through labeling non-post-translationally 
modified peptides. This offers a limited view of the biological activity of cells, 
because many biological functions are dependent on temporal protein 
modifications, specifically, protein phosphorylation. The available methods for 
phosphoprotein quantitation provide good specificity for the site of 
phosphorylation, however, they have limited applicability for peptides of 
increasing mass. In this work, we have demonstrated the utility of PhECAT for 
relative quantitation of phosphorylated peptides using  
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Figure 22. Spectra illustrating the lanthanide-based labeling (PhECAT strategy) 
of the uncomplexed phosphorylated residue in the MARCKS peptide. Note that 
the % intensity of the labeled species is significantly greater than the intensity of 
the Michael addition product in Figure 19, indicating that the lanthanide-based 
label improves ionization and detection, which is an added advantage in 
phosphoproteomic characterization. (inset) Relative quantitation between Tb-and 
Ho-labeled species aquired on a DE-Voyager MALDI-TOFMS. Here, a 6-Da 
mass shift was not sufficient to resolve labeled peptides of masses greater than 
3000 m/z on a typical MALDI-TOFMS, illustrating the need for larger mass shifts 
provided by lanthanide encoded labeling.  
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MALDI-MS. We propose that this method may circumvent challenges 
encountered by label-free quantitation, such as gas-phase phosphorylation site 
rearrangement, and has potential utility in quantitating the relative expression of 
protein phosphorylation with the additional utility of providing a confident 
phosphorylation site assignment.   
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CHAPTER 4 
 
 
 
RAPID SEPARATION, IDENTIFICATION, AND QUANTITATION OF 
PHOSPHORYLATED PEPTIDES AND PROTEINS USING LANTHANIDE-
BASED LABELS AS ION MOBILITY-MASS SPECTROMETRY MOBILITY 
SHIFT LABELS 
 
 
4.1 Introduction 
 
The stoichiometry of protein phosphorylation regulates numerous 
biological processes. As addressed in the previous chapter, current mass 
spectrometry-based strategies for quantifying sites of protein phosphorylation 
include isotopologue strategies that limit the size of the peptide quantitated and 
require high resolution MS instruments, which are less common and costly to 
operate. Lanthanide-based labeling strategies allow for greater mass separation 
than current isotope-based strategies due to incorporation of lanthanide metals of 
greater mass differences (2-36 Da), and may be used as mobility shift “anchors” 
for rapid visualization in ion mobility-mass spectrometry (IM-MS) analysis. 
Moreover, lanthanide-based labels may provide mobility shift and selective 
separation of the labeled phosphorylated peptides. This facilitates rapid 
identification and selection of labeled ions for further characterization. 
In this chapter, we demonstrate lanthanide-based labeling for 
phosphorylated peptides, or Phosphopeptide Element-Coded Affinity Tagging 
(PhECAT), for rapid identification, relative quantitation, and phosphorylation site 
identification of phosphorylated peptides and proteins in complex mixtures using 
IM-MS as a separation platform. Briefly, in the PhECAT method, phosphorylated 
peptides are selectively modified at the phosphorylation site via beta-
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elimination/anionic thiol Michael addition chemistry. In this manner, 
phosphorylated peptides are converted to cysteine-like residues, which then 
readily react with cysteine-specific labels. A lanthanide-chelating label is added 
via maleimide chemistry and selected lanthanide metals are subsequently 
chelated to a macrocycle moiety. Labeled phosphorylated peptides are then 
visually identified by a mobility shift from the anticipated peptide correlation line 
generated in IM-MS, quantitated, and fragmented in the transfer portion of the 
instrument to provide comprehensive phosphopeptide analysis. To demonstrate 
this technique, phosphorylated peptides and protein mixtures from proteolytic 
digestion are identified and quantitated in various molar ratios with comparable 
sensitivity and relative error to current isotopologue-based relative quantitation 
strategies. Moreover, site identification of the modified phosphorylation site is 
achieved, demonstrating that the label is covalent on the site of modification and 
more stable than b and y ions generated by cleaving peptide bonds. This 
strategy provides more confident site identification than that obtained in data-
dependent LC-MS/MS strategies because this method circumvents 
phosphorylation-site rearrangement in the collision cell. 
 
4.2 Experimental 
 
4.2.1 Materials 
Model phosphorylated peptides and proteins were investigated for proof-
of-concept experiments. Phosphorylated protein bovine β-casein was purchased 
from Sigma-Aldrich (St. Louis, MO). Trypsin was purchased from Promega Corp. 
(Madison, WI). C-18 spin columns were purchased from Pierce (Rockford, IL). 
Maleimido-mono-amide-DOTA was purchased from Macrocyclics (Dallas, TX) 
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and dissolved in DMSO. 1,2-ethanedithiol (EDT) was purchased from Fluka (St. 
Gallen, Switzerland). 2,5-dihydroxybenzoic acid (DHB) was purchased from 
Sigma and dissolved in 50% methanol to a final concentration of 30 mg/mL. 
Lanthanide metals were purchased from Strem Chemicals (Newburyport, MA) in 
chloride salt form and dissolved in distilled deionized water (18 MΩ cm-1) to a 
final concentration of 25 mg/mL. Dimethylsulfoxide, acetonitrile, and ethanol were 
purchased from Sigma. 
 
4.2.2 Digestion of phosphorylated proteins 
Proteins were dissolved in ammonium bicarbonate buffer (pH 8.0) and 
thermally denatured at 90˚C for 20 minutes and quenched at -20˚C.34 Cysteine-
cysteine bonds and free cysteines were reduced with dithiothreitol (final molarity 
of 4 mM) and alkylated with iodoacetamide (final molarity of 20 mM). Proteins 
were subsequently digested with trypsin in a 1:40 weight to weight ratio for 16-20 
hours at room temperature and purified by C-18 spin columns (Pierce, Rockford, 
IL) prior to derivatization. Digestion was confirmed by MALDI-TOFMS (data not 
shown). 
 
4.2.3 Selective derivatization of phosphorylated peptides and proteins  
Tryptic peptides were subjected to a beta-elimination (Figure 23(i)) and 
anionic thiol Michael addition reaction (Figure 23(ii)) resulting in the selective 
elimination of phosphoric acid followed by addition of ethanedithiol. In the beta-
elimination/Michael addition reaction, each sample was derivatized in a 
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Figure 23. Reaction scheme for PhECAT (i) Phosphoric acid is selectively 
removed (ii) Ethanedithiol is subsequently added to the conjugated diene via 
anionic thiol Michael addition (iii) The remaining free thiol is attached to the 
macrocylic via maleimide chemistry (iv) Finally, lanthanides are chelated to the 
macrocyclic portion of the tag. 
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reaction mixture containing 2.5 mM EDTA, 0.2 M ethanedithiol, 0.5 M NaOH, 1.5 
M acetonitrile, 1.5 M ethanol, 5 M DMSO, and water for 1-2 hrs under nitrogen at 
55ºC. This resulted in conversion of phosphorylated serine or threonine into 
dehydroalanine or dehydroaminobutyric acid, respectively. The samples were 
then neutralized and purified by polyacrylamide gel (size range >1800 Da, 
Thermo) and reaction completion was confirmed by MALDI-TOFMS. 
Subsequently, the thiolated peptides were labeled with a 10- to 50-fold excess of 
maleimido-DOTA (Figure 23(iii)) in a mixture containing acetate buffer (pH 5.5) 
and DMSO in 1:1 ratio (v/v), resulting in a covalent bond between the free 
sulfhydryl group and the maleimide portion of the lanthanide-based tag. Finally, 
samples were encoded with lanthanide metals by chelation to the DOTA portion 
of the tag by adding a 100- to 500-fold molar excess of metal to peptide and 
heating to 80ºC to speed up chelation for 45 minutes (Figure 23(iv)). Differentially 
labeled samples were then combined and purified by C-18 spin columns and 
analyzed MALDI-IM-TOFMS.  
 
4.2.4 Instrumentation and data analysis 
Spectra were obtained using a Synapt HDMS (Waters Corp., Manchester, 
UK) MALDI-IM-TOFMS in positive, reflector mode. MALDI matrix preparation 
consisted of 2,5-dihydroxybenzoic acid (DHB) in 50% methanol. The samples 
were spotted using the dried-droplet method. Data analysis was performed using 
MassLynx (Waters Corp., for Synapt data) and DriftScope (Waters Corp., for 
Synapt data). At least 3 trials were analyzed for each relative quantitation 
experiment. Spectra were acquired by rastering the MALDI laser at random over 
the entire matrix spot.  
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Labeled peaks were identified by mobility shift (<3%) in MALDI-IM-
TOFMS data and quantitated. Relative molar amounts were calculated by 
dividing the relative peak area of the derivatized state 1 by the relative peak area 
of derivatized state 2. Fragmentation of the labeled phosphorylated peptides and 
proteins were performed on a Waters Synapt HDMS (Figure 24a) in the transfer 
portion of the instrument, which was chosen because of the added advantage of 
having fragmentation spectra organized by mobility (Figure 24b).  
Peaks shifted out of peptide correlation space were manually selected for 
fragmentation and analyzed for potential phosphorylation sites in order to assess 
the stability of the lanthanide label and confirm the site of phosphorylation. 
Fragmentation spectra were processed using MassLynx software using the 
Subtract, Smooth, and Center processing tools and subsequently sequenced de 
novo using an anticipated peak list generated from the ExPASy Peptide Mass © 
program.  
 
4.3 Results and Discussion 
 
While methods for MS-based relative quantitation of peptides and 
proteins using chemical modification methodologies have been described in 
detail, there are few reports of label-based relative quantitation strategies that are 
selective for phosphorylation. The available methods have great utility in 
quantitation of phosphorylated peptides and proteins, but three important 
challenges exist – (i) they are limited to low mass peptides due to spectral 
congestion caused by an overlap of increasingly larger isotopic envelopes, (ii) 
identification of labeled species is challenging in complex mixtures, and 
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Figure 24. a) A schematic of the mobility cell portion of the Synapt HDMS G2. In 
these experiments, ions were separated in the mobility portion and subsequently 
fragmented in the transfer portion of the instrument. b) An advantage of this 
fragmentation strategy is that fragment ions are organized by mobility. 
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 (iii) the number of simultaneously analyzed peptides is limited (simultaneous 
quantitation of 2-8 samples are commonly reported). 
Here, we report a multiplexed relative quantitation strategy that addresses 
these limitations using lanthanide-based labels with MALDI-IM-MS in addition to 
the MALDI-TOFMS platform described in Chapter 3. A schematic diagram of this 
comprehensive phosphoproteomic strategy is illustrated in Figure 25. In this 
strategy, phosphorylated peptides and proteins are selectively labeled with a 
lanthanide-chelated tag. Quantitative information is obtained in both platforms by 
encoding each sample with a different lanthanide, which provides the necessary 
mass shift for quantitative comparisons (Figure 25, top and middle, right). The 
number of samples that may be quantitated is only limited by the number of 
available isotopically enriched lanthanide metals (simultaneous quantitation of 2-
14 samples is possible, excluding radioactive Promethium). Used in the MALDI-
TOFMS platform, these labels provide larger mass differences to avoid isotopic 
overlap while quantitating phosphorylated peptides of higher mass. Used in the 
MALDI-IM-TOFMS platform, these labels have added utility in converting the 
phosphorylation site into a high-density “anchor” (Figure 25, bottom left).  This 
anchor shifts the labeled peptide below the peptide correlation line in IM-MS 
space. Shifting labeled peaks away from unlabeled peaks facilitates selection 
and identification in complex mixtures for further site localization. Site 
identification is achieved by fragmenting peptides with an observed shift in IM-
MS conformation space and identifying b and y ions exhibiting the additional 
mass of the covalent label (Figure 25, bottom right).  
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Figure 25. Labeling of multiple sample states with DOTA tags coordinated to 
different lanthanide metals. In this illustrative figure, a 5:1:2.5 may be encoded 
with different lanthanide metals and quantitated using either MALDI-IM-TOFMS 
or MALDI-TOFMS platforms. Thus, the number of simultaneous samples that can 
be combined for relative quantitation is limited only be the number of different 
metals (or metal isotopes) that are used. An added advantage to using this 
strategy and the MALDI-IM-TOFMS platform is rapid visual identification of 
labeled species for subsequent tandem MS analysis of the phosphorylation site. 
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4.3.1 Relative quantitation of phosphorylated peptides and proteins using 
PhECAT.  
 
Varying molar amounts of phosphorylated peptides and proteins were 
derivatized and quantitated in proof-of-concept experiments. The results of these 
quantitation experiments are provided in Table 6. An example of a typical relative 
quantitation experiment using the MALDI-IM-MS platform is illustrated in Figure 
26. In this experiment, labeled phosphorylated peptides are visually identified by 
their shift away from the peptide correlation line. A mass spectrum is extracted 
from the 2D plot using MassLynx Chromatogram software and relative peak area 
information is obtained (Figure 26, inset). In this example, a 1:5 molar ratio of Tb- 
and Ho-labeled FQpSEEQQQTEDELQDK is shown. In conjunction with 
fragmentation data, PhECAT strategies in IM-MS provide rapid identification and 
relative quantitation of the labeled peptide for characterization of phosphorylated 
peptides. Relative quantitation data and spectra for PhECAT strategies using 
MALDI-IM-TOFMS is provided in the Appendices of this work. 
The reported error for this strategy is comparable to current isotope 
coded affinity labels, with the added advantages of larger shifts in mass doublets 
(i.e. 2-36 Da for single phosphorylation sites), allowing for quantitation of high-
mass peptides without peak convolution from adjacent isotopes. For multiple 
phosphorylation sites, the mass difference scales with the number of the labels, 
which provides even greater separation. These results also indicate that this 
method has error competitive to current quantitative phosphoproteomic methods 
and should have utility in relative quantitative studies of complex biological 
samples. The utility of lanthanide ions as luminescent chromophores in 
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Table 6. Relative Quantitation of phosphorylated peptides and proteins using 
lanthanide-chelating tags in MALDI-IM-TOFMS. 
 
Peptide Sequence
a,b 
 
 
 
[M+H]
+ c 
 
 
 
 
[M*+H]
+
 
Tb, Ho
d
 
 
 
 
 
Molar ratio 
of 
derivatized 
peptides 
 
 
 
Measured 
molar ratio of 
peptides 
derivatized with 
Ho-tag and Tb-
tag 
(average # of 
trials)
 e
 
 
 
Relative 
Percent 
Error
f
 
48 FQpSEEQQQTEDELQDK 63 
from bovine B-casein 
 
2060.7 
 
 
 
 
2739.1
‡
, 
2745.1
‡
 
 
 
 
1.0: 5.0 
(Ho:Tb) 
 
 
 
 
0.172 (3) 
 
 
 
 
 
+14.0 
48 FQpSEEQQQTEDELQDK 63 
from bovine B-casein 
 
2060.7 
 
 
 
2739.1
‡
,
 
 
2745.1
‡
 
 
1.0: 1.0 
(Tb:Ho) 
 
 
 
1.159 (3) 
 
 
 
 
+15.9 
48 FQpSEEQQQTEDELQDK 63 
from bovine B-casein 
 
2060.7 
 
 
 
2739.1
‡
, 
2745.1
‡
 
 
1.0: 5.0 
(Tb:Ho) 
 
 
 
0.293 (3) 
 
 
 
 
+46.6 
48 FQpSEEQQQTEDELQDK 63 
from bovine B-casein 
 
2060.7 
 
 
 
2739.1
‡
, 
2745.1
‡
 
 
3.0: 1.0 
(Ho:Tb) 
 
 
 
2.341 (3) 
 
 
 
-17.1 
48 FQpSEEQQQTEDELQDK 63 
from bovine B-casein 
 
2060.7 
 
 
 
2721.1
‡
, 
2739.1
‡
, 
2745.1
‡
 
 
1.0: 1.0: 5.0 
(Pr:Tb:Ho) 
 
 
 
 
0.140, 0.130 (3) 
 
 
 
-30.0,-35.0 
 
__________________________________________________________________________ 
a. "p" denotes phosphorylation, sequence positions bracket the sequence for tryptic 
peptides 
b. Phosphorylated proteins purchased and used without additional purification. 
c. Monoisotopic masses for unlabeled phosphorylated peptides. 
d. Calculated monoisotopic peaks for labeled phosphorylated peptides. “*”denotes 
PhECAT labeling, “‡“ denotes relative quantitation calculations where the peak having 
the highest relative abundance was selected for peak area quantitation rather than the 
monoisotopic peaks. This is primarily due to the fact that, here, the monoisotopic peak 
has the lowest intensity. In this case, the peaks of highest intensity (2741.1, 2747.1) were 
selected. [M*+H]
+
 of Pr, Tb, Ho
 
where applicable. 
e. 1.0: 1.0: 5.0 (Pr:Tb:Ho) relative ratios expressed as Pr:Ho and Tb:Ho, respectively. 
f. 1.0: 1.0: 5.0 (Pr:Tb:Ho) relative ratios expressed as Pr:Ho and Tb:Ho, respectively. 
Percent errors are reported according to the following formula: 
(Average Peak Area Ratio – Anticipated Peak Area Ratio) / Anticipated Peak Area Ratio  
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Figure 26. 2D IM-MS plot of derivatized tryptic beta-casein. The peptide mixture 
was first proteolytically digested with trypsin followed by selective labeling 
according to scheme 1. Unlabeled tryptic peaks establish the peptide correlation 
line, indicated by the dashed line. The phosphorylated peptide having the 
sequence FQpSEEQQQTEDELQDK was derivatized with Tb- and Ho-chelated 
labels in a 1:5 mixture and exhibit a structural shift below the peptide correlation 
line. (inset) Upon identification of labeled species, extraction of the relative peak 
areas of the labeled species provides quantitative information.  
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LC separations have been well described, and may increase confidence in 
phosphorylation site labeling at an additional stage of analysis. Moreover, the 
addition of a macrocycle may shift LC elution times for phosphorylated peptides, 
which may assist in separation of closely spaced phosphorylated and non-
phosphorylated species.  
 
4.3.2 Selection, fragmentation, and identification of the site of 
phosphorylation 
 
PhECAT experiments performed using only MALDI-TOFMS as the 
analysis platform utilize anticipated mass shifts (i.e., labeling with known 
lanthanides generates predictable mass multiplets which can be identified with 
quantitation software) to identify labeled quantitated species (data not shown). 
PhECAT experiments performed using MALDI-IM-TOFMS as the analytical 
platform take advantage of the high density of the PhECAT labels which result in 
a shift of labeled phosphorylated peptides away from the anticipated peptide 
correlation line, facilitating selection of phosphopeptides for fragmentation. 
PhECAT selection and fragmentation using MALDI-IM-TOFMS is demonstrated 
in Figure 27. Labeled peptides were first visually identified by their shift from 
peptide correlation space (Figure 27(i)) and selected for fragmentation in the 
transfer portion of the Synapt instrument. An example of a typical tandem 
spectrum is shown in Figure 27(ii). The expected b/y series ions were observed, 
including full b ion coverage from the b3 to the b15 ion, all labeled and several 
unlabeled y ions including y8-12, several labeled water loss ions, and the intact 
label with little evidence for fragmentation of the label. It should be noted that all 
fragment ions  
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Figure 27. i) 2D IM-MS plot of derivatized tryptic beta-casein. Underivatized 
tryptic peaks establish the peptide correlation line, indicated by the dashed line. 
The signal corresponding to derivatized FQpSEEQQQTEDELQDK exhibits a 
negative deviation from the peptide correlation line, facilitating rapid identification 
prior to fragmentation. ii) Structure and fragmentation spectrum of a terbium-
labeled tryptic beta-casein phosphorylated peptide having the sequence 
FQpSEEQQQTEDELQDK. An asterisk indicates that the ion is covalently 
modified with the PhECAT label. Fragmentation coverage of 86.7% and 46.7% of 
the labeled peptide was observed for b and y ions, respectively. Fragmentation 
coverage of 66.7% and 26.7% for the labeled peptide was observed for b and y 
water loss ions, respectively (an anticipated peak list and additional spectra from 
replicate experiments are provided in the supplementary material). Importantly, 
all of the anticipated ions corresponding to labeled positions are observed, 
demonstrating the utility of this label for phosphopeptide site identification as well 
as relative quantitation. It should also be noted that labeled fragment ion species 
exhibit greater intensity than non-labeled fragment ion species. Spectral peaks 
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from 500 m/z to 2600 m/z were intensified 2x to increase visibility of b and y 
spectral assignments. 
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covalently bound to the PhECAT label exhibit higher intensities than unlabeled 
fragment ions. The stability of this label enables predictable mass shifts of 
anticipated b and y ions which gives an indication of the site of modification 
previously phosphorylated.44 Furthermore, because this tag is not labile and does 
not show phosphorylation site rearrangement (as is the case with phosphoric 
acid and phosphate plus water loss), it has an added advantage of more 
confident phosphorylation site assignment. Thus, complete phosphoproteomic 
characterization is accomplished using a single strategy. 
 
4.4 Conclusions 
 
Current methods of MS-based protein quantitation primarily focus on 
quantifying relative expression profiles through labeling non-post-translationally 
modified peptides. This offers a limited view of the biological activity of cells, 
because many biological functions are dependent on protein modifications, 
specifically, protein phosphorylation. The available methods for phosphoprotein 
quantitation provide good specificity for the site of phosphorylation, however, 
they have limited applicability for peptides of increasing mass and are seldom 
used for phosphorylation site identification. In this work, we have demonstrated 
the utility of lanthanide-based labels for phosphopeptides and proteins (PhECAT) 
for relative quantitation of phosphorylated peptides using MALDI-MS and as 
mobility shift labels using MALDI-IM-MS for rapid visual identification and 
subsequent quantitative and site analysis. We propose that this method may 
circumvent challenges encountered by quantitation and site localization, such as 
gas-phase phosphorylation site rearrangement, with the added utilities described 
above. 
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CHAPTER 5 
 
 
 
ENHANCED SEPARATION AND CHARACTERIZATION OF GLYCOSYLATED 
PROTEINS USING LANTHANIDE-BASED LABELING AND ION MOBILITY-
MASS SPECTROMETRY 
 
 
 
5.1 Introduction 
 
 
Much like protein phosphorylation, protein glycosylation regulates 
numerous biological processes such as cell signaling, recognition, differentiation, 
and proliferation and is often observed to dynamically occupy the same 
sequence position that harbors phosphorylation as part of an ON/OFF switch in 
biological systems.28 Thus, the stoichiometry between phosphorylation and 
glycosylation is significant for a complete understanding of a phosphorylated 
protein’s role in a system.  As with any PTM characterization, elucidation of the 
site of modification is critical to better understand the nature of modification-
dependent protein function and to design and optimize protocol to quantify and 
structurally characterize the site of modification. Elucidation of the site of 
glycosylation is challenging for similar reasons as phosphorylation localization, 
namely – i) glycans are labile, and either beta-eliminate readily or fragment easily 
in MS ion sources and collision cells, ii) these labile modifications predominate in 
MS/MS spectra, as the bulk of fragmentation occurs at the site of modification 
confounding MS sequencing attempts, and iii) due to the temporal nature of the 
modification, only substoichiometric amounts are available and create difficulties 
in detection of the modification.  
Application of the previously described lanthanide-based labeling 
strategies may provide relative quantitation information for glycosylated peptides 
 86 
as well as phosphorylation occupation versus glycosylation occupation. 
Furthermore, by modifying the site of glycosylation prior to analysis, the labile 
glycosylation site is converted to a stable covalently bound label, which may 
circumvent challenges associated with glycosylation site identification. Moreover, 
removal of glycans through beta-elimination is routinely performed in glycan 
structural analysis, and this chemistry is compatible with structural analysis of 
glycans. 
In this chapter, PhECAT strategies are applied toward the challenge of 
glycan site quantitation. In this benchmarking report, labeling of a glycosylated 
peptide from erythropoietin is demonstrated. In a manner similar to previously 
discussed, glycosylated tryptic peptides are selectively modified at the 
glycosylation site via beta-elimination/anionic thiol Michael addition chemistry. 
Thus, glycosylated peptides are converted to cysteine-like residues, which then 
readily react with cysteine-specific labels. This lanthanide-chelating label is 
added via maleimide chemistry and selected lanthanide metals are subsequently 
chelated to a macrocycle moiety.  
 
5.2 Experimental 
 
5.2.1 Materials 
Model glycosylated peptides were investigated for proof-of-concept 
experiments. Glycosylated erythropoietin was purchased from Anaspec 
(Freemont, CA). Adrenocorticotropic hormone (ACTH) peptide clips 18-39, 1-17, 
and 7-38 were purchased from American Peptide (Sunnyvale, CA) and used 
without further purification. Polyacrylamide gel columns were purchased from 
Thermo (San Jose, CA). C-18 spin columns were purchased from Pierce 
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(Rockford, IL). Maleimido-mono-amide-DOTA was purchased from Macrocyclics 
(Dallas, TX) and dissolved in DMSO. 1,2-ethanedithiol (EDT) was purchased 
from Fluka (St. Gallen, Switzerland). 2,5-dihydroxybenzoic acid (DHB) was 
purchased from Sigma and dissolved in 50% methanol to a final concentration of 
30 mg/mL. Lanthanide (in LnCl3 form) metals were purchased from Strem 
Chemicals (Newburyport, MA) in chloride salt form and dissolved in distilled 
deionized water (18 MΩ cm-1) to a final concentration of 25 mg/mL. 
Dimethylsulfoxide, acetonitrile, and ethanol were purchased from Sigma. 
 
5.2.2 Selective derivatization of glycosylated peptides and proteins using 
lanthanide-based labeling strategies 
 
Glycosylated erythropoietin peptide (sequence EAISPPDAAS*AAPLR, 
where * denotes glycosylation of serine) was subjected to a beta-elimination 
(Figure 28(i)) and anionic thiol Michael addition35 reaction (Figure 28(ii)) resulting 
in the selective elimination of phosphoric acid followed by addition of 
ethanedithiol. In this reaction, each sample was derivatized in a reaction mixture 
containing 2.5 mM EDTA, 0.2 M ethanedithiol, 0.5 M NaOH, 1.5 M acetonitrile, 
1.5 M ethanol, 5 M DMSO, and water for 2-3 hrs under nitrogen at 55ºC in a 
manner similar to reaction conditions described previously.36-38 This resulted in 
conversion of O-GlnAc-modified serine and threonine into dehydroalanine or 
dehydroaminobutyric acid, respectively. The samples were then neutralized and 
purified by polyacrylamide 1800 desalting gel (Thermo) and reaction completion 
was confirmed by MALDI-TOFMS. Subsequently, the thiolated peptides were 
labeled with a 10-fold excess of maleimido-DOTA (Figure 28 (iii)) in a mixture 
containing acetate buffer (pH 5.5) and DMSO in 1:1 ratio (v/v), resulting in a 
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covalent bond between the free sulfhydryl group and the maleimide portion of the 
lanthanide-based tag. Finally, selected lanthanide  
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Figure 28. Reaction scheme for using PhECAT for O-linked glycans (i) O-linked 
glycans are removed via beta-elimination in basic conditions, generating a 
conjugated diene (ii) Ethanedithiol is subsequently added to the conjugated diene 
via anionic thiol Michael addition (iii) The remaining free thiol is attached to the 
macrocylic via maleimide chemistry (iv) Finally, samples are encoded by 
chelating lanthanides to the macrocyclic portion of the tag. 
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metals were chelated to the maleimide portion of the tag by adding a 100-fold 
molar excess of metal to peptide and heating to 80ºC to speed up chelation for 
45 minutes (Figure 28(iv)).39 Differentially labeled samples were then combined 
and purified by C-18 spin columns and analyzed using MALDI-IM-TOFMS.  
 
5.2.3 Instrumentation and data analysis 
Spectra were obtained using a Voyager MALDI-TOFMS in positive, 
reflector mode. MALDI matrix preparation consisted of 2,5-dihydroxybenzoic acid 
(DHB) in 50% methanol. The samples were spotted using the dried-droplet 
method.40 Data analysis was performed using Data Explorer software version 4.3 
(Applied Biosystems, Foster City, CA). At least 3 trials were analyzed for each 
relative quantitation experiment. Spectra were acquired by rastering the MALDI 
laser at random over the entire matrix spot.  
Peaks were identified manually and quantitation spectra were processed 
using the baseline correction, noise filter/smooth, and centroiding processing 
tools of Data Explorer.  
 
5.3 Results and Discussion 
 
Here, we report successful labeling of a glycosylated peptide with 
lanthanide-based labels, termed “PhECAT” when used to characterize 
phosphorylated peptides. Lanthanide-based labeling of glycosylation sites 
circumvents challenges associated with the lability of the modification and 
provides quantitative information and selective separation of glycosylated 
peptides from concomitants. The stoichiometry of glycosylation vs. 
phosphorylation occupation may be elucidated with a selective purification 
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strategy outlined in Figure 29 prior to lanthanide encoding.  In this proposed 
strategy, a glycosylated and phosphorylated protein mixture is digested before 
being subjected to antibody purification and divided out into two samples of 
phosphopeptides and glycopeptides. Each sample is then derivatized and 
encoded with a specific lanthanide and characterized by MS. If structural 
information is desired, the beta-elimination step of the labeling may be used to 
release the glycans for subsequent structural analysis. Simultaneous glycomics 
and proteomics has been reported in our group and can be applied toward 
comprehensive glycoproteomics as well.70 
Preliminary data demonstrating the labeling of glycosylated peptides is 
presented in Figure 30. The GlcNAc-modified peptide was derivatized using 
beta-elimination/Michael addition chemistry followed by maleimide and 
lanthanide chelation chemistry as used previously for the derivatization of 
phosphorylated peptides. Erythropoietin (EAISPPDAAS*AAPLR, where * 
denotes glycosylation of serine) was derivatized in a 1:1 mixture of Tb to Ho-
labeled peptides. A peptide mixture containing ACTH peptides was spiked into 
the sample to establish the underivatized peptide correlation line in IM-MS 2D 
conformation space (Figure 30, top). One sample was quantitated so that 
application of this strategy resembled characterization of an unknown biological 
sample, which is frequently limited in concentration. Labeled erythropoietin signal 
was identified by its negative deviation from the established peptide correlation 
line and mass spectra were subsequently extracted for quantitative information 
(Figure 30, bottom). Table 7 presents the results from this single quantitation 
experiment. Extracted mass spectra and quantitation raw data are provided in 
the Appendices. The relative percent error associated with this experiment was  
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Figure 29. Proposed strategy for the selective separation, site identification, and 
relative quantitation of glycosylated and phosphorylated peptides and proteins. 
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Figure 30. (top) O-GlcNAc-modified peptides are labeled by lanthanide-based 
labels and separated from a complex peptide mixture. The labeled peptide is 
indicated in a dashed circle. Underivatized ACTH clips 1-17, 7-38, and 18-39 are 
spiked in to the sample to establish the peptide correlation line and guide the eye 
for visual identification of labeled species. Peptide correlation line is indicated by 
a dashed line. (bottom) Extracted and zoomed mass spectra of Tb- and Ho-
encoded erythropoietin. Here, a 1:1 mixture was quantitated. Normalized 
observed peak areas for this acquisition were 1.0 to 0.89.  
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Table 7. Relative Quantitation of O-GlcNAc modified peptide erythropoietin using 
lanthanide-chelating tags in MALDI-IM-TOFMS. 
 
Peptide Sequence
a 
 
 
 
[M+H]
+ b 
 
 
 
 
[M*+H]
+
 
Tb, Ho
c
 
 
 
 
 
Molar ratio 
of 
derivatized 
peptides 
 
 
 
Measured 
molar ratio of 
peptides 
derivatized with 
Ho-tag and Tb-
tag 
(average # of 
trials)
 d
 
 
 
Relative 
Percent 
Error
e
 
117 EAISPPDAASAAPLR 131 
human 
 
1670.7 
 
 
 
 
2223.7
‡
, 
2229.7
‡
 
 
 
 
1.0: 1.0 
(Tb:Ho) 
 
 
 
 
0.833 (1) 
 
 
 
 
 
-17.0 
 
__________________________________________________________________________ 
a. Bold denotes site of O-GlcNAc modification, sequence position indicated 
b. Monoisotopic masses for unlabeled peptide. 
c. Calculated monoisotopic peaks for labeled peptide. “*”denotes PhECAT labeling, “‡“ 
denotes relative quantitation calculations where the peak having the highest relative 
abundance was selected for peak area quantitation rather than the monoisotopic peaks. 
This is primarily due to the fact that, here, the monoisotopic peak has the lowest intensity.  
d. One sample was rastered 10 times and the result was averaged. 
d. Percent errors are reported according to the following formula: 
(Average Peak Area Ratio – Anticipated Peak Area Ratio) / Anticipated Peak Area Ratio
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found to be 17%, which is comparable to current isotopologue quantitation 
strategies. It should also be noted that these isotopologue quantitation strategies 
are generally not demonstrated for PTMs and particularly not demonstrated as 
quantitative strategies between two PTMs occupying the same site of 
modification.  
 
5.4 Conclusions 
 
Glycosylation and phosphorylation have been shown to occupy the same 
site of modification in a number of cases, and switching modifications has been 
shown to be a critical regulatory mechanism for a number of cellular functions. 
Characterization of glycopeptides provides a more complete picture of a picture 
of the resident modification, and quantitation of phosphorylated vs. glycosylated 
species may provide a better understanding of the mechanisms controlled by 
modification switching. A 1:1 molar mixture of O-GlcNAc-modified peptide 
erythropoietin was quantitated using Tb- and Ho-chelated labels. In this initial 
experiment, performed with a single sample in the manner expected for unknown 
samples, the relative percent error was calculated to be 17%, which is 
comparable to current quantitative experiments that do not profile glycosylation 
stoichiometry. Moreover, labeled glycosylated species were visually identified by 
their negative deviation from the peptide correlation in 2D IM-MS conformation 
space, illustrating the additional advantage of lanthanide-based labeling for IM 
separations. 
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CHAPTER 6 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Summary and conclusions 
 
The primary aim of this dissertation research was to simplify 
characterization of phosphorylated and glycosylated peptides and proteins. 
These post-translational modifications have profound significance in molecular 
biology and understanding the mechanisms of disease.  
Complete phosphoproteomic characterization is accomplished through 
elucidating the site of phosphorylation and its stoichiometry. These are typically 
performed in separate experiments, and each determination has demonstrated 
challenges. Site identification by data-dependent tandem MS is often confounded 
by phosphorylation site rearrangement, HPLC co-elution, and heterogeneous 
phosphorylation. Quantitation between two states is typically accomplished using 
isotopologue labeling and subsequent MS analysis, which provides limited mass 
shift and requires high resolution instrumentation. These challenges are 
described in detail in Chapters 1 and 2. Chapters 3 and 4 address these 
challenges using lanthanide-based labeling. Chapter 4 introduces the utility of ion 
mobility-mass spectrometry separations and the use of these labels as mobility 
shift reagents for rapid visual identification of labeled ions. Lanthanide-based 
tagging provides increased mass separation to quantitate peptides of increasing 
mass and also provides separation from concomitant species in IM-MS 
conformation space so that site identification is more easily achieved. Together, 
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these strategies provide comprehensive phosphoproteomic characterization. This 
was demonstrated in a benchmarking experiment using the model 
phosphorylated protein, bovine beta-casein. In Chapter 3, the quantitative 
advantages of lanthanide-based labeling were first explored. Error comparable to 
current isotopologue strategies (including those that do not label 
phosphopeptides) was achieved. Moreover, fragmentation of labeled species 
indicated that derivatization of the phosphorylation site produced a more stable 
modification in which to identify the site of phosphorylation. In Chapter 4, the 
additional utility of lanthanide-based labeling as mobility shift tags for separation 
from unphosphorylated peptides in IM-MS conformation space was explored. 
Lanthanide tags provided sufficient mobility and mass shift to successfully 
separate phosphorylated peptides away from the anticipated peptide 
conformation space, facilitating further characterization without concomitant 
contamination.   
A number of reports have described a dynamic “ON/OFF” switching of 
phosphorylation sites with glycosylation. Thus, contemporary phosphoproteomics 
must incorporate glycoproteomic identification and quantitation. Contemporary 
glycoproteomic characterization includes identification of the site of modification 
and determination of the glycan’s stoichiometry. Glycoproteomic characterization 
entails the same challenges as phosphoproteomic characterization. Lanthanide-
based labeling and IM-MS separations for selective separation may circumvent 
these challenges and moreover provide quantitative information. This is 
discussed in detail in Chapter 5. In this experiment, a O-GlcNAc-modified 
peptide, human erythropoietin, was labeled and visually identified by its negative 
deviation form the peptide correlation line in 2D conformation space. 
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Furthermore, a 1:1 molar ratio of Tb- to Ho-labeled sample was quantitated with 
comparable error to current isotopologue-based quantitation strategies.   
 
 
6.2 Future directions 
 
6.2.1 Custom labels for labeling and ionization efficiency 
Through these studies, significant progress was made in developing a 
simplified, comprehensive strategy for multiplexed characterization of 
phosphorylated and glycosylated peptides and proteins, but there are many 
opportunities for further research. Our laboratory is presently pursuing a number 
of custom labels that further enhance the ionization efficiency of the label and 
that accommodate single reaction, or “one-pot,” phosphoproteomic labeling.  
One label that was conceptualized in our laboratory, illustrated in Figure 
30a, contains an arginine residue, which through labeling substitutes the 
negatively charged phosphorylation or glycosylation residue for a positively 
charged residue. This is especially advantageous to improve ionization efficiency 
and to enhance detection of phosphopeptides or glycopeptides for relative 
quantitation strategies. Another label envisioned, illustrated in Figure 30b, 
contains a DOTA macrocycle and a reactive thiol replacing the maleimide. Using 
this label, phosphopeptides may be labeled without a dithiol linker, reducing 
reaction time and desalting steps required when converting the phosphorylation 
site to a thiol-terminated residue. Reducing desalting and chromatographic steps 
in phosphoproteomic labeling reduces losses associated with each process, and 
can potentially improve the overall limit of detection of the method. 
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Figure 31. Custom labels that may provided added utility to the overall labeling 
strategy. i) Thiol-terminated labels circumvent sample losses associated with 
chromatography cleanup of the intermediate labeling steps. ii) Lanthanide-based 
labels that contain an arginine or other positive charges may enhance signal from 
substoichiometric modifications and enhance phosphoproteomic 
characterization. 
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6.2.2 Mobility shift labeling for selective separation and structural analysis 
of glycosylated peptides 
 
Another avenue envisioned for future research is the use of mobility shift 
“balloon” labels for structural analysis of glycans, illustrated in detail in Chapter 1. 
Although lanthanide-based labeling provides quantitative and site identification 
information of the glycan, structural information is lost. A number of biological 
processes are highly dependent on glycan structure and the composition of 
terminal saccharides on the glycan.3, 4, 8, 33-35, 37, 108-110 Thus, this information is of 
critical importance to comprehensive glycoproteomics.  
The potential for balloon mobility shift labeling of post-translationally 
modified peptides in IM-MS has not been explored. Due to the curvature of each 
biomolecular class, mobility shift separation experiments must be tuned to the 
target biomolecule class to achieve maximum separation. For underivatized 
glycosylated peptides and proteins, mobility shift strategies that place labeled 
glycopeptides signals above the carbohydrate/protein correlation line may 
provide the optimal separation for rapid visual identification and further 
characterization. Characteristics of “balloon” shift reagents include labels with 
high surface area and low mass such that surface area scales disproportionately 
with mass.  
Addition of a balloon mobility shift reagent may provide enhanced 
separation of a glycosylated peptide having a labeled terminal group from its 
isobaric counterparts. This separation also provides added utility by reducing 
concomitant species fragmented in structural elucidation. Moreover, O-GlcNAc-
modified peptides separated by labeling strategies may be selected for 
fragmentation to obtain structural information on the glycan.  
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6.2.3 Relative quantitation of dynamic interchange between protein 
phosphorylation and protein glycosylation 
 
Lanthanide-based quantitative mobility-shift labeling may also be applied 
toward characterization between PTM states such as glycosylation vs. 
phosphorylation states. As mentioned previously, glycosylation and 
phosphorylation are known to occupy the same sequence position, and dynamic 
regulation between the modifications are known to control signaling functions of 
the cell. A strategy for glyco/phospho quantitation is illustrated in figure 29 in 
Chapter 5.  
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APPENDIX A 
 
Supplementary Information for Mass Spectrometry Data Acquisition according to 
MIAPE-MS format. 
  
 
General Features 
Global Descriptors 
Dates obtained can be found in the file names behind 
“sh_RG_1270_” or “sh_RG_1368_.” 
These samples were processed and analyzed by the Vanderbilt 
Proteomics Core. 
     Contact info: Hayes McDonald – Assistant Director  
  Email: hayes.mcdonald@Vanderbilt.Edu 
    Contact info: Salisha Hill – Laboratory Technician 
Email: salisha.sobratee@vanderbilt.edu  
Phone: (615) 343-7334 
 
Instrument Manufacturer and Model : 
LTQMS : ThermoFinnigan LTQ LC-MS-MS  
LTQ-Orbitrap : Thermo Scientific LTQ XL™ 
Customizations : none 
Control and Analysis Software : 
Software Name and Version: Thermo Xcalibur 1.3 and Bioworks 3.1 
software 
Switching criteria: available in supplementary raw MS files 
Isolation Width: 2.00 
Ion Sources: Electrospray Ionisation (ESI):  Instrumental, source, 
and tune parameter settings are available in the raw data files 
provided at the following url:  
http://www.mc.vanderbilt.edu/msrc/bioinformatics/data.php or at 
the following link: https://proteomecommons.org/tranche/data-
downloader.jsp?fileName=ZEb8WJQd75%2Fi4%2FPOlusCyfWI7czMK%
2BUT3kcIGy8P6caR3iYgUJdGR958BvUpwYS8v6Q56Pe1eiGKjK5H2Y8L
%2FYG%2FA3kAAAAAAAAEDg%3D%3D 
 
Post-Source Component: 
Ion Trap Final MS Stage Achieved: MS3 
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APPENDIX B 
 
Table of initial APPL1 phosphorylation site identifications by LTQ-MS and 
reasons for acceptance or rejection. 
 
LTQ-MS/MS 
DATA             
Sequence position X-corr z mh MS3 comments 
F.SKVIDELSS@CHA
VL.S 90-103 2.49 2 1580.77 NO 
Top 3 ions don't match 
prospector output, 
losses 
Y.IFESNNEGEKICDS
@VGLAKQIAL.H 605-627 4.10 3 2558.25 NO 
Top 4 out of 10 ions 
don't match prospector 
output 
F.DIIS@PVC*EDQPG
QAKAF.G 456-472 3.76 2 1954.93 YES 
Triggered MS3, top ions 
match prospector output 
F.DIIS@PVC*EDQPG
QAKAF.G 456-472 3.85 2 1954.93 YES 
Top ions match 
prospector output 
              
E.GQFVVLSSS@QS
EESDLGEGGKKRE.S 683-706 4.62 3 2633.24 YES 
Triggered MS3, top ions 
match prospector output 
E.GQFVVLSSS@QS
EESDLGEGGKKRE.S 683-706 5.53 3 2633.24 ---- 
Replicate of previously 
confirmed assignment. 
E.GQFVVLSSSQS@
EES@DLGEGGKKR
E.S 683-706 4.40 3 2713.24 YES 
Top ions match 
prospector output.  
Some ambiguity of site 
assignment.  
Reasonably confident. 
E.GQFVVLSSS@QS
EESDLGEGGKKRE.S 683-706 5.38 3 2633.24 ---- 
Replicate of previously 
confirmed assignment. 
E.GQFVVLSSS@QS
EESDLGEGGKKRE.S 683-706 5.03 3 2633.24 ---- 
Replicate of previously 
confirmed assignment. 
E.GQFVVLSSSQS@
EESDLGEGGKKRE.S 683-706 3.23 3 2633.24 NO 
No neutral loss, some 
mismatched 
assignments, sites of 
phosphorylation not 
bracketed. 
Q.IY@LS@ENPEETA
ARVNQSALE.A 377-396 2.19 2 2394.09 YES 
Top 6 of 10 ions don't 
correspond to b ions, y 
ions or any losses of b 
and y ions. 
E.GQFVVLSSSQS@
EESDLGEGGKKRE.S 683-706 4.52 3 2633.24 YES 
Ions bracketing sites not 
confident. 
A.AS@S@RPNQASS
EGQFVVLSSSQSEE
SDLGEGGKKRE.S 672-706 3.27 3 3827.74 NO 
Proposed 
phosphorylation sites 
not bracketed 
             
R.LIAASSRPNQASS
EGQFVVLS@SSQSE
ESDLGEGGK.K 669-703 6.32 3 3631.71 YES 
Top ions match 
prospector output.  
Some ambiguity of site 
assignment.  
Reasonably confident. 
R.VIDELSS@CHAVL
STQLADAMMFPITQF
K.E 92-119 5.56 3 3175.53 NO 
Top ions match 
prospector output.  
Some ambiguity of site 
assignment.  
Reasonably confident. 
R.LIAASSRPNQASS
EGQFVVLS@SSQSE
ESDLGEGGK.K 669-703 5.86 3 3631.71 ---- 
Replicate of previously 
confirmed assignment. 
K.MGS@ENLNEQLE
EFLANIGTSVQNVR.
R 213-237 3.46 3 2872.35 NO 
Top ions don't match 
prospector output. 
R.LIAASSRPNQASS
EGQFVVLS@SSQSE 669-703 5.94 3 3631.71 --- 
Replicate of previously 
confirmed assignment. 
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ESDLGEGGK.K 
R.TNPFGESGGSTKS
@ETEDSILHQLFIVR.
F 479-505 3.85 3 3029.46 YES 
Top ions above 1000m/z 
match 
R.LIAASSRPNQASS
EGQFVVLS@SSQSE
ESDLGEGGK.K 669-703 4.88 3 3631.71 ---- 
Replicate of previously 
confirmed assignment. 
R.LIAASSRPNQASS
EGQFVVLS@SSQSE
ESDLGEGGK.K 669-703 6.11 3 3631.71 ---- 
Replicate of previously 
confirmed assignment. 
R.SESNLSSVCY@IF
ESNNEGEK.I 595-614 4.14 3 2315.97 NO 
Top ions match 
prospector output.  
Some ambiguity of site 
assignment.  
Reasonably confident. 
R.LIAASSRPNQASS
EGQFVVLS@SSQSE
ESDLGEGGK.K 669-703 5.99 3 3631.71 ---- 
Replicate of previously 
confirmed assignment. 
R.LIAASSRPNQASS
EGQFVVLS@SSQSE
ESDLGEGGK.K 669-703 5.46 3 3631.71 ---- 
Replicate of previously 
confirmed assignment. 
R.LIAASSRPNQASS
EGQFVVLS@SSQSE
ESDLGEGGK.K 669-703 5.99 3 3631.71 ---- 
Replicate of previously 
confirmed assignment. 
R.LIAASSRPNQASS
EGQFVVLS@SSQSE
ESDLGEGGK.K 669-703 5.52 3 3631.71 ---- 
Replicate of previously 
confirmed assignment. 
R.SESNLSS@VCYIF
ESNNEGEK.I 595-614 3.00 3 2315.97   
Ions do not bracket site 
of phosphorylation.  
Numerous mismatches. 
R.LIAASSRPNQASS
EGQFVVLS@SSQSE
ESDLGEGGK.K 669-703 4.37 3 3631.71 ---- 
Replicate of previously 
confirmed assignment. 
R.LIAASSRPNQASS
EGQFVVLS@SSQSE
ESDLGEGGK.K 669-703 6.12 3 3631.71 ---- 
Replicate of previously 
confirmed assignment. 
R.SESNLSSVCY@IF
ESNNEGEK.I 595-614 3.15 2 2315.97 NO 
Top ions match 
prospector output.  
Some ambiguity of site 
assignment.  
Reasonably confident. 
R.VNQSALEAVTPS
@PSFQQR.H 390-407 4.95 2 2038.99 NO 
Top ions match 
prospector output.  
Some ambiguity of site 
assignment.  
Reasonably confident. 
R.SESNLSSVCY@IF
ESNNEGEK.I 595-614 4.75 2 2315.97 NO 
Numerous low intensity 
peaks do not match. 
K.QIY@LSENPEETA
AR.V 376-389 3.65 2 1700.79 NO 
Top ions match 
prospector output.   
R.LIAASSRPNQASS
EGQFVVLS@SSQSE
ESDLGEGGK.K 669-703 4.05 3 3631.71  ---- 
Replicate of previously 
confirmed assignment. 
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APPENDIX C 
 
Table of initial APPL1 phosphorylation site identifications by LTQ-Orbitrap-MS 
and reasons for acceptance or rejection. 
 
LTQ-ORBITRAP-MS/MS  
DATA 
Pos-
ition 
X 
corr ppm 
MS3 
triggered Conf-irmed comments 
           
Q.SRPPTARTSS@SGS@LGS 
ESTNL.A 
418-
438 2.52 0.93 YES YES 
Ions bracket site of 
phosphorylation, 
reasonably 
confident but some 
ambiguity of exact 
site. 
A.AGQSRPPTARTSS@SGSL 
GSESTNL.A 
415-
438 2.68 -0.62 NO YES 
Bracket site of 
phosphorylation 
and appear to 
support site 
assignment. 
L.SLDSLVAPDTPIQFDIIS@P 
VC*EDQPGQAKAF.G 
442-
472 4.43 0.87 NO NO 
Numerous 
unassigned peaks. 
D.TPIQFDIIS@PVC*EDQPGQ 
AKAF.G 
451-
472 4.36 -0.08 YES YES 
Confident 
assignments, site 
bracketed, neutral 
loss observed. 
W.IC*TINNIS@KQIYLSENPEE 
TAARVNQSAL.E 
367-
395 4.77 3.30 NO YES 
Ions bracket site of 
phosphorylation, 
reasonably 
confident but some 
ambiguity of exact 
site. 
Q.SRPPTARTSSSGS@LGSES 
TNL.A 
418-
438 2.97 1.10 YES YES 
Confident 
assignments, site 
bracketed, neutral 
loss observed. 
D.SLVAPDTPIQFDIIS@PVC*E 
DQPGQAKAF.G 
445-
472 4.65 -0.77 NO NO 
Some mismatched 
peaks, no neutral 
loss observed, site 
uncertain. 
F.DIIS@PVC*EDQPGQAKAF.G 
456-
472 3.55 0.82 YES NO 
Can't confirm 
charge state by 
precursor peaks. 
D.IIS@PVC*EDQPGQAKAF.G 
457-
472 3.2 0.33 YES YES 
Confident 
assignments, site 
bracketed, neutral 
loss observed. 
             
E.GQFVVLSSSQS@EESDLG 
EGGKKRE.S 
683-
706 4.92 383.76 YES NO 
Parts per million 
error too large. 
E.GQFVVLSSSQS@EESDLG 
EGGKKRE.S 
683-
706 4.04 11.61 NO YES 
Ions bracket site of 
phosphorylation, 
reasonably 
confident but some 
ambiguity of exact 
site. 
A.AS@S@RPNQASSEGQFV 
VLSSSQSEESDLGEGGKKRE.S 
672-
706 3.8 435.00 NO NO 
Parts per million 
error too large. 
E.GQFVVLSSSQS@EESDLG 
EGGKKRE.S 
683-
706 5.16 0.91 YES YES 
Confident 
assignments, site 
bracketed, neutral 
loss observed. 
I.AASSRPNQASS@EGQFVVL 
SSSQSEESDLGEGGKKRE.S 
671-
706 3.44 292.72 NO NO 
Parts per million 
error too large. 
E.GQFVVLSSS@QSEESDLG 683- 5.93 -0.23 NO YES Ions bracket site of 
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EGGKKRE.S 706 phosphorylation, 
reasonably 
confident but some 
ambiguity of exact 
site. 
E.GQFVVLSSS@QSEESDLG 
EGGKKRE.S 
683-
706 4.08 2.28 YES YES 
Replicate of 
previously 
confirmed 
assignment. 
E.GQFVVLSSSQS@EESDLG 
EGGKKRESE.A 
683-
708 4.45 5.58 YES YES 
Replicate of 
previously 
confirmed 
assignment. 
F.VVLSSSQS@EES@DLGEG 
GKKRE.S 
686-
706 2.83 -4.53 YES YES 
Confident 
assignments, site 
bracketed, neutral 
loss observed. 
G.QFVVLS@S@S@QSEESDLG 
EGGKKRE.S 
684-
706 3.41 
-
858.54 NO NO 
Parts per million 
error too large. 
E.GEKICDS@VGLAKQIALHAE.L 
612-
630 3.65   YES NO 
Isotopic overlap of 
potential precursor 
peaks confounds 
precursor 
assignment. 
E.GQFVVLSSSQS@EESDLGEG 
GKKRE.S 
683-
706 4.75 378.98 NO NO 
Parts per million 
error too large. 
A.AS@S@RPNQASSEGQFVVL 
SSSQSEESDL 
GEGGKKRE.S 
672-
706 3.96 445.65 NO NO 
Parts per million 
error too large. 
E.GQFVVLSSSQS@EESDLGEG 
GKKRE.S 
683-
706 5.66 0.23 YES ---- 
Replicate of 
previously 
confirmed 
assignment. 
F.VVLSSS@QSEESDLGEGGKK 
RE.S 
686-
706 2.9 -2.34 YES YES 
Ions bracket site of 
phosphorylation, 
reasonably 
confident but some 
ambiguity of exact 
site. 
P.NQAS@S@EGQFVVLSSSQS 
EESDLGEGGKKRE.S 
677-
706 3.73 516.98 NO NO 
Parts per million 
error too large. 
              
R.LIAASSRPNQASSEGQFVVL 
S@SSQSEESDLGEGGK.K 
669-
703 6.99 -7.93 YES YES 
Ions bracket site of 
phosphorylation, 
reasonably 
confident but some 
ambiguity of exact 
site. 
R.SESNLSSVCY@IFESNNEG 
EK.I 
595-
614 4.08 
-
415.58 NO NO 
Parts per million 
error too large. 
R.TSSSGS@LGSESTNLAAL 
SLDSLVAPDTPIQFDIISPVC* 
EDQPGQAK.A 
425-
470 4.68 210.77 NO NO 
Parts per million 
error too large. 
R.TNPFGESGGSTKS@ETE 
DSILHQLFIVR.F 
479-
505 4.67   YES NO 
Isotopic overlap of 
potential precursor 
peaks confounds 
precursor 
assignment. 
R.SESNLSSVCY@IFESNNE 
GEK.I 
595-
614 4.49 
-
836.53 NO NO 
Precursor peak not 
readily evident, 
error too large. 
R.LIAASSRPNQASSEGQFV 
VLS@SSQSEESDLGEGGK.K 
669-
703 5.17   NO NO 
Isotopic overlap of 
potential precursor 
peaks confounds 
precursor 
assignment. 
R.LIAASSRPNQASSEGQFV 
VLS@SSQSEESDLGEGGK.K 
669-
703 7.16 277.49 NO NO 
Parts per million 
error too large. 
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K.DHEEWICT@INNISK.Q 
362-
375 3.02 
-
533.48 NO NO 
Parts per million 
error too large. 
R.LIAASSRPNQASSEGQF 
VVLS@SSQSEESDLGEGGK.K 
669-
703 6.88 3.96 YES Yes 
Replicate, good 
parts per million 
error. 
R.LIAASSRPNQASSEGQFV 
VLS@SSQSEESDLGEGGK.K 
669-
703 7.54 5.28 NO ---------------- 
Replicate of 
previously 
confirmed 
assignment. 
R.LIAASSRPNQASSEGQFV 
VLS@SSQSEESDLGEGGK.K 
669-
703 5.13   NO NO 
Isotopic overlap of 
potential precursor 
peaks confounds 
precursor 
assignment. 
K.MGS@ENLNEQLEEFLANI 
GTSVQNVR.R 
213-
237 4.6   YES NO 
Isotopic overlap of 
potential precursor 
peaks confounds 
precursor 
assignment. 
R.VNQSALEAVTPS@PSFQ 
QR.H 
390-
407 3.92 -2.45 NO YES 
Some bracketing of 
assignments, error 
within confident 
range, ambiguity of 
exact 
phosphorylation 
sites. 
R.LIAASSRPNQASSEGQFV 
VLS@SSQSEESDLGEGGK.K 
669-
703 5.15 0.50 NO ---------------- 
Replicate of 
previously 
confirmed 
assignment. 
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APPENDIX D 
 
Supplementary data for confirmation of BEMA in labeling on beta-casein.  
 
The confirmation of beta-casein fragment 48-63 (FQpSEEQQQTEDELQDK) is 
shown. For this peptide, the BEMA reaction is near quantitative. 
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APPENDIX E 
 
Normalized peak area ratios for varying molar concentrations of Tb and Ho 
labeled phosphorylated peptides in MALDI-TOFMS. 
 
 
5 (Tb-labeled):1 (Ho-labeled) molar ratio WAGGDApSGE analyzed by MALDI-TOFMS 
 
        
 
1 (Tb):1 (Ho) 
 
sample # 
Selected Tb-
labeled m/z 
Tb-labeled 
peak area 
Selected Ho-
labeled m/z 
Ho-
labeled 
peak area 
Relative Peak 
Area Ratio 
           
1 1607.43 1423.22 1613.43 172.99 8.23 
1 1607.28 9851.83 1613.27 2517.59 3.91 
1 1607.24 3715.28 1613.16 526.79 7.05 
1 1607.24 2506.79 1613.21 837.87 2.99 
1 1607.25 1420.09 1613.21 191.52 7.41 
2 1607.59 2622.48 1613.62 587.23 4.47 
2 1607.58 2603.36 1613.60 660.74 3.94 
2 
peak 
intensity too 
low        
2 1607.66 2429.36 1613.59 390.70 6.22 
2 
peak 
intensity too 
low        
3 1607.56 441.06 1613.66 104.41 4.22 
3 1607.67 1087.55 1613.66 309.52 3.51 
3 
peak 
intensity too 
low        
3 1607.63 1413.01 1613.62 198.66 7.11 
3 1607.41 3781.71 1613.28 477.87 7.91 
    average 5.4075 
relative 
error 0.08 
 
 
 
1 (Tb-labeled):5 (Ho-labeled) molar ratio WAGGDApSGE analyzed by MALDI-TOFMS  
 
        
Sample # 
Selected Tb-
labeled m/z 
Tb-labeled 
peak area 
Selected Ho-
labeled m/z 
Ho-
labeled 
peak area 
Relative Peak 
Area Ratio 
          
1 1607.14 774.93 1613.20 3816.00 0.20 
1 1607.23 1490.58 1613.21 5142.25 0.29 
1 1607.28 1107.85 1613.27 4087.57 0.27 
1 1607.14 722.26 1613.20 2357.26 0.31 
1 1607.18 705.90 1613.16 3710.51 0.19 
 111 
2 1607.98 1726.10 1613.00 10414.48 0.17 
2 1607.11 714.03 1613.14 6500.69 0.11 
2 1606.89 217.05 1613.04 1965.50 0.11 
2 1606.99 352.08 1613.99 1974.91 0.18 
2 1607.10 1047.98 1613.12 5465.97 0.19 
3 1607.23 1904.65 1613.20 11115.08 0.17 
3 1607.14 714.90 1613.11 2986.33 0.24 
3 1607.99 852.08 1613.00 5932.84 0.14 
3 1607.04 729.15 1613.07 3967.66 0.18 
3 1607.27 2295.76 1613.27 12673.50 0.18 
4 1607.13 3004.65 1613.12 14170.80 0.21 
4 1607.12 5066.96 1613.12 24952.40 0.20 
4 1606.99 1427.47 1612.98 5494.21 0.26 
4 1607.04 1898.93 1613.03 9520.45 0.20 
4 1607.17 3071.98 1613.18 13470.76 0.23 
5 1607.20 615.82 1613.25 4392.40 0.14 
5 1607.23 1596.99 1613.22 7732.68 0.21 
5 1607.21 2735.46 1613.19 9531.61 0.29 
5 1606.91 744.02 1612.91 2987.99 0.25 
5 1607.09 2055.87 1613.09 8062.50 0.25 
  average 0.2070 
relative 
error 0.04 
 
 
 
1 (Tb-labeled):1 (Ho-labeled) molar ratio WAGGDApSGE analyzed by MALDI-TOFMS  
 
        
sample # 
Selected Tb-
labeled m/z 
Tb-labeled 
peak area 
Selected Ho-
labeled m/z 
Ho-
labeled 
peak area 
Relative Peak 
Area Ratio 
            
1 1607.72 3228.61 1613.69 4625.82 1.43 
1 1607.70 7004.42 1613.70 7856.04 1.12 
1 1607.72 12904.85 1613.74 14640.67 1.13 
1 1607.70 7874.79 1613.69 8990.98 1.14 
1 1607.70 7619.63 1613.30 8047.21 1.06 
2 1607.66 8426.09 1613.66 6004.65 0.71 
2 1607.56 8586.85 1613.53 6870.04 0.80 
2 1607.60 15273.02 1613.57 12639.61 0.83 
2 1607.57 5338.15 1613.57 1892.91 0.35 
2 1607.58 5206.04 1613.55 4319.97 0.83 
3 1607.46 12767.89 1613.44 9846.99 0.77 
3 1607.38 5605.78 1613.40 6690.62 1.19 
3 1607.35 6125.84 1613.36 5709.91 0.93 
3 1607.36 1025.96 1613.33 1681.95 1.64 
3 1607.54 14342.52 1613.46 10558.51 0.74 
4 1607.43 4255.02 1613.39 2219.92 0.52 
 112 
4 1607.41 14361.34 1613.38 17776.02 1.24 
4 1607.58 4985.82 1613.59 4702.94 0.94 
4 1607.63 4988.10 1613.57 11084.98 2.22 
4 1607.58 3721.85 1613.52 3615.98 0.97 
    average 1.0290 
relative 
error 0.03 
 
 
1 (Tb-labeled):1 (Ho-labeled) molar ratio FQpSEEQQQTEDELQDK analyzed by MALDI-TOFMS  
 
        1 (Tb):1 (Ho) 
sample # 
Selected Tb-
labeled m/z 
Tb-labeled 
peak area 
Selected Ho-
labeled m/z 
Ho-
labeled 
peak area 
Relative Peak 
Area Ratio 
           
1 2741.60 1705.80 2747.57 1793.72 0.95 
1 2741.49 1420.79 2747.52 1391.32 1.02 
1 2741.46 1705.03 2747.47 1666.97 1.02 
2 2741.22 1107.12 2747.18 1069.85 1.03 
2 2741.25 1239.22 2747.22 1230.74 1.01 
2 2741.84 457.16 2747.78 587.11 0.78 
3 2741.18 987.30 2747.18 989.74 1.00 
3 2741.25 1251.91 2747.26 1194.11 1.05 
3 2741.53 801.12 2747.58 598.75 1.34 
    average 1.0330 
relative 
error 0.03 
 
 
 
1 (Tb-labeled):5 (Ho-labeled) molar ratio FQpSEEQQQTEDELQDK analyzed by MALDI-TOFMS 
 
       1 (Tb):5 (Ho) 
sample # 
Selected Tb-
labeled m/z 
Tb-labeled 
peak area 
Selected Ho-
labeled m/z 
Ho-
labeled 
peak area 
Relative Peak 
Area Ratio 
           
1 2741.34 82.97 2747.35 481.98 0.17 
1 2741.22 226.92 2747.22 725.12 0.31 
1 2741.49 804.28 2747.45 3436.81 0.23 
2 2741.52 305.00 2747.49 1535.90 0.20 
2 2741.51 400.34 2747.49 1867.19 0.21 
2 2741.77 455.77 2747.76 2241.51 0.20 
3 2741.31 665.05 2747.26 2688.99 0.25 
3 2741.07 241.02 2747.01 963.76 0.25 
3 2741.83 223.55 2747.90 1130.44 0.20 
   average 0.2256 
relative 
error 0.13 
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5 (Tb-labeled):1 (Ho-labeled) molar ratio FQpSEEQQQTEDELQDK analyzed by MALDI-TOFMS  
 
 
        1 (Ho):5 (Tb) 
sample # 
Selected Tb-
labeled m/z 
Tb-labeled 
peak area 
Selected Ho-
labeled m/z 
Ho-
labeled 
peak area 
Relative Peak 
Area Ratio 
            
1 2740.60 2961.21 2746.63 581.79 0.20 
1 2741.54 2665.33 2747.46 410.48 0.15 
1 2741.38 2370.88 2747.41 522.00 0.22 
2 2740.59 1465.75 2746.55 406.55 0.28 
2 2741.39 2898.14 2747.40 546.68 0.19 
2 2741.30 2287.42 2747.32 509.73 0.22 
3 2741.55 1309.88 2747.56 297.34 0.23 
3 2741.56 2985.48 2747.55 566.89 0.19 
3 2741.54 1275.04 2747.59 245.97 0.19 
    average 0.2077 
relative 
error 0.04 
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APPENDIX F 
 
Spectra of relative quantitation of phosphorylated peptides by PhECAT in 
MALDI-TOFMS. 
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APPENDIX G 
 
G. Predicted and observed ions for Tb-labeled FQSEEQQQTEDELQDK as 
represented in Figure 18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*s,y,t = phosphorylated S,Y,T 
Predicted b ion m/z       
Predicted b-H2O ion 
m/z   
  # 
Predicted 
b ion m/z Tb-labeled Observed   
Predicted 
b-H2O ion 
m/z Tb-labeled Observed 
F 1 --- --- ---   --- --- --- 
Q 2 276.13 --- ---   --- --- --- 
s* 3 443.13 1121.58 1121.33   ---   --- 
E 4 572.18 1250.62 1250.62   554.16 1232.61 1232.53 
E 5 701.22 1379.66 1379.47   683.21 1361.65 1361.73 
Q 6 829.28 1507.72 1507.50   811.27 1489.71 --- 
Q 7 957.34 1635.78 1635.51   939.32 1617.77 1618.54 
Q 8 1085.39 1763.84 1763.60   1067.38 1745.83 1745.51 
T 9 1186.44 1864.89 1865.58   1168.43 1846.87 1846.73 
E 10 1315.48 1993.93 1993.68   1297.47 1975.92 1975.82 
D 11 1430.51 2108.95 2108.74   1412.50 2090.94 2090.29 
E 12 1559.55 2238.00 2237.80   1541.54 2219.99 --- 
L 13 1672.64 2351.08 2350.86   1654.63 2333.07 2332.80 
Q 14 1800.70 2479.14 2479.96   1782.69 2461.13 2461.77 
D 15 1915.72 2594.17 2594.97   1897.71 2576.16 2576.87 
K 16 ---  ---   --- --- --- 
                 
Predicted 
y ion m/z       
Predicted y-H2O ion 
m/z   
 
ion 
# 
Predicted 
y ion m/z 
Tb-
Labeled Observed   
Predicted 
y-H2O 
ion m/z Tb-labeled Observed 
F 16 --- --- ---   --- --- --- 
Q 15 1914.76 2593.20 2593.55   1896.75 2575.19 --- 
s* 14 1786.70 2465.15 2465.85   1768.69 2447.13 2447.90 
E 13 1619.70 --- ---   1601.69 --- --- 
E 12 1490.66 --- ---   1472.65 --- --- 
Q 11 1361.62 --- ---   1343.61 --- --- 
Q 10 1233.56 --- ---   1215.55 --- --- 
Q 9 1105.50 --- ---   1087.49 --- --- 
T 8 977.44 --- ---   959.43 --- --- 
E 7 876.39 --- ---   858.38 --- --- 
D 6 747.35 --- ---   729.34 --- --- 
E 5 632.33 --- ---   614.31 --- --- 
L 4 503.28 --- ---   485.27 --- --- 
Q 3 390.20 --- ---   372.19 --- --- 
D 2 262.14 --- ---   244.13 --- --- 
K 1 147.11 --- ---   --- --- --- 
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APPENDIX H 
 
Normalized peak area ratios for varying molar concentrations of Tb and Ho 
labeled phosphorylated peptides in MALDI-IM-TOFMS. 
 
 
1(Pr-labeled):1(Tb-
labeled):5(Ho-labeled)  
FQpSEEQQQTEDELQDK 
analyzed by MALDI-IM-
TOFMS      
1(Pr):5(Ho), 
1(Tb):5(Ho) 
 
sam-
ple # 
Pr, Tb, and Ho-labeled 
m/z 
Pr-
labeled 
peak 
area 
Tb-
labeled 
peak 
area 
Ho-
labeled 
peak 
area 
Relative Peak 
Area Ratio 
          
1 
2723.30, 2741.77, 
2747.20 36.31 31.14 375.00 0.10, 0.08 
1 
2723.17, 2741.23, 
2747.21 27.81 30.19 451.00 0.06, 0.07 
1 
2723.25, 2741.09, 
2747.19 55.64 42.56 551.70 0.10, 0.08 
2 
2723.30, 2741.50, 
2747.23 79.97 74.28 380.40 0.21, 0.20 
2 
2723.37, 2741.42, 
2747.24 101.00 81.28 458.40 0.22, 0.18 
2 
2723.27, 2741.43, 
2747.24 65.38 66.75 448.60 0.15, 0.15 
3 
2723.37, 2741.43, 
2747.23 85.00 179.00 507.00 0.17, 0.35 
3 
2723.22, 2741.68, 
2747.23 43.25 52.57 364.40 0.12, 0.14 
3 
2723.30, 2741.72, 
2747.23 55.58 39.42 413.80 0.13, 0.10 
    average 
0.1400, 
0.1300 
relative 
error -0.30, -0.35 
 
3 (Tb-labeled):1 (Ho-
labeled) molar ratio 
FQpSEEQQQTEDELQDK 
analyzed by MALDI-IM-
TOFMS        
3 (Tb):1 (Ho) 
 
 
sam-
ple # 
Selected Tb-labeled m/z 
 
Tb-
labeled 
peak 
area 
Selected 
Ho-
labeled 
m/z 
Ho-
labeled 
peak 
area 
Relative Peak 
Area Ratio 
            
1 2741.99 168.40 2747.01 64.19 2.62 
2 2741.00 142.40 2747.01 58.98 2.41 
3 2740.98 377.10 2747.01 132.00 2.86 
4 2740.99 61.52 2747.00 36.29 1.70 
5 2740.98 559.70 2747.00 241.50 2.32 
6 2740.99 485.00 2747.01 226.40 2.14 
    average 2.3416 
relative 
error -0.22 
 
1 (Tb-labeled):1 (Ho-
labeled) molar ratio 
FQpSEEQQQTEDELQDK       
1 (Tb):1 (Ho) 
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analyzed by MALDI-IM-
TOFMS  
acq 
# 
 
Selected Tb-labeled m/z 
 
Tb-
labeled 
peak 
area 
Selected 
Ho-
labeled 
m/z 
Ho-
labeled 
peak 
area 
Relative Peak 
Area Ratio 
            
1 2741.03 2767.00 2747.04 2512.00 1.10 
2 2741.02 3449.00 2747.03 2877.00 1.20 
3 2741.01 5924.00 2747.02 4981.00 1.19 
4 2741.03 2697.00 2747.03 2315.00 1.17 
5 2741.02 3312.00 2747.03 2910.00 1.14 
    average 1.1586 
relative 
error 0.16 
 
1 (Tb-labeled):5 (Ho-
labeled) molar ratio 
FQpSEEQQQTEDELQDK 
analyzed by MALDI-IM-
TOFMS        
1 (Tb):5 (Ho) 
 
 
acq 
# 
 
Selected Tb-labeled m/z 
 
Tb-
labeled 
peak 
area 
Selected 
Ho-
labeled 
m/z 
Ho-
labeled 
peak 
area 
Relative Peak 
Area Ratio 
          
1 2741.04 1275.00 2747.01 4451.00 0.29 
2 2741.04 1599.00 2747.01 5222.00 0.31 
3 2741.04 1102.00 2747.01 3907.00 0.28 
4 2741.04 1234.00 2747.01 4274.00 0.29 
5 2741.03 1198.00 2747.01 3964.00 0.30 
    average 0.2931 
relative 
error 0.47 
 
5 (Tb-labeled):1 (Ho-
labeled) molar ratio 
FQpSEEQQQTEDELQDK 
analyzed by MALDI-IM-
TOFMS        
1 (Ho):5 (Tb) 
 
 
acq 
# 
 
Selected Tb-labeled m/z 
 
Tb-
labeled 
peak 
area 
 
Selected 
Ho-
labeled 
m/z 
Ho-
labeled 
peak 
area 
Relative Peak 
Area Ratio 
            
1 2741.99 12050.00 2748.04 2105.00 0.17 
2 2741.99 6300.00 2748.03 1075.00 0.17 
3 2742.00 3153.00 2748.04 575.20 0.18 
4 2741.98 8306.00 2747.04 1371.00 0.17 
5 2741.98 6976.00 2747.04 1170.00 0.17 
    average 0.1721 
relative 
error -0.14 
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APPENDIX I 
 
Sample spectra and data from relative quantitation of phosphorylated peptides by 
PhECAT in MALDI-IM-TOFMS. 
 
 
I. 1.  1 to 1 Tb to Ho-labeled beta-casein.  
 
m/z
2640 2650 2660 2670 2680 2690 2700 2710 2720 2730 2740 2750 2760 2770 2780 2790 2800 2810 2820 2830
%
0
100
m/z
2640 2650 2660 2670 2680 2690 2700 2710 2720 2730 2740 2750 2760 2770 2780 2790 2800 2810 2820 2830
%
0
100
090423_RANDI_TAG1TO1TBHO_001_dt_01 75 (9.491) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (48:165) TOF MS LD+ 
3.28e32742.0249
2741.0273
2740.0508
2730.03082724.0300
2698.0305
2638.1816 2697.0999
2679.08792653.0435 2660.9856 2671.0884
2703.0437
2722.0435
2707.0347
2718.0449
2731.0366
2748.0313
2749.0322
2750.0427
2751.0488
2752.0457
2770.0552
2760.1865 2787.02122772.0652 2830.00442808.0137
2792.9810 2825.0464
090423_RANDI_TAG1TO1TBHO_001_dt_01  75 (9.491) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (48:165) TOF MS LD+ 
2452742.0090
2741.0222
2739.9973
2724.0068
2723.0234
2704.0659
2697.9985
2638.1697
2683.98782681.0410
2722.02102707.0449
2730.0073
2732.0156
2748.0095
2749.0168
2750.0242
2751.0515
2752.0398
2770.0754
2753.0867 2780.0017
2786.0244 2792.9712
2824.08472808.0068
 
 
Sample 01 – 1 
mass  peak area 
Tb 2741.0273 2.767e3 
Ho  2747.0354 2.512e3 
 
m/z
2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790
%
0
100
m/z
2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790
%
0
100
090423_RANDI_TAG1TO1TBHO_002_dt_01 75 (9.491) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (43:172) TOF MS LD+ 
4.05e32742.0166
2741.0242
2740.0447
2730.04222724.0447
2697.0205 2705.0291
2699.5562
2722.0696
2707.0344
2711.0520
2714.0552 2718.0605
2732.0530
2733.0264
2738.4492
2748.02592743.0137
2747.0327
2749.0239
2750.0327
2751.0435
2752.0549
2764.03912753.0803 2762.0698 2770.0588 2772.0476
2787.0137
2784.9956
2779.9976 2789.0200
090423_RANDI_TAG1TO1TBHO_002_dt_01  75 (9.491) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (43:172) TOF MS LD+ 
2892742.0090
2741.0032
2740.0359
2730.02692724.0068
2723.0430
2698.0176
2696.0605 2704.0278 2706.0068 2722.0791
2712.9497
2732.0347
2733.0391
2748.0095
2742.9958
2747.0222 2749.0168
2750.0242
2751.0515
2752.0203
2769.02562765.06082763.00172753.0671
2771.0281
2786.9995
2784.9912
 
 
Sample 01-2 
mass  peak area 
Tb 2741.0242 3.449e3 
Ho  2747.0327 2.877e3 
 142 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG1TO1TBHO_003_dt_01 71 (8.978) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (42:175) TOF MS LD+ 
6.83e32742.0007
2741.0115
2740.0400
2724.0371
2723.0413
2722.0510
2720.0183
2716.0100
2730.03982725.0352
2726.0293
2731.0269
2733.0327
2736.0488
2748.01422743.0024
2747.0217
2744.0134
2746.0374
2749.0176
2750.0278
2751.0332
2752.0508
2765.06352764.0581
2753.1060 2760.05762754.0173 2759.1257
2770.03252769.0461 2771.00932773.0425 2776.0530
090423_RANDI_TAG1TO1TBHO_003_dt_01  71 (8.978) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (42:175) TOF MS LD+ 
5252741.9895
2740.9836
2740.0164
2724.0454
2723.0430
2722.0210
2730.02692725.0293
2726.0127
2731.0112
2733.0195
2748.0095
2742.9958
2744.0022
2748.9978
2750.0242
2751.0125
2752.0784
2764.03102763.0212 2770.05592765.0413
 
 
Sample 01-3 
 mass  peak area 
Tb 2741.0115 5.924e3 
Ho  2747.0217 4.981e3 
 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG1TO1TBHO_004_dt_01 74 (9.363) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (44:179) TOF MS LD+ 
3.12e32742.0110
2741.0254
2740.0432
2730.03222724.0493
2723.0344
2722.0959
2716.03642720.0662
2725.0457
2726.0320
2731.0378
2733.0422
2739.0002
2737.9072
2748.02762743.0139
2747.0332
2744.0273
2746.0437
2749.0271
2750.0320
2751.0408
2752.0540
2770.03762763.0459
2752.9905 2762.04372757.0566
2769.0303 2771.0410 2774.0706
2778.3013
090423_RANDI_TAG1TO1TBHO_004_dt_01  74 (9.363) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (44:179) TOF MS LD+ 
2282741.9895
2741.0222
2740.0359
2730.02692724.02642723.0234
2722.0981
2725.0483
2731.0112
2732.0542
2734.0435
2748.0095
2743.0149
2747.0222
2744.0022
2749.0168
2750.0242
2751.0320
2752.0203
2770.01682765.0217
2763.0403
2753.9978
2769.0256
2771.0476
 
 
Sample 01-4 
 mass  peak area 
Tb 2741.0254 2.697e3 
Ho  2747.0332 2.315e3 
 
 143 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG1TO1TBHO_005_dt_01 74 (9.363) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (46:177) TOF MS LD+ 
3.92e32742.0110
2741.0166
2740.0447
2724.0300
2723.0500
2722.0635
2720.16632718.0459
2730.03782725.0259 2731.0403
2732.0344
2734.0100
2739.1648
2748.0176
2743.0078
2747.0295
2744.0154
2746.0342
2749.0247
2750.0361
2751.0352
2752.0447
2764.0134
2763.03172753.0713
2758.1350
2754.1707
2770.02982769.0325 2771.0378
2773.0222 2777.9946
090423_RANDI_TAG1TO1TBHO_005_dt_01  74 (9.363) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (46:177) TOF MS LD+ 
2802742.0090
2741.0032
2740.0359
2725.02932724.0264
2723.0234
2722.0596
2730.00732729.0420
2731.0498
2733.0581
2734.0244
2748.0095
2742.9958
2747.0027
2744.0022
2748.9978
2750.0242
2751.0125
2752.0398
2763.9924
2763.02122753.1057
2770.03642769.0256 2771.0476 2774.1023
 
 
Sample 01-5 
 mass  peak area 
Tb 2741.0166 3.312e3 
Ho  2747.0295 2.910e3 
 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG1TO5TBHO_001_dt_01 74 (9.363) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (37:180) TOF MS LD+ 
5.11e32747.9946
2747.0068
2746.0352
2742.0217
2741.0381
2730.0222
2729.0391
2728.0549
2724.03832723.05402719.9260
2731.0200
2732.0271
2740.0576
2733.0334
2734.99492737.0630
2743.0281
2748.9998
2750.0120
2751.0325
2752.0281
2770.03492753.0215 2769.0251
2765.03222764.02812760.12162756.4512
2771.0459 2774.0129
2777.1250
090423_RANDI_TAG1TO5TBHO_001_dt_01  74 (9.363) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (37:180) TOF MS LD+ 
3832747.9709
2747.0027
2746.0154
2742.0281
2741.0417
2731.01122730.0269
2728.0581
2724.02642723.0234
2732.0156 2740.0554
2733.0195
2743.0149
2748.9783
2750.0051
2751.0320
2752.0203
2769.99782769.06422753.0090
2771.0476
 
 
Sample 02-1 
 mass  peak area 
Tb 2741.0381 1.279e3 
Ho  2747.0068 4.451e3 
 144 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG1TO5TBHO_002_dt_01 75 (9.491) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (45:174) TOF MS LD+ 
5.95e32747.9968
2747.0085
2746.0337
2742.0344
2741.0381
2730.0264
2729.0405
2728.0471
2724.02862723.05182715.95852717.9878
2731.0347
2740.0430
2732.0322
2734.0286
2738.0227
2743.0278
2749.0012
2750.0134
2751.0254
2752.0369
2770.04662769.0354
2753.0283
2765.0671
2764.0500
2760.0613
2758.0471 2771.0283
2778.0327
2774.0154
090423_RANDI_TAG1TO5TBHO_002_dt_01  75 (9.491) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (45:174) TOF MS LD+ 
4512747.9905
2747.0027
2746.0344
2742.0281
2741.0222
2730.04592729.0229
2728.0581
2724.06492723.0430
2731.0308
2740.0554
2732.0156
2734.0244
2743.0344
2748.9783
2750.0051
2751.0125
2752.0398
2770.07542752.9700 2768.9866 2772.0007
 
 
Sample 02-2 
 mass  peak area 
Tb 2741.0381 1.599e3 
Ho  2747.0085 5.222e3 
 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG1TO5TBHO_003_dt_01 74 (9.363) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (33:171) TOF MS LD+ 
4.59e32748.0051
2747.0149
2746.0393
2742.0330
2741.0422
2730.0359
2729.0383
2728.0569
2724.04352723.0513
2718.9968 2727.0386
2731.0266 2740.0544
2733.0188
2735.03522737.0637
2743.0281
2749.0112
2750.0149
2751.0278
2752.0325
2770.04392769.03912753.0212
2763.07932758.2593
2755.0435 2760.0430 2771.0479
2776.0425
2778.0190
090423_RANDI_TAG1TO5TBHO_003_dt_01  74 (9.363) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (33:171) TOF MS LD+ 
3462747.9905
2747.0027
2746.0344
2742.0281
2741.0417
2730.02692729.0034
2728.0386
2724.99072724.0264
2730.9922 2740.0745
2733.0005
2734.0435
2743.0344
2748.9978
2749.9856
2751.0125
2752.0203
2769.04472753.0286 2770.0168
 
 
Sample 02-3 
 mass  peak area 
Tb 2741.0422 1.102e3 
Ho  2747.0149 3.907e3 
 145 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG1TO5TBHO_004_dt_01 74 (9.363) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (40:186) TOF MS LD+ 
4.94e32748.0000
2747.0093
2746.0330
2742.0330
2741.0354
2730.0273
2729.0320
2728.0276
2724.0330
2723.03712716.0479 2718.5881
2731.0310
2740.0498
2732.0198
2733.0146
2736.0337
2743.0259
2749.0029
2750.0149
2751.0234
2752.0313
2770.00812769.0537
2753.0364
2765.1245
2764.07372761.9961
2758.1738
2771.0173
2773.0576 2778.0527
090423_RANDI_TAG1TO5TBHO_004_dt_01  74 (9.363) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (40:186) TOF MS LD+ 
3732747.9905
2746.9832
2746.0154
2742.0090
2741.0222
2730.0269
2729.0229
2728.0195
2724.02642723.0044
2731.0308 2740.0554
2733.0005
2743.0344
2748.9783
2750.0051
2751.0125
2752.0203
2769.99782769.0837
2753.0286 2771.0090
 
 
Sample 02-4 
 mass  peak area 
Tb 2741.0354 1.234e3 
Ho  2747.0093 4.274e3 
 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG1TO5TBHO_005_dt_01 74 (9.363) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (42:170) TOF MS LD+ 
4.67e32748.0015
2747.0107
2746.0356
2742.0278
2741.0337
2730.0371
2729.0371
2728.0520
2724.02932723.0488
2716.9519 2719.1270
2731.0276 2740.0417
2733.0278
2735.0313 2738.0037
2743.0256
2749.0056
2750.0159
2751.0293
2752.0393
2770.02812769.05032753.0378
2765.00492762.0691
2761.0488
2756.1326
2771.0107
2773.0168 2777.0566
090423_RANDI_TAG1TO5TBHO_005_dt_01  74 (9.363) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (42:170) TOF MS LD+ 
3672747.9905
2747.0027
2746.0344
2742.0476
2741.0222
2730.0073
2729.0420
2728.0386
2724.04542723.0234
2731.0498
2740.0359
2733.0195
2743.0344
2748.9978
2750.0051
2751.0125
2752.0398
2770.01682769.08372753.0476 2771.0090
 
 
Sample 02-5 
 mass  peak area 
Tb 2741.0337 1.198e3 
Ho  2747.0107 3.964e3 
 
 146 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG5TO1TBHO_001_dt_01 75 (9.491) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (41:175) TOF MS LD+ 
1.21e42741.9856
2740.9980
2740.0244
2724.0259
2723.0264
2722.0457
2718.0759 2721.4893
2725.0186
2726.0251
2727.0193 2730.0388
2732.0337 2738.06182735.9636
2742.9878
2744.0012
2745.0134
2748.0371
2749.0349
2750.0403 2764.0303
2763.03712751.0420
2759.0308
2753.9221
2765.0247
2769.0288 2770.0320 2773.0398 2775.9971
090423_RANDI_TAG5TO1TBHO_001_dt_01  75 (9.491) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (41:175) TOF MS LD+ 
8962741.9700
2740.9836
2740.0164
2724.0264
2723.0234
2722.0596
2725.0098
2726.0127
2729.0420 2730.0459
2742.9763
2743.9827
2745.0085
2748.0291
2749.0364
2750.0242
2764.03102763.02122751.0320 2765.0022
 
 
Sample 03-1 
 mass  peak area 
Tb 2741.9856 1.205e4 
Ho  2748.0371 2.105e3 
 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG5TO1TBHO_002_dt_01 71 (8.978) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (43:180) TOF MS LD+ 
6.30e32741.9883
2740.9990
2740.0308
2724.0266
2723.0308
2722.0518
2721.04862718.1470
2725.0247
2727.0181
2730.0518 2731.0332
2738.0242
2736.9653
2742.9939
2744.0061
2745.0200
2747.0354 2748.0310
2750.0505
2764.01442751.0466 2763.0229
2758.0955
2757.0342 2765.0176 2768.0374 2770.03562772.0576 2778.0122
090423_RANDI_TAG5TO1TBHO_002_dt_01  71 (8.978) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (43:180) TOF MS LD+ 
4722741.9700
2740.9836
2740.0164
2724.02642723.0044
2722.0405
2725.0293
2727.01612729.0420
2742.9763
2743.9827
2745.0281
2748.0291
2749.0559
2750.0437
2763.99242751.0706 2763.0212 2764.9832
 
 
Sample 03-2 
 mass  peak area 
Tb 2741.9883 6.300e3 
Ho  2748.0310 1.075e3 
 
 147 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG5TO1TBHO_003_dt_01 72 (9.106) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (39:178) TOF MS LD+ 
3.17e32742.0007
2741.0103
2740.0295
2724.0291
2723.0286
2722.0461
2716.8298 2719.0002
2725.0259
2727.0330
2729.0454 2732.0142
2737.0881
2743.0017
2744.0105
2745.0195
2747.0422 2748.0437
2764.02862750.0474 2763.0166
2751.0161 2762.03442754.0156
2755.9751
2765.0090
2767.0134 2770.0337 2773.0342
2777.1672
090423_RANDI_TAG5TO1TBHO_003_dt_01  72 (9.106) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (39:178) TOF MS LD+ 
2372741.9895
2740.9836
2740.0164
2724.04542723.0044
2722.0596
2724.9907
2727.0352 2730.0073
2731.9961
2742.9958
2744.0022
2744.9890
2747.0413 2748.0486
2764.05052763.00172750.0632
2751.0125 2762.0891
2764.9832
2767.0427
 
 
Sample 03-3 
 mass  peak area 
Tb 2741.0103 2.729e3 
Ho  2742.0007 3.168e3 
 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG5TO1TBHO_004_dt_01 73 (9.234) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (41:186) TOF MS LD+ 
8.31e32741.9800
2740.9917
2740.0249
2724.0237
2723.0283
2722.0435
2721.16142719.0515
2725.0198
2726.0159
2727.0168 2730.0193
2738.0325
2732.0701
2734.0291
2742.9856
2744.0027
2745.0129
2748.0410
2749.0398
2750.0464
2751.0559 2763.0369
2762.0483
2759.1060
2754.0671
2764.0479 2769.0332 2771.9773 2774.1047 2777.9893
090423_RANDI_TAG5TO1TBHO_004_dt_01  73 (9.234) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (41:186) TOF MS LD+ 
6382741.9700
2740.9836
2740.0164
2724.0068
2723.0234
2722.0791
2725.0098
2726.0322
2726.9966 2730.0073
2742.9568
2743.9827
2745.0085
2748.0486
2749.0364
2750.0437
2763.0403
2765.0217
 
 
Sample 03-4 
 mass  peak area 
Tb 2741.9800 8.306e3 
Ho  2747.0408 1.371e3 
 
 148 
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
m/z
2716 2718 2720 2722 2724 2726 2728 2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768 2770 2772 2774 2776 2778
%
0
100
090423_RANDI_TAG5TO1TBHO_005_dt_01 73 (9.234) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (43:179) TOF MS LD+ 
6.98e32741.9846
2740.9966
2740.0225
2724.0198
2723.0361
2722.0469
2721.05422719.0303
2725.0168
2726.0190
2727.0115 2730.0332
2732.0271 2739.0769
2734.0544
2742.9871
2744.0037
2745.0181
2748.0388
2749.0442
2750.0498
2751.0305 2763.0391
2762.06792756.0757
2765.0095
2770.0457 2771.01712773.0513 2777.9917
090423_RANDI_TAG5TO1TBHO_005_dt_01  73 (9.234) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (43:179) TOF MS LD+ 
5232741.9700
2740.9836
2740.0164
2724.0068
2723.0044
2722.0210
2725.0098
2726.0127
2728.00002730.0459
2742.9763
2744.0022
2745.0085
2748.0291
2749.0364
2750.0437
2764.03102751.0125 2763.0403 2764.9832
 
 
Sample 03-5 
 mass  peak area 
Tb 2741.9846 6.976e3 
Ho  2747.0439 1.170e3 
 
 
 
 149 
APPENDIX I. PART 2. 
 
1 to 3 Tb to Ho-labeled beta-casein. 
 
20090326_RANDI_BCAS_1to3TbHo_1_001.raw  : 1
 
 
m/z
700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400 2500 2600 2700 2800 2900 3000 3100 3200 3300 3400
%
0
100
20090326_Relative quantitation extract 1_dt_02 77 (9.747) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (48:163) TOF MS LD+ 
1.60e3742.4800
1383.8320
743.4853
764.4696
821.4299
891.0459
1137.6088
897.0669
935.0217
1067.0660
1300.7452
1197.5980
1252.7710
1384.8287
1385.8462
2187.1833
2186.1963
1406.8318
1760.9860
1529.8711
1407.8274
1483.9487
1728.9465
1531.8839
1533.9419
1761.9683
1925.1013
1823.0430 1926.1049
2180.1624
1957.1166
2188.1868
2225.1843
2226.1865
2741.9934
2227.1792
2265.2000
2739.9863
2341.9995
2742.9673
2744.0085 2981.4915
2840.9324
3034.1038
3155.0349
3088.9519 3330.6777
 
 
Sample 01 – 1 
 mass  peak area 
Tb 2741.9939 1.684e2 
Ho  2747.0100 6.419e1 
 150 
 
 
20090326_RANDI_BCAS_1to3TbHo_2_001.raw  : 1
 
 
 
m/z
2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768
%
0
100
m/z
2730 2732 2734 2736 2738 2740 2742 2744 2746 2748 2750 2752 2754 2756 2758 2760 2762 2764 2766 2768
%
0
100
20090326_Relative quantitation extract 2_dt_01 77 (9.747) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (50:172) TOF MS LD+ 
1652741.9949
2740.9956
2739.9863
2734.9717
2733.9346
2733.0911
2728.9487
2730.9229
2739.4324
2737.81982735.9631
2742.9690
2744.0066
2747.0051
2745.0012
2746.0129
2747.9832
2763.99342748.9526
2750.9685
2749.9524 2763.03252762.0518
2759.2310
2756.9412
2756.0002
2752.9631
2755.2488
2760.2305
2765.9636
2764.9482
2767.0920
2768.5085
20090326_Relative quantitation extract 2_dt_01  77 (9.747) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (50:172) TOF MS LD+ 
12.92741.9895
2740.9836
2739.9973
2728.9648
2739.4363
2731.0112
2729.9106
2733.9277 2734.9707
2737.0386 2737.9277
2742.9568
2744.0022
2747.0027
2745.0471
2746.0154
2747.9709
2748.9783
2749.0750
2764.94412750.0437 2764.0115
2756.9265
2752.9509 2756.0144
2757.9353
2763.0793
2765.8376
2767.9172
 
 
Sample 01-2 
 mass  peak area 
Tb 2740.9956 1.424e2 
Ho  2747.0051 5.898e1 
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20090326_RANDI_BCAS_1to3TbHo_3_001.raw  : 1
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20090326_Relative quantitation extract 3_dt_01 78 (9.876) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (49:156) TOF MS LD+ 
4102741.9778
2740.9807
2740.0046
2737.92212728.9731 2735.01592734.0728
2732.0046
2729.8730 2735.8762
2742.9895
2748.0120
2744.0132 2746.9922
2744.9907
2763.93122748.9543 2749.9551
2762.9797
2752.0027 2755.99442754.9436 2760.98852758.95462758.1211
2764.9827
2765.9246
2767.0471
2767.9583
20090326_Relative quantitation extract 3_dt_01  78 (9.876) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (49:156) TOF MS LD+ 
30.12741.97002740.9836
2740.0359
2728.9844
2735.87892731.97662730.8955 2734.1206 2737.8506
2742.9958
2744.0212
2748.0291
2747.02222746.0154
2745.0281
2763.9338
2748.9397
2749.9856 2762.9626
2750.9353 2761.9529
2752.0203 2754.9480
2754.0754
2758.98322756.0144 2761.3513
2764.9832
2765.8962
2767.0427
 
 
Sample 01-3 
 mass  peak area 
Tb 2740.9812 3.771e2 
Ho  2747.0063 1.320e2 
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20090326_RANDI_BCAS_1to3TbHo_4_001.raw  : 1
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20090326_Relative quantitation extract 4_dt_01 75 (9.491) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (47:153) TOF MS LD+ 
61.52740.9885
2740.0398
2728.9216
2732.0879
2730.9243
2737.99632734.8730
2732.5120
2736.6472
2738.7144
2741.9836
2742.9702
2747.00052743.9614
2744.9993
2745.9373
2747.9795
2763.9946
2761.9614
2748.9866
2753.9546
2749.9829 2750.9690
2752.8674
2751.9651
2755.0188 2759.0784
2756.7053
2759.9272
2761.2373
2763.0474
2764.9424
2765.8752
2766.1050
2768.0330
20090326_Relative quantitation extract 4_dt_01  75 (9.491) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (47:153) TOF MS LD+ 
5.632741.9895
2740.9836
2740.0554
2739.9006
2734.87452728.8491
2730.9146
2730.0845
2732.9810 2736.6328 2739.4558
2742.9763
2744.9890
2743.9441
2747.0413
2745.8992
2764.0115
2748.0291 2749.0168
2750.0051 2761.93382750.9543
2756.09202754.73462753.8621
2752.8347
2761.8367
2758.7502
2760.2634
2764.9441
2766.9260
 
 
Sample 4 
 mass  peak area 
Tb 2740.9885 6.152e1 
Ho  2747.0005 3.629e1 
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20090326_RANDI_BCAS_1to3TbHo_5_001.raw  : 1
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20090326_Relative quantitation extract 5_dt_01 78 (9.876) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (40:178) TOF MS LD+ 
5962741.9880
2740.9841
2739.9951
2728.0361
2739.24342730.0461 2736.12672732.0479 2734.5923
2738.1384
2742.9741
2743.9663
2747.0002
2744.9749
2745.9973
2748.9907
2749.9895 2762.9912
2761.99342751.0264
2752.0039
2757.99562753.9761 2756.0515 2758.9961
2763.9468
2767.96852766.9883
2768.6421
20090326_Relative quantitation extract 5_dt_01  78 (9.876) Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (40:178) TOF MS LD+ 
44.62740.9641
2739.9973
2728.9844 2733.0391
2730.0654 2739.20432733.9277
2738.0825
2741.9509
2742.9568
2743.9246
2746.9832
2744.9504
2745.9958
2747.9514 2748.9783
2750.0051
2763.0212
2751.0125
2761.91432752.9509 2756.98462756.0339
2758.0320 2760.9241
2763.9534
2766.9841 2767.9563
 
 
Sample 5 
 mass  peak area 
Tb 2740.9841 5.597e2 
Ho  2747.0002 2.415e2 
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20090326_RANDI_BCAS_1to3TbHo_6_001.raw  : 1
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20090326_Relative quantitation extract 6_dt_01 79 (10.004) AM (Cen,4, 80.00, Ar,10000.0,0.00,0.70); Sm (SG, 1x5.00); Sb (15,10.00 ); Cm (45:168) TOF MS LD+ 
5602741.9795
2740.9868
2739.9966
2729.9541 2734.04392731.0684 2736.1477
2735.1975 2738.79712737.9365
2742.9822
2743.9702
2747.0068
2745.0056
2746.0129
2747.9658
2763.95292748.9973 2762.9460
2749.9849
2761.9155
2756.0334
2751.0681
2752.9404 2754.0476
2759.13482758.0872
2761.0706
2764.9404
2765.9456
2768.0024
 
 
Sample 6 
 mass  peak area 
Tb 2740.9868 4.850e2 
Ho  2747.0068 2.264e2 
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APPENDIX J 
 
Predicted and observed ions for Tb-labeled FQSEEQQQTEDELQDK as 
represented in Figure 27. 
 
 
Predicted b ion m/z       Predicted b-H2O ion m/z   
  
ion 
# 
unlabeled 
** Tb-labeled Observed   
unlabeled 
** Tb-labeled Observed 
F 1 --- --- ---   --- --- --- 
Q 2 276.13 --- ---   --- --- --- 
s* 3 443.13 1121.5766 1121.3558   ---   --- 
E 4 572.18 1250.6192 1250.4181   554.1647 1232.6087 1232.3909 
E 5 701.22 1379.6618 1379.4369   683.2072 1361.6512 1362.4300 
Q 6 829.28 1507.7204 1507.5013   811.2658 1489.7098 1490.47 
Q 7 957.34 1635.7790 1635.6525   939.3244 1617.7684 1617.6461 
Q 8 1085.39 1763.8375 1763.7114   1067.383 1745.827 1745.6090 
T 9 1186.44 1864.8852 1864.681   1168.4307 1846.8747 1846.7239 
E 10 1315.48 1993.9278 1993.8141   1297.4733 1975.9173 1975.7067 
D 11 1430.51 2108.9548 2109.7825   1412.5002 2090.9442 --- 
E 12 1559.55 2237.9974 2237.8542   1541.5428 2219.9868 --- 
L 13 1672.64 2351.0814 2351.8511   1654.6269 2333.0709 2333.9512 
Q 14 1800.70 2479.1400 2478.9624   1782.6854 2461.1294 2461.7742 
D 15 1915.72 2594.1669 2594.0896   1897.7124 2576.1564 2576.0229 
K 16 ---   ---   --- --- --- 
            
Predicted y ion m/z       Predicted y-H2O ion m/z   
  ion # 
unlabeled 
** 
Tb-
Labeled Observed   unlabeled ** Tb-labeled Observed 
F 16 --- --- ---   --- --- --- 
Q 15 1914.7601 2593.2041 2593.052   1896.7495 2575.1935 2575.0928 
s* 14 1786.7015 2465.1455 2466.0413   1768.6909 2447.1349 2446.9009 
E 13 1619.7031 --- ---   1601.6926 --- --- 
E 12 1490.6605 --- ---   1472.65 --- --- 
Q 11 1361.6179 --- ---   1343.6074 --- --- 
Q 10 1233.5594 --- ---   1215.5488 --- --- 
Q 9 1105.5008 --- ---   1087.4902 --- --- 
T 8 977.4422 --- ---   959.4316 --- --- 
E 7 876.3945 --- ---   858.384 --- --- 
D 6 747.3519 --- ---   729.3414 --- --- 
E 5 632.325 --- ---   614.3114 --- --- 
L 4 503.2824 --- ---   485.2718 --- --- 
Q 3 390.1983 --- ---   372.1878 --- --- 
D 2 262.1397 --- ---   244.1292 --- --- 
K 1 147.1128 --- ---   --- --- --- 
 
 
*s,y,t = phosphorylated S,Y,T 
** identified unlabeled ions indicated in bold 
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APPENDIX K 
 
Beta-elimination/Michael addition typical spectra for labeled Erythropoietin as 
discussed in Chapter 5. 
 
 
 
 
 
 
For the model O-linked GlcNAc glycopeptide Erythropoietin, beta-elimination was 
observed to go to completion. Michael addition was observed to be limited, and 
further work will show optimization of BEMA conditions to maximize the Michael 
addition product. Nonetheless, relative quantitation data may be achieved as the 
percent product yield is consistent between varying stoichiometries of samples.   
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APPENDIX L 
 
Preliminary relative quantitation data for 1:1 molar ratios of Tb- and Ho-labeled 
erythropoietin. 
 
 
 
 
m/z  peak area 
Tb-label 2223.6550 1.829e5 
Ho-labeled 2229.6577 1.527e5 
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m/z  peak area 
Tb-labeled  2223.6504 4.267e5 
Ho-labeled 2229.6521 3.480e5 
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m/z  peak area 
Tb-labeled 2223.6504 4.265e5 
Ho-labeled 2229.6521 3.479e5 
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m/z  peak area 
Tb-labeled 2223.6482 2.309e5 
Ho-labeled 2229.6519 1.925e5 
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m/z  peak area 
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m/z  peak area 
Tb-labeled 2223.6541 2.210e5 
Ho-labeled 2229.6565 1.796e5 
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APPENDIX N 
 
References for the adaptation of chapters 
 
 
Chapter 1:  
Sections adapted from Randi L. Gant-Branum, Thomas J. Kerr, and John A. 
McLean, "Labeling Strategies in Mass Spectrometry-Based Protein Quantitation", 
Analyst, 2009, 134, 1525 – 1530. 
 
Chapter 2:  
Sections adapted from Randi L. Gant-Branum, Joshua A. Broussard, and John 
A. McLean, "Identification of Phosphorylation Sites within the Signaling Adaptor 
APPL1 by Mass Spectrometry." J. Proteome Res., 2010, 9 (3), 1541–1548. 
 
Chapter 3:  
Sections adapted from Relative Quantitation of Phosphorylated Peptides and 
Proteins using Phosphopeptide Element-Coded Affinity Tagging (PhECAT). In 
preparation for submission to Bioconjugate Chemistry. 
 
Chapter 4:  
Sections adapted from Relative Quantitation of Phosphorylated Peptides and 
Proteins using Phosphopeptide Element-Coded Affinity Tagging (PhECAT). In 
preparation for submission to Bioconjugate Chemistry. 
 
 
 
 169 
 
REFERENCES 
 
 
(1) Floyd, R. A. Exp. Biol. Med. 1999, 222, 236-245. 
(2) Kovacech, B.; Zilka, N.; Novak, M. Cellular and Molecular Neurobiology 
2009, 29, 799-805. 
(3) Liu, F.; Iqbal, K.; Grundke-Iqbal, I.; Hart, G. W.; Gong, C.-X. 
Proceedings of the National Academy of Sciences of the United States of America 
2004, 101, 10804-10809. 
(4) Shental-Bechor, D.; Levy, Y. Proceedings of the National Academy of 
Sciences 2008, 105, 8256-8261. 
(5) Hitosugi, T.; Kang, S.; Vander Heiden, M. G.; Chung, T.-W.; Elf, S.; 
Lythgoe, K.; Dong, S.; Lonial, S.; Wang, X.; Chen, G. Z.; Xie, J.; Gu, T.-L.; 
Polakiewicz, R. D.; Roesel, J. L.; Boggon, T. J.; Khuri, F. R.; Gilliland, D. G.; 
Cantley, L. C.; Kaufman, J.; Chen, J. Sci. Signal. 2009, 2, ra73-. 
(6) Savage, K.; Baur, P. J Cell Sci 1983, 64, 295-306. 
(7) Mimura, Y.; Sondermann, P.; Ghirlando, R.; Lund, J.; Young, S. P.; 
Goodall, M.; Jefferis, R. Journal of Biological Chemistry 2001, 276, 45539-
45547. 
(8) Parekh, R. B.; Dwek, R. A.; Sutton, B. J.; Fernandes, D. L.; Leung, A.; 
Stanworth, D.; Rademacher, T. W.; Mizuochi, T.; Taniguchi, T.; Matsuta, K.; 
Takeuchi, F.; Nagano, Y.; Miyamoto, T.; Kobata, A. Nature 1985, 316, 452-457. 
(9) Gant-Branum, R. L.; Kerr, T. J.; McLean, J. A. The Analyst 2009, 134, 
1525-1530. 
(10) Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. 
Science 2002, 298, 1912-1934. 
(11) Thingholm, T. E.; Jensen, O. N.; Larsen, M. R.; WILEY-VCH Verlag, 
2009; Vol. 9, pp 1451-1468. 
(12) Reinders, J.; Sickmann, A.; WILEY-VCH Verlag, 2005; Vol. 5, pp 4052-
4061. 
(13) Chen, P.-L.; Scully, P.; Shew, J.-Y.; Wang, J. Y. J.; Lee, W.-H. Cell 1989, 
58, 1193-1198. 
(14) Webb, D. J.; Schroeder, M. J.; Brame, C. J.; Whitmore, L.; Shabanowitz, 
J.; Hunt, D. F.; Horwitz, A. R. J Cell Sci 2005, 118, 4925-4929. 
(15) Webb, D. J.; Donais, K.; Whitmore, L. A.; Thomas, S. M.; Turner, C. E.; 
Parsons, J. T.; Horwitz, A. F. Nat Cell Biol 2004, 6, 154-161. 
(16) Webb, D. J.; Kovalenko, M.; Whitmore, L.; Horwitz, A. F. Biochemical 
and Biophysical Research Communications 2006, 346, 1284-1288. 
(17) Webb, D. J.; Mayhew, M. W.; Kovalenko, M.; Schroeder, M. J.; Jeffery, 
E. D.; Whitmore, L.; Shabanowitz, J.; Hunt, D. F.; Horwitz, A. F. J Cell Sci 2006, 
119, 2847-2850. 
(18) Gant-Branum, R. L.; Broussard, J. A.; Mahsut, A.; Webb, D. J.; McLean, 
J. A. Journal of Proteome Research 2010, 9, 1541-1548. 
(19) Matsuoka, S.; Ballif, B. A.; Smogorzewska, A.; McDonald, E. R.; Hurov, 
K. E.; Luo, J.; Bakalarski, C. E.; Zhao, Z.; Solimini, N.; Lerenthal, Y.; Shiloh, Y.; 
Gygi, S. P.; Elledge, S. J. Science 2007, 316, 1160-1166. 
 170 
(20) Graves, J. D.; Krebs, E. G. Pharmacology & Therapeutics 1999 
82, 111-121. 
(21) López, E. M., R.; López, I.; Ashman, K.; Mendieta, J.; Wesselink, J.; 
Gómez-Puertas, P.; Ferreir, A. Journal of Integrated OMICS 2010, accepted 
October 2010. 
(22) Hunter, T. Cell 2000, 100, 113-127. 
(23) Mann, M.; Ong, S.-E.; Grønborg, M.; Steen, H.; Jensen, O. N.; Pandey, A. 
Trends in Biotechnology 2002, 20, 261-268. 
(24) Palumbo, A. M.; Reid, G. E. Analytical Chemistry 2008, 80, 9735-9747. 
(25) Palumbo, A. M.; Tepe, J. J.; Reid, G. E. Journal of Proteome Research 
2008, 7, 771-779. 
(26) Apweiler, R.; Hermjakob, H.; Sharon, N. Biochimica et Biophysica Acta 
(BBA) - General Subjects 1999, 1473, 4-8. 
(27) Becker, K. L. Principles and practice of endocrinology and metabolism; 
Lippincott Williams & Wilkins, 2001. 
(28) Taoka, K.-i.; Ham, B.-K.; Xoconostle-Cazares, B.; Rojas, M. R.; Lucas, 
W. J. Plant Cell 2007, 19, 1866-1884. 
(29) Chen, D.; Juarez, S.; Hartweck, L.; Alamillo, J. M.; Simon-Mateo, C.; 
Perez, J. J.; Fernandez-Fernandez, M. R.; Olszewski, N. E.; Garcia, J. A. J. Virol. 
2005, 79, 9381-9387. 
(30) Haines, N.; Irvine, K. D. Nat Rev Mol Cell Biol 2003, 4, 786-797. 
(31) Varki, A. C., R.D.; Esko, J.D.; Freeze, H.H.; Stanley, P.; Bertozzi, C.R.; 
Hart, G.W. and Etzler, M.E., Ed. Essentials of Glycobiology, 2nd ed.; Cold Spring 
Harbor Laboratory Press: Cold Spring Harbor 2009. 
(32) Huhn, C.; Selman, M. H. J.; Ruhaak, L. R.; Deelder, A. M.; Wuhrer, M. 
PROTEOMICS 2009, 9, 882-913. 
(33) Jacquemin, M.; Radcliffe, C. M.; Laven'homme, R.; Wormald, M. R.; 
Vanderelst, L.; Wallays, G.; Dewaele, J.; Colllen, D.; Vermylen, J.; Dwek, R. A.; 
Saint-Remy, J.-M.; Rudd, P. M.; Dewerchin, M. Journal of Thrombosis and 
Haemostasis 2006, 4, 1047-1055. 
(34) Kaneko, Y.; Nimmerjahn, F.; Ravetch, J. V. Science 2006, 313, 670-673. 
(35) Mori, K.; Iida, S.; Yamane-Ohnuki, N.; Kanda, Y.; Kuni-Kamochi, R.; 
Nakano, R.; Imai-Nishiya, H.; Okazaki, A.; Shinkawa, T.; Natsume, A.; Niwa, R.; 
Shitara, K.; Satoh, M. Cytotechnology 2007, 55, 109-114. 
(36) Hartweck, L. M.; Scott, C. L.; Olszewski, N. E. Genetics 2002, 161, 1279-
1291. 
(37) Shafi, R.; Iyer, S. P. N.; Ellies, L. G.; O'Donnell, N.; Marek, K. W.; Chui, 
D.; Hart, G. W.; Marth, J. D. Proceedings of the National Academy of Sciences of 
the United States of America 2000, 97, 5735-5739. 
(38) Vosseller, K.; Wells, L.; Lane, M. D.; Hart, G. W. Proceedings of the 
National Academy of Sciences of the United States of America 2002, 99, 5313-
5318. 
(39) Boyle, W. J.; van der Geer, P.; Hunter, T.; Tony, H.; Bartholomew, M. S. 
In Methods in Enzymology; Academic Press, 1991; Vol. Volume 201, pp 110-149. 
 171 
(40) Loo, R. R. O.; Mitchell, C.; Stevenson, T. I.; Martin, S. A.; Hines, W. M.; 
Juhasz, P.; Patterson, D. H.; Peltier, J. M.; Loo, J. A.; Andrews, P. C. 
ELECTROPHORESIS 1997, 18, 382-390. 
(41) Neville, D. C. A.; Townsend, R. R.; Rozanas, C. R.; Verkman, A. S.; 
Price, E. M.; Gruis, D. B. Protein Science 1997, 6, 2436-2445. 
(42) Porath, J.; Carlsson, J. A. N.; Olsson, I.; Belfrage, G. Nature 1975, 258, 
598-599. 
(43) Zhong, J.; Molina, H.; Pandey, A. Phosphoproteomics; John Wiley & 
Sons, Inc., 2001. 
(44) Marcus, K.; Immler, D.; Sternberger, J.; Meyer, H. E. 
ELECTROPHORESIS 2000, 21, 2622-2636. 
(45) Sun, T.; Campbell, M.; Gordon, W.; Arlinghaus, R. B.; John Wiley & 
Sons, Inc., 2001; Vol. 60, pp 61-75. 
(46) Desiderio, D. M.; Kai, M. Biological Mass Spectrometry 1983, 10, 471-
479. 
(47) Mirgorodskaya, O. A.; Kozmin, Y. P.; Titov, M. I.; Körner, R.; Sönksen, 
C. P.; Roepstorff, P.; John Wiley & Sons, Ltd., 2000; Vol. 14, pp 1226-1232. 
(48) Yao, X.; Freas, A.; Ramirez, J.; Demirev, P. A.; Fenselau, C. Analytical 
Chemistry 2001, 73, 2836-2842. 
(49) Ong, S.-E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D. B.; Steen, H.; 
Pandey, A.; Mann, M. Mol Cell Proteomics 2002, M200025-MCP200200. 
(50) Ahrends, R.; Pieper, S.; Kuhn, A.; Weisshoff, H.; Hamester, M.; 
Lindemann, T.; Scheler, C.; Lehmann, K.; Taubner, K.; Linscheid, M. W. Mol 
Cell Proteomics 2007, 6, 1907-1916. 
(51) Chen, M.; Su, X.; Yang, J.; Jenkins, C. M.; Cedars, A. M.; Gross, R. W. 
Analytical Chemistry 2009, 82, 163-171. 
(52) Goshe, M. B.; Conrads, T. P.; Panisko, E. A.; Angell, N. H.; Veenstra, T. 
D.; Smith, R. D. Analytical Chemistry 2001, 73, 2578-2586. 
(53) Gygi, S. P.; Rist, B.; Gerber, S. A.; Turecek, F.; Gelb, M. H.; Aebersold, 
R. Nat Biotech 1999, 17, 994-999. 
(54) Kerr, T. J.; McLean, J. A. Chemical Communications, 46, 5479-5481. 
(55) Liu, H.; Zhang, Y.; Wang, J.; Wang, D.; Zhou, C.; Cai, Y.; Qian, X. 
Analytical Chemistry 2006, 78, 6614-6621. 
(56) Oda, Y.; Huang, K.; Cross, F. R.; Cowburn, D.; Chait, B. T. Proceedings 
of the National Academy of Sciences of the United States of America 1999, 96, 
6591-6596. 
(57) Qian, W.-J.; Goshe, M. B.; Camp, D. G.; Yu, L.-R.; Tang, K.; Smith, R. 
D. Analytical Chemistry 2003, 75, 5441-5450. 
(58) Whetstone, P. A.; Butlin, N. G.; Corneillie, T. M.; Meares, C. F. 
Bioconjugate Chemistry 2004, 15, 3-6. 
(59) Ross, P. L.; Huang, Y. N.; Marchese, J. N.; Williamson, B.; Parker, K.; 
Hattan, S.; Khainovski, N.; Pillai, S.; Dey, S.; Daniels, S.; Purkayastha, S.; 
Juhasz, P.; Martin, S.; Bartlet-Jones, M.; He, F.; Jacobson, A.; Pappin, D. J. 
Molecular & Cellular Proteomics 2004, 3, 1154-1169. 
(60) Zieske, L. R. Journal of Experimental Botany 2006, 57, 1501-1508. 
 172 
(61) Shadforth, I.; Dunkley, T.; Lilley, K.; Bessant, C. BMC Genomics 2005, 6, 
145. 
(62) Zhou, H.; Watts, J. D.; Aebersold, R. Nat Biotech 2001, 19, 375-378. 
(63) Wada, Y.; Azadi, P.; Costello, C. E.; Dell, A.; Dwek, R. A.; Geyer, H.; 
Geyer, R.; Kakehi, K.; Karlsson, N. G.; Kato, K.; Kawasaki, N.; Khoo, K.-H.; 
Kim, S.; Kondo, A.; Lattova, E.; Mechref, Y.; Miyoshi, E.; Nakamura, K.; 
Narimatsu, H.; Novotny, M. V.; Packer, N. H.; Perreault, H.; Peter-Katalinic, J.; 
Pohlentz, G.; Reinhold, V. N.; Rudd, P. M.; Suzuki, A.; Taniguchi, N. 
Glycobiology 2007, 17, 411-422. 
(64) Harvey, D. J. Expert Review of Proteomics 2005, 2, 87-101. 
(65) Tao, L.; McLean, J. R.; McLean, J. A.; Russell, D. H. Journal of the 
American Society for Mass Spectrometry 2007, 18, 1232-1238. 
(66) Fenn, L.; Kliman, M.; Mahsut, A.; Zhao, S.; McLean, J. Analytical and 
Bioanalytical Chemistry 2009, 394, 235-244. 
(67) Kliman, M.; Vijayakrishnan, N.; Wang, L.; Tapp, J. T.; Broadie, K.; 
McLean, J. A. Molecular BioSystems 2010, 6, 958-966. 
(68) McLean, J. A.; Ruotolo, B. T.; Gillig, K. J.; Russell, D. H. International 
Journal of Mass Spectrometry 2005, 240, 301-315. 
(69) Ruotolo, B. T.; Gillig, K. J.; Woods, A. S.; Egan, T. F.; Ugarov, M. V.; 
Schultz, J. A.; Russell, D. H. Analytical Chemistry 2004, 76, 6727-6733. 
(70) Fenn, L. S.; McLean, J. A. Molecular BioSystems 2009, 5, 1298-1302. 
(71) McLean, J. A., Russell, D. H American Biotechnology Laboratory 2005, 
23, 18-21. 
(72) Hilderbrand, A. E.; Myung, S.; Clemmer, D. E. Analytical Chemistry 
2006, 78, 6792-6800. 
(73) McLean, J. A.; Ridenour, W. B.; Caprioli, R. M.; John Wiley & Sons, 
Ltd., 2007; Vol. 42, pp 1099-1105. 
(74) Howdle, M. D.; Eckers, C.; Laures, A. M. F.; Creaser, C. S. Journal of the 
American Society for Mass Spectrometry 2009, 20, 1-9. 
(75) Corneillie, T. M.; Lee, K. C.; Whetstone, P. A.; Wong, J. P.; Meares, C. F. 
Bioconjugate Chemistry 2004, 15, 1392-1402. 
(76) Clark, R. C.; Dijkstra, J. International Journal of Biochemistry 1980, 11, 
577-585. 
(77) Clark, R. C. International Journal of Biochemistry 1981, 13, 233-236. 
(78) Annan, W. D.; Manson, W.; Nimmo, J. A. Analytical Biochemistry 1982, 
121, 62-68. 
(79) Meyer, H. E.; Hoffmann-Posorske, E.; Korte, H.; Heilmeyer jr, L. M. G. 
FEBS Letters 1986, 204, 61-66. 
(80) Poot, A. J.; Ruijter, E.; Nuijens, T.; Dirksen, E. H. C.; Heck, A. J. R.; 
Slijper, M.; Rijkers, D. T. S.; Liskamp, R. M. J.; WILEY-VCH Verlag, 2006; 
Vol. 6, pp 6394-6399. 
(81) Zheng, Y.; Guo, Z.; Cai, Z. Talanta 2009, 78, 358-363. 
(82) Mitsuuchi, Y. J., Steven W.; Sonoda, Gonosuke; Tanno, Satoshi; 
Golemis,Erica A.; and  Testa Joseph R. Oncogene 1999, 18, 8. 
(83) Deepa, S. S.; Dong, L. Q. American Journal of Physiology - 
Endocrinology And Metabolism 2009, 296, E22-E36. 
 173 
(84) Dephoure, N.; Zhou, C.; VillÃ©n, J.; Beausoleil, S. A.; Bakalarski, C. E.; 
Elledge, S. J.; Gygi, S. P. Proceedings of the National Academy of Sciences 2008, 
105, 10762-10767. 
(85) Sugiyama, N.; Masuda, T.; Shinoda, K.; Nakamura, A.; Tomita, M.; 
Ishihama, Y. Molecular & Cellular Proteomics 2007, 6, 1103-1109. 
(86) Beausoleil, S. A.; Jedrychowski, M.; Schwartz, D.; Elias, J. E.; VillÃ©n, 
J.; Li, J.; Cohn, M. A.; Cantley, L. C.; Gygi, S. P. Proceedings of the National 
Academy of Sciences of the United States of America 2004, 101, 12130-12135. 
(87) Ballif, B. A.; VillÃ©n, J.; Beausoleil, S. A.; Schwartz, D.; Gygi, S. P. 
Molecular & Cellular Proteomics 2004, 3, 1093-1101. 
(88) Miaczynska, M.; Christoforidis, S.; Giner, A.; Shevchenko, A.; 
Uttenweiler-Joseph, S.; Habermann, B.; Wilm, M.; Parton, R. G.; Zerial, M. Cell 
2004, 116, 445-456. 
(89) Habermann, B. EMBO reports 2004, 5, 6. 
(90) VÃ¡rnai, P. t.; Lin, X.; Lee, S. B.; Tuymetova, G.; Bondeva, T.; SpÃ¤t, 
A.; Rhee, S. G.; HajnÃ³czky, G. r.; Balla, T. Journal of Biological Chemistry 
2002, 277, 27412-27422. 
(91) Schenck, A.; Goto-Silva, L.; Collinet, C.; Rhinn, M.; Giner, A.; 
Habermann, B.; Brand, M.; Zerial, M. Cell 2008, 133, 486-497. 
(92) Li, J.; Mao, X.; Dong, L. Q.; Liu, F.; Tong, L. Structure 2007, 15, 525-
533. 
(93) Zhu, G.; Chen, J.; Liu, J.; Brunzelle, J. S.; Huang, B.; Wakeham, N.; 
Terzyan, S.; Li, X.; Rao, Z.; Li, G.; Zhang, X. C. EMBO J 2007, 26, 3484-3493. 
(94) Zerial, M.; McBride, H. Nat Rev Mol Cell Biol 2001, 2, 107-117. 
(95) Lin, D. C.; Quevedo, C.; Brewer, N. E.; Bell, A.; Testa, J. R.; Grimes, M. 
L.; Miller, F. D.; Kaplan, D. R. Mol. Cell. Biol. 2006, 26, 8928-8941. 
(96) Mao, X.; Kikani, C. K.; Riojas, R. A.; Langlais, P.; Wang, L.; Ramos, F. 
J.; Fang, Q.; Christ-Roberts, C. Y.; Hong, J. Y.; Kim, R.-Y.; Liu, F.; Dong, L. Q. 
Nat Cell Biol 2006, 8, 516-523. 
(97) Nechamen, C. A.; Thomas, R. M.; Cohen, B. D.; Acevedo, G.; 
Poulikakos, P. I.; Testa, J. R.; Dias, J. A. Biology of Reproduction 2004, 71, 629-
636. 
(98) Liu, J.; Yao, F.; Wu, R.; Morgan, M.; Thorburn, A.; Finley, R. L.; Chen, 
Y. Q. Journal of Biological Chemistry 2002, 277, 26281-26285. 
(99) Posner, B. I.; Faure, R.; Burgess, J. W.; Bevan, A. P.; Lachance, D.; 
Zhang-Sun, G.; Fantus, I. G.; Ng, J. B.; Hall, D. A.; Lum, B. S. Journal of 
Biological Chemistry 1994, 269, 4596-4604. 
(100) Nichols, A. M. W., Forest M. Methods in Molecular Biology - Springer 
Protocols 2009, 492, 18. 
(101) Taylor, C. F.; Paton, N. W.; Lilley, K. S.; Binz, P.-A.; Julian, R. K.; Jones, 
A. R.; Zhu, W.; Apweiler, R.; Aebersold, R.; Deutsch, E. W.; Dunn, M. J.; Heck, 
A. J. R.; Leitner, A.; Macht, M.; Mann, M.; Martens, L.; Neubert, T. A.; 
Patterson, S. D.; Ping, P.; Seymour, S. L.; Souda, P.; Tsugita, A.; 
Vandekerckhove, J.; Vondriska, T. M.; Whitelegge, J. P.; Wilkins, M. R.; 
Xenarios, I.; Yates, J. R.; Hermjakob, H. Nat Biotech 2007, 25, 887-893. 
(102) Tanabe, H. H., T.; Murayama, K.; Terada, T.; Shirouzu, M.; Yokoyama, S. 
 174 
(103) Mega, T.; Hamazume, Y.; Nong, Y.-M.; Ikenaka, T. J Biochem 1986, 100, 
1109-1116. 
(104) Fadden, P.; Haystead, T. A. J. Analytical Biochemistry 1995, 225, 81-88. 
(105) Woods, A. S. Journal of Proteome Research 2004, 3, 478-484. 
(106) Woods, A. S.; Moyer, S. C.; Jackson, S. N. Journal of Proteome Research 
2008, 7, 3423-3427. 
(107) Jackson, S. N.; Wang; Woods, A. S. Journal of Proteome Research 2005, 
4, 2360-2363. 
(108) Holland, M.; Yagi, H.; Takahashi, N.; Kato, K.; Savage, C. O. S.; Goodall, 
D. M.; Jefferis, R. Biochimica et Biophysica Acta (BBA) - General Subjects 2006, 
1760, 669-677. 
(109) Krapp, S.; Mimura, Y.; Jefferis, R.; Huber, R.; Sondermann, P. Journal of 
Molecular Biology 2003, 325, 979-989. 
(110) Parekh, R.; Roitt, I.; Isenberg, D.; Dwek, R.; Rademacher, T. The Journal 
of Experimental Medicine 1988, 167, 1731-1736. 
 
 
 
 175 
 
 
Randi L. Gant-Branum 
Vanderbilt University    C:(931) 206-5092  
Department of Chemistry   W:(615) 343-4563 
7330 Stevenson Center    randi.l.gant@vanderbilt.edu 
Nashville, TN 37235     randigant@yahoo.com  
____________________________________________________________________________ 
   
Education 
 
Bachelor of Science - (2006) - University of Tennessee at Chattanooga  
 - Major- Chemistry (Biochemistry Concentration) 
   Minor- Biology 
- Cum Laude - 3.71 GPA 
- Research Mentor: Manuel F. Santiago – (423) 425-5364 
- University Honors for completion of Honors coursework and GPA above 3.5 
- Departmental Honors for completion of a Departmental Honors Dissertation 
   Thesis Title: “Degradation of Pyrimidines by Pseudomonas syringae” 
  
Doctor of Philosophy in Chemistry– (August 2011) – Vanderbilt University 
- Degree Focus – Analytical Chemistry, Mass Spectrometry, Ion Mobility-Mass Spectrometry, 
  Proteomics, and Quantitative Proteomics and Glycomics 
- 3.18 GPA  
- Research  Mentor: John A. McLean - (615) 322-1195 
- Thesis Title: “Characterization of Post-Translationally Modified Peptides and Proteins Using    
  Lanthanide-based Labeling Strategies.”  
 
 
Professional Experience 
 
 
Instrumentation:   
HPLC-ESI-MS/MS – High-Performance Liquid Chromatography- Electrospray 
Ionization-Tandem Mass Spectrometer  
DE-MALDI-TOFMS – Delayed Extraction-Matrix-Assisted Laser Desorption  
Ionization-Time of Flight Mass Spectrometer  
GC-MS – Gas Chromatography-Mass Spectrometer  
DT-IM-MS – Drift Tube-Ion Mobility-Mass Spectrometer (custom)  
TW-IM-MS/MS – Travelling Wave-Ion Mobility-Mass Spectrometer (Waters  
Synapt© G1 and G2 models)  
UV-Visible Spectrophotometry (with automated scans for enzyme kinetics)  
ICP-OES – Inductively Coupled Plasma-Optical Emission Spectrometry  
NMR – Nuclear Magnetic Resonance  
CV – Cyclic Voltammetry  
ICP-MS – Inductively Coupled Plasma-Mass Spectrometry 
  
Software:   
Data Explorer – DE-MALDI-TOFMS software 
Xcalibur – HPLC-ESI-MS/MS software 
Mass Lynx – TW-IM-MS/MS software 
Simion (LabView)- Instrument building software 
SEQUEST – algorithm for searching tandem MS data 
GPMAW – (a customized algorithm for searching tandem MS data) 
ExPASy Proteomics Server and all related programs such as  
 176 
 
Peptide Mass, Protein Prospector, Mascot, BLAST, GlycoMod,  
and GlycanMass. 
P-mod - (a customized algorithm for searching tandem MS data) 
ExPASy Proteomics Server  
Adobe Professional 
EndNote 
CorelDraw 
ChemDraw 
Microsoft Word, Outlook, Powerpoint, Excel 
    
Grant Writing:    
NIH-RO1 Grants 
NIH-R21 Grants 
Independent Research Proposal – Prepared and presented an original NIH 
                             Research proposal unrelated to the graduate mentor’s field as required 
                             by the Vanderbilt Chemistry PhD program. 
 
Training:   
Lab Safety and Fire Safety Training Course (VU Chemistry) 
Responsible Conduct of Research though the Collaborative Institutional Training 
Initiative and the NIH. 
 
- Also possesses experience in critical peer review of scientific journals, undergraduate and 
graduate mentoring, and purchasing. 
 
Publications  
 
Vanderbilt (Chronological Order) 
 
R. L. Gant-Branum, T. J. Kerr, and J. A. McLean. Labeling Strategies in Mass Spectrometry-Based 
Protein Quantitation. Analyst. 2009, 134, 1525 – 1530. 
 
R. L. Gant-Branum, J. A. Broussard, D. J. Webb, and J. A. McLean. Identification of Phosphorylation 
Sites within the Signaling Adaptor APPL1 by Mass Spectrometry. Journal of Proteome Research, 2010, 9 
(3), 1541–1548 
 
R. L. Gant-Branum, T. J. Kerr, and J. A. McLean. Phosphoproteomic Selection, Relative Quantitation, 
and Localization using Phosphopeptide Element-Coded Affinity Tagging (PhECAT). Submitted to 
Analytical Chemistry. 2011. 
 
T. J. Kerr, R. L. Gant-Branum, and J. A. McLean. Multiplexed Relative Quantitation of Peptide 
Functionality Using Lanthanide-based Structural Shift Reagents. International Journal of Mass 
Spectrometry. in press. 2011. 
 
R. L. Gant-Branum and J. A. McLean. Targeted Selection of Glycoproteins and Phosphoproteins Using 
Mobility Shift Strategies and Ion Mobility-Mass Spectrometry. In preparation. 
 
 
University of Tennessee at Chattanooga (Chronological Order) 
 
E. B. Burnette, R. L. Gant, G. M. Meyer, and M. F. Santiago. Regulation of Pyrimidine Catabolism in 
Pseudomonas lemonnieri ATCC 12983. Journal of Undergraduate Chemistry Research. 2006, 5, 9-13. 
 
R. L. Gant, M. L. Hacker, G. M. Meyer, and M. F. Santiago. Degradation of Pyrimidines by Pseudomonas 
syringae. Research Journal of Microbiology. 2007, 2(11), 851-855. 
 177 
 
Presentations (Primary Presenter) 
 
Vanderbilt (Chronological Order) 
 
Phosphoproteomic Tagging Strategies for Ion Mobility-Mass Spectrometry. R. L. Gant, T. J. Kerr, and J. 
A. McLean. Presented at the annual meeting of the Tennessee Academy of Sciences (TAS), 2007 in 
Nashville, TN. 
 
Structural Separation of Phosphorylated Peptides Using Chemical Derivatization and Ion-Mobility Mass 
Spectrometry.  R. L. Gant, T. J. Kerr, and J. A. McLean. Presented at the annual Vanderbilt Institute for 
Chemical Biology (VICB) retreat, 2008 in Florence, AL. 
 
Phosphoproteomics using selective derivatization and structural separations by ion mobility-mass 
spectrometry. R. L. Gant, T. J. Kerr, and J. A. McLean. Presented at the annual meeting of the American 
Society for Mass Spectrometry (ASMS), 2008 in Denver, CO. 
 
Phosphoproteomic Mapping with Two-dimensional Structural Separations by Ion Mobility-Mass 
Spectrometry. R. L. Gant and J. A. McLean. Presented at the annual meeting of the Federation of 
Analytical Chemistry and Spectroscopy Societies (FACSS) meeting, 2008 in Reno, NV. 
 
Multiplexed Quantitiative Phosphoproteomics using a Lanthanide Based Tagging Strategy with MALDI-
TOFMS. R. L. Gant and J. A. McLean. Presented at the South Eastern Regional Meeting of the American 
Chemical Society (SERMACS), 2009 in Nashville, TN.   
 
Identification of protein phosphorylation sites of human APPL1 using MS, MS/MS, and IM-MS. R. L. 
Gant-Branum and J. A. McLean. Presented at the annual meeting of the American Society for Mass 
Spectrometry (ASMS), 2009 in Philadelphia, PA. 
 
Quantitative Proteomic Strategies using Ion Mobility Shift Labels. R. L. Gant-Branum, T. J. Kerr, J. A. 
McLean. Invited talk at the annual meeting of the Federation of Analytical Chemistry and Spectroscopy 
Societies (FACSS) meeting, 2009 in Louisville, KY.  
 
University of Tennessee at Chattanooga (Chronological Order) 
 
Degradation of Pyrimidines by Pseudomonas syringae. R. L. Gant, G. M. Meyer, and M. F. Santiago. 
Presented at the 56th Southeast Regional Meeting of the American Chemical Society, 2004 in Research 
Triangle Park, NC. 
 
Pyridine Nucleotide Transhydrogenase Activity in Pseudomonas syringe. R. L. Gant, M. F. Santiago. 
Abstracts of Papers, 61
st
 Southwest and the 57
th
 Southeast Joint Regional Meeting of the ACS, 2005 in 
Memphis, TN. 
 
Reducing Agent of Dihydropyrimidine Dehydrogenase. R. L. Gant, G. M. Meyer, and M. F. Santiago. 
Presented at the 229th American Chemical Society National Meeting, 2005 in San Diego, CA. 
 
Reductive pathway of penicillin-resistant Pseudomonas syringae. R. L. Gant, S. Prince, M. F. Santiago, 
G. M. Meyer. 229th American Chemical Society National Meeting, 2005. in San Diego, CA. 
 
 
Professional Organizations and Societies 
 
American Chemical Society Student Affiliates, UTC Chapter (2003-2006) – Vice President 
American Chemical Society  
American Society for Mass Spectrometry 
Federation of Analytical Chemistry and Spectroscopy Societies 
 178 
 
Tennessee Academy of Sciences 
 
 
 
 
 
 
